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Muscle contraction is a finely tuned mechanism involving cyclical interactions between 
actin and myosin, regulated by calcium through troponin and tropomyosin and 
modulated by myosin binding protein-C. Genetic mutations of the proteins involved in 
such complex mechanism can thus lead to potential life threatening diseases, such as 
Hypertrophic Cardiomyopathy (HCM). Although being mostly asymptomatic, HCM 
affects 1 in 500 people, ultimately leading to poor prognosis and sudden death, 
thought to occur through the impairment of relaxation during diastole. 
In this thesis I present the experiments conducted to improve our current 
understanding of the molecular mechanism behind HCM, specifically on the role of 
tropomyosin and myosin binding protein-C in modulating thin filament activation and 
relaxation. Using a single molecule approach, we first visualised fluorescent myosin 
binding to reconstituted thin filaments and examined their dynamics in the presence 
of the tropomyosin HCM causing E180G mutation, demonstrating a shift of the thin 
filament activation state towards the closed state, facilitating myosin binding at low 
calcium, and a reduction of the thin filament regulatory unit. 
We then looked at the dynamics of very highly concentrated clusters of myosin, 
showing how the sudden collapse of these active regions cannot be explained by 
normal relaxation mechanisms, thus suggesting an alternative mechanistic role for 
tropomyosin and how its mutations could lead to impaired relaxation in HCM. 
Finally, we turned our focus on N-terminal fragments of cardiac myosin binding 
protein-C (cMyBP-C) and study their role in thin filament activation, by looking at how 
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they affect acto-myosin interactions. We found that only the presence of the whole 
cMyBP-C N-terminus was able to promote acto-myosin interactions at low Ca2+ or 
repressing them at high Ca2+. Moreover, by looking at the dynamics of the fragments, 
we were able to determine that cMyBP-C possesses a two steps binding mechanism to 
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1.1  ? The muscle and its smallest contractile unit: the 
sarcomere  
 
Muscles can be classified based on their appearance and function. There are three 
main types of muscle, skeletal, cardiac and smooth. Smooth muscle is found in the 
oesophagus, blood vessels and trachea, skeletal muscle is the one responsible for the 
motion of limbs and cardiac muscle is found in the heart. Smooth and cardiac muscles 
are also termed involuntary, as their contraction or relaxation cannot be controlled. 
Moreover, skeletal and cardiac muscle are called striated because of their appearance 
under the microscope, being organised in a highly hierarchical and repetitive structure. 
Figure 1.1 shows a drawing of this structure, where it can be seen that each muscle is a 
fasciculus made of myofibres, each one subsequently composed of a network of 
myofibrils, in turn made of thousands of smaller repetitive units called sarcomeres. 
Shown in figure 1.2, a sarcomere is the smallest contractile unit of a muscle, its length 
varying from about 1-3 µm during contraction-relaxation (Gordon et al., 1966; Walker 




Figure 1.1: The hierarchy of muscle. Drawing of the hierarchical structure of striated muscle, down to its 
smallest contractile unit, the sarcomere. Adapted from Study of Arms, Leonardo da Vinci and Histology 




Figure 1.2: The bands structure of the sarcomere. a) electron micrograph of a sarcomere, adapted from 
(Luther and Craig, 2011) and b) schematic of a sarcomere with the main proteins involved in muscle 
contraction, adapted from (Kobirumaki-Shimozawa et al., 2012). 
 
Under optical illumination, the sarcomere appears as an alternation of dark and white 
patches, with the two major ones named the A (anisotropic) and I (isotropic) bands 
(figure 1.2a). Although reports that showed how contraction is caused by the 
interaction between two main proteins found in muscle purifications, myosin and actin, 
date back to the late 1930s (for a review of the history of the biochemistry of muscle 
contraction see (Szent-Györgyi, 2004)), it was the work of (Huxley and Niedergerke, 
4 
 
1954) and (Huxley and Hanson, 1954) that correlated the bands to the actin containing 
thin filament and the myosin containing thick filaments, giving birth to the sliding 
filament theory. More specifically, the A band corresponds to the region where both 
the thin and thick filaments are found, while, in the I band and the H zone, only the 
thin filament or the thick filament are present, respectively (figure 1.2). 
The sarcomere structural integrity is kept together by two other proteins, ɲ-actinin 
and titin, with the former being responsible for crosslinking antiparallel actin filaments, 
forming the Z-disk, with titin, which in turns acts as a molecular ruler and scaffold, 
connecting the Z disk to the M line and to which the myosin binds to form the thick 
filament (Sjöblom et al., 2008; Luther, 2009; Gautel, 2011; Ribeiro et al., 2014). 
In the next sections, I will describe the main players involved in muscle contraction and 
their role, as well as highlighting some of the structural properties that can be of help 
to better understand the data reported in the following chapters. 
 
 
1.2  ? The thin filament 
1.2.1  ? Actin 
Discovered by Straub in 1942 (Straub, 1943), actin is one of the most common protein 
in eukaryotic cells and the main constituent protein of the thin filament (Hanson and 
Huxley, 1953), and it has been extensively reviewed (Tobacman, 1996; Dominguez and 
Holmes, 2011). Actin can be either monomeric (G-actin) or filamentous (F-actin), 
where the polymerisation of G-actin gives rise to a double helix with a 36 nm pitch 




Figure 1.3: The two different forms of Actin. a) structure of G-actin (adapted from PDB-2ZWH (Oda et 
al., 2009)) in the ADP (in red) bound state and coordinated by Ca2+ and colour coded to highlight the 
different subdomains; b) structure of F-actin, depicting the two different ends and highlighting its 36 nm 
periodicity, followed by the red curve (adapted from (Dominguez and Holmes, 2011)). 
 
The structure of G-actin, shown in figure 1.3a, has been resolved in numerous studies, 
mostly using small molecules to prevent polymerisation (Kabsch et al., 1990; 
McLaughlin et al., 1993; Schutt et al., 1993; Wang et al., 2010). It appears as a globular 
protein (55 x 55 x 35 Å) structured into four subdomains separated by a central cleft 
(Kabsch et al., 1990). In the cleft is a binding site for ATP, which hydrolysis functions as 
a modulator of G-actin polymerisation (Cooke, 1975; Carlier et al., 1984). Throughout 
the subdomains there are also multiple binding sites for divalent ions such as Ca2+ and 
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Mg2+, with the most important one being just next to the ATP binding site and termed 
catalytic, for its role in coordinating water molecules which are thought to promote 
the ATPase mechanism (Carlier et al., 1986; Otterbein et al., 2001; Wang et al., 2010). 
G-actin assembles into filaments with a period of 13 monomers every six left-handed 
turns, corresponding to a genetic right-handed helix with a period of about 36 nm, as 
shown in figure 1.3b (Holmes et al., 1990; Lorenz et al., 1993; Lorenz et al., 1995; Fujii 
et al., 2010). When G-actin polymerises into F-actin, structural changes in the 
subdomains occur, most notably domain 2 twists by 20° towards the outside of the F-
actin filament while domain 4 twists by 7° towards the centre of the filament, making 
the G-actin monomer in the F-actin state flatter than free G-actin (Oda et al., 2009). 
With this reconfiguration, the nucleotide cleft opens up, resulting in residue Gln137 
mŽǀŝŶŐ ĐůŽƐĞƌ ƚŽ ƚŚĞ ɶ-phosphate of ATP and promoting hydrolysis, starting the 
polymerisation process (Iwasa et al., 2008; Fujii et al., 2010). In the filamentous state, 
all actin monomers points towards the same direction, making the thin filament a 
polar structure with two different ends, termed barbed (or plus (+)) end and pointed 
(or (-)) end. 
ĐƚŝŶ ƉŽůǇŵĞƌŝǌĂƚŝŽŶ ŽĐĐƵƌƐ ŝŶ Ă ƉƌŽĐĞƐƐ ŬŶŽǁŶ ĂƐ  “ƚƌĞĂĚŵŝůůŝŶŐ ? Žƌ  “ŚĞĂĚ  Wto-tail 
ƉŽůǇŵĞƌŝǌĂƚŝŽŶ ? ?ĨŝŐƵƌĞ ? ?4), where the two ends of the filament have different growth 
rates (Pollard and Mooseker, 1981): the fast end is the barbed end while the slow one 
is the pointed end. Defining the critical concentration ܥ଴ as the concentration at which 
the dissociation and association process of monomers at one end are in equilibrium, 
(Wegner and Isenbergt, 1983) found that under physiological conditions, ܥ଴ is about 
12 fold higher at the pointed end (ܥ଴ି = 1.5 µM for the pointed end vs. ܥା଴ = 0.12 µM 
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for the barbed end, see figure 1.4). Above the critical concentration the growth will be 
net at both ends but still going at a faster rate for the barbed end. 
 
 
Figure 1.4: Actin treadmilling. Cartoon of the F-actin polymerisation/depolymerisation dynamics, 
highlighting its dependence on the nucleotide state within each actin monomer.  
 
Actin treadmilling can be altered by several molecules or proteins, most notably formin, 
profilin and cofilin, and completely stopped by end capping proteins CapZ and 
tropomodulin. In particular, formin stabilises actin nuclei and enhances actin 
polymerisation by processive capping, where it binds to the barbed end of the actin 
filaments and provides a template to which G-actin binds (Goode and Eck, 2007; 
Sherer et al., 2018), activity that has been linked to the assembly and maintenance of 
myofibrils (Iskratsch and Ehler, 2011; Fenix et al., 2018). Profilin can instead both 
hamper and accelerate actin polymerisation, by either binding to G-actin in solution, 
sequestering actin monomers, or by increasing the rate of nucleotide exchange, 
respectively (Krishnan and Moens, 2009). Finally, cofilin works to depolymerise actin, 
either by increasing the detachment rate of ADP-actin monomers from the filaments 
or by severing parts of the ADP-actin filaments, to increase the amount of 
depolymerising ends (Carlier et al., 1997; Ichetovkin et al., 2000). 
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End capping proteins CapZ and tropomodulin binds at the (+) and (-) end of F-actin 
respectively, preventing both actin assembly and disassembly. CapZ can be found at 
the Z-disk of the sarcomere and is composed of two ɲ and ɴ subunits very similar in 
sequence. It has been shown that its capping properties come from the last 30 amino 
acids on the C-ƚĞƌŵŝŶĂůƌĞŐŝŽŶŽĨĞĂĐŚƐƵďƵŶŝƚ ?ĂůƐŽƌĞĨĞƌƌĞĚƚŽĂƐ “ƚĞŶƚĂĐůĞƐ ? ) ?ǁŚŝĐŚ
bind to hydrophobic regions of multiple actin subunits and can independently block 
polymerisation (Casellas and Torres, 1994; Wear et al., 2003; Yamashita et al., 2003). 
CapZ has also demonstrated a functional role in the myocytes, with its capping 
dynamics being dependent on exercise (Lin et al., 2013), hypertrophy (Lin et al., 2016) 
or cardiac arrest (Yang and Pyle, 2011). Tropomodulin capping function is instead 
achieved by its binding to three actin monomers and to the two tropomyosin chains on 
either side of the filament at the same time through several low affinity interactions 
(Rao et al., 2014). Tropomodulin does not completely inhibit actin monomer 
dissociation but functions instead as a leaky cap, controlling the thin filament length 
through the alteration of G-actin depolymerisation dynamics (Littlefield et al., 2001; 
Yamashiro et al., 2012; Gokhin et al., 2015). 
A mention as an actin assembly modifier should also go to phalloidin (Estes et al., 
1981). Originating from the poisonous mushroom Amanita Phalloides (Wieland and 
Heinz, 1995), phalloidin binds actin in its cleft region and it has been proven to stabilise 
F-actin and prevent depolymerisation or denaturation when in stoichiometric 
concentrations as low as 1:2 phalloidin:actin (Vandekerckhove et al., 1985; Miyamoto 
et al., 1986; De La Cruz and Pollard, 1994). This stabilisation has proven to not affect 
the contractile properties of myosin binding to actin and cross bridge formation 
(VanBuren et al., 1998), therefore this molecule is nowadays commonly used in a 
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variety of assays to fluorescently label actin filaments, including the experiments in this 
thesis. 
 
1.2.2  ? Tropomyosin 
Tropomyosin is 40 nm long protein dimer, forming a ɲ-helical coiled-coil wrapped 
around actin. In striated muscle, it can be found in two different isoforms, ɲ and ɴ, 
which can assemble ŝŶƚŽ ɲɲ ŚŽŵŽĚŝŵĞƌƐ Žƌ ɲɴ ŚĞƚĞƌŽĚŝŵĞƌ, with percentages in 
cardiac muscle varying between species and age ? ďƵƚ ƚŚĞ ɲɲ ďĞŝŶŐ ƉƌĞĚŽŵŝŶĂŶƚ 
(Lehrer and Qian, 1990; Boussouf et al., 2007). Due to its coiled-coil structure, it is 
arranged in a-b-c-d-e-f-g pseudo-heptad repeats, as seen in figure 1.5a and b, where a 
and d are non-polar amino acids, and e and g are charged. Within the coiled-coil, the 
two monomers are in contact through hydrophobic interactions between amino acids 
a-Ă ? ĂŶĚ Ě-Ě ? ĂŶĚ ƚŚƌŽƵŐŚ ĞůĞĐƚƌŽƐƚĂƚŝĐ ĨŽƌĐĞƐ ďĞƚǁĞĞŶ Ğ-Ő ? ĂŶĚ Ő-Ğ ? ? &ŝŶĂůůǇ ? Ă ƐĂůƚ
bridge between residues e and g confers stability to the whole structure (McLachlan 




 Figure 1.5 : The coiled-coil structure of tropomyosin. The heptad repeat of tropomyosin visualised in a) 
section and b) linearly, where amino acids denoted as N are non-polar, A are acidic, B are basic and X are 
polar; c) Structural view of one of the coiled coil tropomyosin filaments as bound to F-actin. Adapted 
from (Perry, 2001) and PDB structures 5JLF from (von der Ecken et al., 2015) and 2G9J from (Greenfield 
et al., 2006). 
 
Tropomyosin polymerizes on actin, spanning along seven actin monomers (a shortened 
version is visualised in figure 1.5c), in a head to tail fashion, in which the N-terminus is 
positioned between the two previous C-ƚĞƌŵŝŶĂůɲ-helices (also called knob-into-hole 
ĐŽŶĨŝŐƵƌĂƚŝŽŶ ) ?ĨŽƌŵŝŶŐĂĨŽƵƌɲ-helices superstructure called the overlap region (figure 
1.5d). This configuration is caused by a water molecule that disrupts the C-terminus of 
tropomyosin, breaking the local 2-fold symmetry and causing its splaying to 
accommodate the N-terminus (Murakami et al., 2008). Although the stability of the 
whole region is decreased, this configuration allows the binding of another thin 
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filament protein, troponin, as will be discussed in the next section, which overall 
creates a stable structure (Li et al., 2002; Palm et al., 2003). The overlap region is also 
highly dynamic and is partly responsible for tropomyosin elasticity and flexibility and it 
acts as a swivel as it transitions and moves across the actin filament (Greenfield et al., 
2006; Murakami et al., 2008). The length of the overlap region varies between 
isoforms, from 9 residues of skeletal tropomyosin to the 15 residues necessary in 
smooth muscle (Frye et al., 2010). Furthermore, the surface of tropomyosin is mostly 
negatively charged therefore on the thin filament it tends to occupy a positively 
charged groove on the actin surface, at ~40 Å from the centre of F-Actin (von der 
Ecken et al., 2015). This position is also responsible for stabilising and increasing the 
stiffness of the actin filament, by strengthening interactions between adjacent actin 
monomers (Kojima et al., 1994; Isambert et al., 1995; Khaitlina et al., 2017). 
Native tropomyosin is acetylated on its N-terminus, which provides extra stability and 
greatly improves tropomyosin binding to actin. In fact, it has been shown that 
unacetylated tropomyosin expressed in E.coli is not capable of binding actin and does 
not show head to tail polymerisation (Hitchcock-DeGregori and Heald, 1987). However, 
substitutes for acetylation have been engineered, such as the addition of an alanine 
followed by a serine at its N-terminus, capable of fully recovering tropomyosin 
function (Monteiro et al., 1994; Urbancikova and Hitchcock-DeGregori, 1994). 
 
1.2.3  ? Troponin 
Troponin is a complex of three proteins, Troponin T (TnT), Troponin I (TnI) and 
Troponin C (TnC). Each of these subunits has a specific role in muscle contraction, 
reflected in their names: TnT is responsible for holding together each of the other 
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subunits on the thin filament, having binding sites for both actin and tropomyosin, TnI 
is the inhibitory part of troponin, since it binds actin and inhibits myosin ATPase while 
TnC can bind calcium, starting the whole process of thin filament activation. 
Troponin T can be cleaved by chymotrypsin into two different subunits, TnT1 (the N-
terminal region, 1-158 amino acids) and TnT2 (the C-terminal region), which possess 
two different functions. TnT1 binds to the overlap region of tropomyosin, specifically 
within residues 258-284 of its C-terminus, as inferred by (Li et al., 2002) by looking at 
the crystal structure of the overlap region and at conserved residues within species. 
TnT2 can bind to TnI (together sharing a coiled coil (Stefancsik et al., 1998)), TnC and 
Tm. It extends from TnT1 to tropomyosin, reaching in the region around its residue 190 
(Chong and Hodges, 1982; Morris and Lehrer, 1984) and possibly stabilising its position 
on actin in the absence of calcium while, in the presence of Ca2+, this interaction is 
weakened for a more stable binding to TnC (Pearlstone and Smillie, 1982). In particular, 
deletion of the last 14 amino acids of TnT2 have been seen causing an increase in 
myosin-S1 ATPase, further suggesting that the C-terminus is partly responsible for 
holding tropomyosin in the blocked position on actin (Franklin et al., 2012). However, 
in (Pearlstone and Smillie, 1982) TnT showed this behaviour only with skeletal and not 
aorta tropomyosin. Furthermore, (Dahiya et al., 1994) have shown that cardiac Tn-Tm 
complex affinity to actin is greater in skeletal muscle compared to cardiac muscle, 
suggesting that these calcium dependences might be caused by small changes in the 
amino acids structures between different isoforms. 
Troponin I is the inhibitory subunit of troponin and is composed of several regions, as 





Figure 1.6: The troponin complex substructure. Cartoon of the troponin complex bound to tropomyosin 
and actin, color coded for TnI (cyan), TnC (red), TnT (yellow and orange), actin (white) and tropomyosin 
(pink), adapted from (Yang et al., 2014). 
 
Its first 30 N-terminal residues are present only in its cardiac isoform and interacts with 
the N-terminus of TnC. Phosphorylation of two sites present in this region weakens 
interaction with TnC, decreasing calcium sensitivity, as well as increasing relaxation 
and cross-bridge cycling (Howarth et al., 2007). Following this region, a pair of ɲ-
helices are connected by a small linker which, together with TnT, form a W-shape 
called the IT arm. This region of TnI is mainly structural and its primary role is to 
orientate TnI and communicate the motion and structural changes within troponin 
itself, upon calcium binding. In particular, of these two helices, the first one (H1) binds 
to TnC while the second one (H2) forms a coiled-coil with one of the ɲ-helices of TnT 
(Takeda et al., 2003; Yang et al., 2014). 
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After the IT arm is the inhibitory region, which is known to bind to actin in a 1:1 
stoichiometry ratio on its own and in a 1:7 ratio in the presence of tropomyosin (Potter 
& Gergely, 1974; Syska et al., 1976). This peptide also shows differences between 
cardiac TnI and skeletal TnI; specifically, in cTnI this peptide tends to be less ordered 
than in sTnI, making it generally difficult to crystallize (Vinogradova et al., 2005). 
The last section of TnI is the switch peptide, fundamental for thin filament activation, 
since it has a strong affinity for the N-terminal of TnC in the presence of calcium. When 
the switch peptide is bound to TnC, it promotes a conformational change in the entire 
troponin complex, resulting in the release of its inhibitory domain from actin and in the 
subsequent movement of tropomyosin in the closed position, favouring myosin 
binding (Jayasundar et al., 2014; Yang et al., 2014). 
The last subdomain of troponin, troponin C, consists of 
two globular domains separated by a ɲ-helix (figure 
1.7) (Houdusse et al., 1997) and is the calcium sensor 
of the thin filament. The short and rigid ɲ-helix 
connecting the N- and C-terminals is thought to 
function as a mediator between the two, with 
thermodynamic studies finding an inverse dependence 
ŽĨĞĂĐŚŽƚŚĞƌ ?ƐƐƚĂďŝůŝƚǇŝŶƚŚĞƉresence of calcium (De 
Oliveira et al., 2013). 
Each globular domain is able to accommodate two 
Mg2+ or Ca2+ ions, however there are differences 
between the two. In particular, the C-terminal binding 
domains have a similar affinity to either Mg2+ and Ca2+ (about 107 M-1), the former 
Figure 1.7: The crystal 
structure of troponin C. 
Cartoon of the crystal structure 
of skeletal TroponinC, showing 
the four coordination sites (I-
IV), adapted from PDB 2TN4. 
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being mostly bound when the muscle is in relaxed conditions, while the N-terminal 
domain is highly specific to calcium, its affinity for it being of about 105 M-1. The C-
terminal sites are also considered to be structural, since they promote TnC to TnI and 
TnT binding (Zot and Potter, 1982; Ingraham and Swenson, 1984) and FRET 
experiments performed by (Badr et al., 2016) have evidenced conformational changes 
upon either Mg2+ or Ca2+ binding to site III or IV. Moreover, in cardiac muscle, due to 
small changes in the amino acid sequence, the N-terminus of TnC can only host one 
Ca2+ ion (van Eerd and Takahashi, 1975). In the N-terminus domain is also a 
hydrophobic pocket which possesses the fundamental role of transmitting the Ca2+ 
signal to the rest of the thin filament. Upon Ca2+ binding to this region, the interaction 
between TnC and TnI is also favoured, leading to the detachment of TnI from actin and 
the release of tropomyosin (Takeda et al., 2003). 
 
 
1.3  ? The thick filament and Myosin II 
 
Myosin II (termed myosin from now on) is the main protein in the thick filament and 
the molecular motor that drives muscle contraction. It is a complex of two heavy 
chains and four light chains (two Essential Light Chains (ELC) and two Regulatory Light 




 Figure 1.8: The structure of myosin II and the thick filament. a) diagram of myosin II, showing the tail 
(LMM and S2), neck and head region (S1) and its crystal structure (adapted from (Squire, 2009)) 
highlighting its lever arm section (red) and motor domain (green); b) cartoon of the thick filament, 
showing the three-stranded helical pattern and the  crowns periodicity of 43 nm, adapted from (Al-
Khayat, 2013); c) cross section of the A band of the sarcomere, showing the hexagonal arrangement of 
thick and thin filaments (taken from (Mijailovich et al., 2016)).  
 
As shown in figure 1.8a, each myosin heavy chain is composed of a tail, a neck region 
and a head. The two heavy chains are bound together through their tails, which form a 
coiled-coil up until the neck region. The tails of several myosin complexes can then 
assemble into the thick filament through electrostatic interactions, forming a structure 
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in which the myosin tails are the main component of a long fibre, from which the 
heads project outwards. The resulting thick filament is then a three-stranded right 
handed quasi-helical fibre, with consecutive heads at a distance of 14.5 nm, requiring 
nine heads for a complete turn (figure 1.8b). However, since the filament is three 
stranded, its periodicity is of 43 nm. Viewing the thick filament along its axis, as shown 
in figure 1.8b, three myosin heads project outwards every 14.5 nm, forming a crown. 
Each thick filament is then surrounded by six thin filaments in a hexagonal 
configuration, with the thick filament in the middle, allowing each thin filament to be 
reached by three myosins (figure 1.8c). 
Myosin can be cleaved by two proteases in two different regions. Digestion with 
chymotrypsin divides myosin in two regions, the heavy meromyosin (HMM) and the 
light meromyosin (LMM), while digestion with papain removes the myosin head (or S1, 
figure 1.8a), keeping both of the light chains (Lowey et al., 1969). The S2 portion of the 
thick filament rod (part of the HMM, figure 1.8a) is only loosely associated with the 
rest of the thick filament (McLachlan and Karn, 1982) and contains a hinge, a section of 
the ɲ-helical coiled-coil which helps the myosin heads reach the actin filament and is 
also partly responsible for tension generation during muscle contraction (Burke et al., 
1973; Stewart and Roberts, 1982; Stewart and Edwards, 1984; Miller et al., 2009). 
The myosin-S1 structure, shown in figure 1.8a, was first solved by (Rayment, W. R. 
Rypniewski, et al., 1993). It consists of three main subdomains, a 25 kDa domain, a 50 
kDa domain and a 20 kDa domain. The 25 kDa domain most notable feature is the P-
loop, to which the ɲ- ĂŶĚɴ-phosphate of the ATP bind. The 50 kDa domain contains 
the actin binding sites. It is separated by a central cleft, dividing it into lower and upper 
50 kDa domain. The last section of the myosin head is the lever arm, a 20 kDa domain 
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constituted by a ɲ-helix coming from the myosin tail or C-terminus, consisting in the 
converter domain (position Phe-707 to Arg-774 (Houdusse et al., 1999; Houdusse et al., 
2000)), and the myosin light chains binding region, the ELC and RLC. 
The role of the two light chains is still a matter of discussion and differences have been 
seen among the various isoforms expressed in muscles (Logvinova and Levitsky, 2018). 
Both the RLC and ELC have been shown to have a structural role in stabilising the neck 
region (Rayment et al., 1993), although they exert different functions on myosin 
binding to actin. Specifically, removing both light chains from myosin reduced the 
speed of actin filaments in the motility assay but without affecting actin-activated 
myosin ATPase (Lowey et al., 1993). Later studies showed that removal of the ELC only 
produces a 50% decrease in the isometric force, ruling out the effect of the RLC in 
force production (VanBuren et al., 1994), while also assigning the ELC a role in myosin 
strong binding to actin (Guhathakurta et al., 2015; Logvinova et al., 2018). However, 
the RLC has been shown to be important for correct folding of smooth muscle myosin 
(Trybus and Lowey, 1988) and lattice spacing (Colson et al., 2010), while its 
phosphorylation is known to be important for myosin head orientation (Scruggs and 
Solaro, 2011; Burghardt and Sikkink, 2013; Kampourakis and Irving, 2015). 
 
 
1.4  ? The cross-bridge cycle 
 
Muscle contraction is caused by the thin and thick filament sliding relative to each 
other, as was suggested by A. F. Huxley and H. Huxley in two separate studies 
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published at the same time in 1954 (Huxley and Hanson, 1954; Huxley and Niedergerke, 
1954). According to the  “sliding filament theory ?, contraction is the result of cyclical 
and highly regulated acto-myosin interactions that generate force, the underlying 




where A indicates actin and M myosin (taken from (Lymn and Taylor, 1971)). Starting 
from the rigor-like acto-myosin complex (AM), adding ATP (step 4, k4 of ~1 µM
-1s-1) 
results in a myosin detachment from actin (steps 5, k5 >1000 s
-1). This provokes the 
opening of the central cleft in myosin 50 kDa domain, promoting ATP hydrolysis into 
ADP and Pi (step 2, k2 of ~125 s
-1 (Johnson and Taylor, 1978)). In this state, M·ADP·Pi is 
ŝŶĂ  “ĐŽĐŬĞĚƐƚĂƚĞ ?ĂŶĚable to bind actin again, first weakly, with the lower 50 kDa 
domain functioning as initial contact, then strongly (AM·ADP·Pi, step 6, k6 of ~0.3 µM
-
1s-1), with the closing of the central cleft resulting in the upper 50 kDa domain binding 
to actin. Finally, the ADP and Pi are released (step 7), while the myosin lever arm 
swings the myosin head producing force and motion in what is called a power stroke 
(Huxley, 1969; Uyeda et al., 1996). The length over which a myosin is able to push the 
thin filament has been calculated by (Kad et al., 2005) to be of approximately 5 nm for 
the first step on regulated thin filaments and 11 nm for subsequent steps and 
unregulated actin. Although myosin II consists of two heavy chains and two heads, only 
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one head has been shown to be necessary to achieve the maximum sliding length, with 
the second head believed to be necessary for the orientation of the first one (Tyska et 
al., 1999; Kad et al., 2003). Moreover, in the absence of actin myosin is still capable of 
binding and hydrolysing ATP (steps 1 to 3) the reaction rate for the product release is 
much slower than in the presence of actin (k3 of ~0.05 s
-1 vs k7 of ~10 s
-1), and the 
latter case is usually referred to as the actin-activated myosin ATPase (Lymn and Taylor, 
1971). Recent studies have also demonstrated that myosin heads can be sequestered 
from actin bindiŶŐ ?ŝŶǁŚĂƚŝƐĐĂůůĞĚƚŚĞ “ƐƵƉĞƌƌĞůĂǆĞĚƐƚĂƚĞ ?(Hooijman et al., 2011). 
In this configuration, associated with a folding back of the myosin head over its tail 
(Alamo et al., 2016; Nogara et al., 2016), myosin exhibits a very slow ATP turnover rate 
(about 30 minutes (Naber et al., 2011)), thought to be necessary to limit the metabolic 
rate of muscle in relaxing conditions (Stewart et al., 2010). 
Myosin binding to actin has been later revealed to occur in two steps, first through a 
weak binding, with the lower 50 kDa domain functioning as initial contact, then 
through strong binding, with the closing of the central cleft resulting in the upper 50 
kDa domain binding to actin (Coates et al., 1985; Behrmann et al., 2012). Particularly, 
this motion is calcium dependent and linked to tropomyosin position on actin, in a 






Figure 1.9: Diagram of the three states of the thin filament. Myosin interacting with the thin filament, 
highlighting the blocked, closed and open position. Taken from (Mckillop and Geeves, 1993) 
 
This model, pictured in figure 1.9, states that tropomyosin can occupy three different 
positions on actin, the blocked (B), closed (C) and open (M) position, or thin-filament 
 “ƐƚĂƚĞƐ ?ŽĨƚŚĞŽƉĞŶŝŶŐŽĨƚŚĞŵǇŽƐŝŶďŝŶĚŝŶŐƐŝƚĞs on actin. When the thin filament is 
in the blocked state, tropomyosin is derepressed by Troponin I and occupies the 
myosin binding sites on actin (Lehman et al., 2000), sterically blocking myosin from 
binding to actin. In this state, tropomyosin interacts through ~30 salt bridges with actin 
subdomain 1 and 2, particularly with actin residues Lys326, Lys328 and Arg147, as well 
as with Asp25 and Arg28. In the closed state, however, tropomyosin moves towards 
subdomains 3 and 4, losing its interaction with actin residues Asp25 and Arg28 but 
approaching residues Asp311 and Lys315 (Li et al., 2011; Lehman et al., 2013). Here, 
myosin binding sites are partially available, allowing myosin to bind weakly to actin 
through the lower 50 kDa domain. Finally, the closure of the myosin cleft pushes 
tropomyosin from the closed to open position, fully uncovering other nearby myosin 
binding sites, resulting in cooperative activation of the thin filament (Mckillop and 
Geeves, 1993; Heeley et al., 2006; Behrmann et al., 2012). Once in the M position, 
tropomyosin interaction with actin is now reduced to ~11 salt bridges with actin 
(residue Lys315) and another 5 with myosin, particularly with Arg288 (Lehman et al., 
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2013). There is still controversy over the precise mechanism of tropomyosin 
movement on actin however, several structural studies have demonstrated that the 
movement occurs and highlighted its different positions (Lorenz et al., 1995; Poole et 
al., 2006; von der Ecken et al., 2015; Rynkiewicz et al., 2016). 
Since tropomyosin is bound to actin and troponin, the population of the thin-filament 
activation states strongly depends on calcium (Fraser and Marston, 1995; Homsher et 
al., 1996). In the absence of Ca2+ about 76% of the thin-filament is in the blocked state, 
about 22% in the closed state and <2% in the open state. In the presence of Ca2+, 
however, these change to <5%, 80% and 20% in the blocked, closed and open position 
respectively (Mckillop and Geeves, 1993). Structural studies using native thin filaments 
have shown that tropomyosin can switch between these three states, with a 
preference for the blocked and closed states 
(Risi et al., 2017; Kiani et al., 2018). However, 
calcium alone is not able to fully activate the 
thin filament and the initial binding of a 
myosin head is necessary for cooperative 
activation (Kad et al., 2005; Heeley et al., 
2006; Desai et al., 2015).  
Cooperative activation of the thin filament 
has been seen as early as (Lehrer and Morris, 
1982), where the authors studied the ATPase 
activity dependence on the myosin-S1 
concentration at saturating ATP, in the 
presence of actin and/or tropomyosin, troponin and Ca2+. As seen in figure 1.10, in the 
Figure 1.10: The effect of regulatory 
proteins on the acto-S1 ATPase. Graph of 
the actin activated ATPase of S1 at 
saturating ATP in the presence and absence 
of regulatory proteins and calcium. Taken 
from (Lehrer and Geeves, 1998). 
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presence of actin only and away from Vmax, the ATPase activity increases linearly with 
increasing amounts of S1, following a standard Michaelis Menten plot. The addition of 
Tm, Tn and calcium turns the relationship into a sigmoidal, with the cooperative 
activation particularly seen for actin.Tm, where the ATPase is lower than that of actin 
alone until about [S1] = 5 µM; the addition of troponin is seen closing the thin filament 
completely until calcium is added, in which case the ATPase is higher than that of actin 
alone (Lehrer and Morris, 1982; Lehrer and Geeves, 1998).  
When considering cooperative activation, the size of the regulatory unit, (i.e. the 
smallest region activated by a single myosin head, also called cooperative unit) 
becomes important. Initial studies had looked at the extension of tropomyosin over 
seven actin subunits and showed the size of the cooperative unit length to be of about 
40 nm. However, as mention in chapter 1.2.2, tropomyosin is a rather stiff polymer 
and can communicate strain to neighbouring monomers via the overlap region. In 
particular, the cooperative unit has been shown to vary within experiments, from the 
one calculated in the absence of troponin to be about 5 to 6 monomers versus 10 to 12 
monomers of the full thin filament in (Geeves and Lehrer, 1994) and up to ~20 
monomers (110 nm) in (Kad et al., 2005). 
 
 
1.5  ? Myosin Binding Protein-C 
 
Myosin Binding Protein-C (MyBP-C or C-protein in some of the older literature) is a 
thick filament protein and was first found as an impurity in myosin purifications (Offer 
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et al., 1973). Since its discovery, it has increasingly shown it is an important player in 
muscle contraction, as will be discussed in more details in this chapter and in chapter 5 
of this thesis. MyBP-C comes in different isoforms, cardiac and slow and fast skeletal, 
depending on the type of muscle where it is produced (Weber et al., 1993; Yasuda et 
al., 1995). However, I will focus this sub-chapter on the cardiac isoform, which is the 
one that has been used in the experiments for this thesis. 
Cardiac MyBP-C is composed of 11 subdomains (figure 1.11), named from C0 to C10, of 
which 8 are Ig-like (C0 to C5, C8 and C10) and 3 are FnIII-like domains (C6, C7 and C9) 
(Okagaki et al., 1993). 
 
 
Figure 1.11: Cardiac MyBP-C and its subdomains in relation with the thick and thin filaments. cMyBP-C 
is composed of eleven subdomains, of which eight are Ig-like domains (C0 to C5, C8 and C10) and three 
Fn(III)-like domains (C6, C7 and C9); PA indicates the short Proline-Alanine rich domain and M the 





Between domain C0 and C1, is a region rich in Proline and Alanine called the PA region 
and between domains C1 and C2 the M-domain is found, which is partially disordered 
and possess three of the four phosphorylation sites found in MyBP-C. 
MyBP-C is found in seven to nine bands, spaced 43 nm apart, in each side of the A 
band in the sarcomere, as shown by (Luther et al., 2011) (figure 1.11). Structural 
studies have shown that its C-terminus is bound to the thick filament and titin in 
particular, through domains C8-C10 (Freiburg and Gautel, 1996; Flashman et al., 2004). 
This interaction is mainly structural, since there seem to be no other function 
associated with MyBP-C C-terminal domains. The N-terminus, instead, seems to have a 
double function in muscle contraction: it has been shown several times that it is both 
capable of binding actin and myosin heavy chain. For instance, the N-terminal domains 
can bind myosin in the S2 region (Starr and Offer, 1978; Gruen and Gautel, 1999) and 
to its regulatory light chain (Lu et al., 2011; Ratti et al., 2011). Studies performed by 
(McNamara et al., 2016) suggest that these interactions serves to stabilise ŵǇŽƐŝŶ ?Ɛ
super-relaxed state, since mice lacking MyBP-C have shown increased ATP turnover. 
Other studies have been focused on the binding properties of the N-terminus to actin 
and on its function as a modulator of cross bridges formation, showing that there are 
several actin binding sites between subdomains C0 and C2. In in vitro motility 
experiments, different N-terminal fragments have been seen exerting different effects 
on thin filaments speed and fraction moving (Razumova et al., 2006). In particular, 
increasing amounts of C0C2 are capable of increasing thin-filament speed at low 
calcium, effectively activating motility, while inhibiting speed at high calcium. A shorter 
fragment, C0C1, has not shown these capabilities while, when using subdomains C2 to 
C4 only, the activation effect at low calcium disappears. Structural studies (Harris et al., 
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2016; Mun et al., 2014; Mun et al., 2011) have later shown that MyBP-C can directly 
push tropomyosin away from its blocked position, suggesting that the activation effect 
seen at low calcium might be caused by an increase in amount of available myosin 
sites on the thin filament; at the same time, they provided evidence that MyBP-C 
shares some of its binding sites on actin with myosin, possibly explaining the inhibition 
effect seen at high calcium with a direct competition for binding. 
It is worth taking into account the possibility that some of these effects could be 
inherent to the assay used and not be present in vivo. For instance, (Walcott et al., 
2015) have shown that direct competition alone does not fully explain thin filament 
behaviour in the presence of MyBP-C N-terminal fragments at high calcium. Hence, to 
fully model the system, we must take into account the viscous drag produced by 
transient interactions between MyBP-C, actin and the surface of the coverslip. 
Similar results have been obtained using laser tweezers by (Weith et al., 2012), where 
they report MyBP-C binding to actin transiently and with two specific lifetimes: a short 
one, of about 20 ms and a long one, greater than 200 ms. In addition, they also show 
the importance of the first 17 amino acids after C1 for actin binding, providing an 
explanation for the behaviour observed by fragments that do not possess the M-
domain. In a following study, Previs et al. were able to measure changes in the speed 
of native thin filaments moving along isolated thick filaments, showing a decrease in 
average speed within the MyBP-C containing C-zone (Previs et al., 2012), further 
supporting the viscous load model. 
Another study reporting activating and inhibitory effects has been performed by 
(Belknap et al., 2014), looking at changes in actin-activated myosin steady-state 





Figure 1.12: The effects of C0C2 on myosin ATPase. S1 ATPase activity at increasing concentration of 
C0C2 and a) naked actin, b) thin filaments at pCa 4 and c) thin filaments at pCa 8, adapted from (Belknap 
et al., 2014). 
 
In their study, they also suggest that MyBP-C cooperatively binds to actin, as evidenced 
by the lag phase seen at low [C0C2] in figure 1.12a and by the Hill coefficients greater 
than 1 calculated from fitting the data in figure 1.12b and c. In addition, they also 
reported intra-species behavioural differences when studying myosin ATPase with 
native thin filaments and C0C1 at low calcium, which they attribute arising from the 
poor amino acids sequence similarities in the PA region between mouse and human 
MyBP-C (Belknap et al., 2014), but could also be caused by an 8-amino acids N-
terminal extension known to interfere with RLC binding (Bunch et al., 2018). 
So far, the properties of the N-terminus as a whole have been discussed; however, a 
particular mention is needed for the M-domain, as it has interestingly different 
structural features compared with the rest of the protein. It is known to be largely 
disordered, with the exception of three compact ɲ-helices at its C-terminal. The last 
helix in particular shares similarities with other actin binding domains found in other 
proteins (Howarth et al., 2012). Upon phosphorylation, MyBP-C N-terminal fragment 
C0C3 has been seen closing in, suggesting the presence of a hinge within the M-
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domain (Colson et al., 2016; Previs et al., 2016). Force-extension curves obtained using 
the atomic force microscope have also found this domain to be extensible at very low 
forces (Karsai et al., 2011, 2013). This could be important when considering MyBP-C 
tether to the thick filament, suggesting that the M-domain might partially extend when 
domains C0 and C1 are bound to the thin filament (Luther and Craig, 2011). 
To date, the physiological role of MyBP-C is still not very well understood but there is a 
clear consensus on it working as a modulator of muscle contraction. The studies so far 
suggest that MyBP-C could alternate between binding to myosin, stabilising its position 
on the thick filament in the super-relaxed state, and actin, activating the thin filament 
when necessary (Kulikovskaya et al., 2003). 
 
 
1.6  ? Hypertrophic Cardiomyopathy 
1.6.1  ? Physiological effects 
Hypertrophic Cardiomyopathy (HCM) is a genetic disease that affects 1:200 individuals 
(Semsarian et al., 2015) and is the leading cause of sudden cardiac death in young 
adults. It was first reported by (Teare, 1958), which noted several cases of 
asymmetrical hypertrophy linked to sudden death of patients, and soon after found to 
be a genetic condition (Hollman et al., 1959).  
When compared to a healthy heart, a HCM affected heart is characterised by an 
increase in thickness of the left ventricular wall and the interventricular septum, as 





Figure 1.13: The effects of hypertrophic cardiomyopathy on the heart. Comparison between a) the 
section of a normal heart versus one affected by HCM and b) the arrangement of the myocytes in 
healthy versus hypertrophic tissue. Adapted from (Chung et al., 2003). 
 
Beside hypertrophy of the heart walls, HCM is also characterised by myocyte disarray 
and an increase in interstitial fibrosis between them (figure 1.13b). To date, however, 
it is still not clear whether this is a cause of HCM or a consequence of the disease. 
Patients affected with HCM have shown an increase in force production during systole 
and an impaired relaxation during diastole (B. J. Maron et al., 2012; M. S. Maron et al., 
2009). It is mostly asymptomatic but patients can show atrial fibrillation and chest pain 
caused by imbalances of blood supply and demand. Today, the annual mortality rate 
for patients affected by HCM is ~ 1% (Houston and Stevens, 2015). 
There is some variability in the symptoms and effects of HCM within different age 
groups (Arad et al., 2002). For instance, young adults have lower chances of showing a 
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genotype, compared to older patients; however, in both cases, about 20% of the 
patients experienced HCM morbidity or mortality (Loar et al., 2015). Furthermore, 
Coppini et al. studied the incidence of thin filament vs. thick filament mutations, 
showing that the former are related to milder hypertrophy but higher prevalence of 
systolic dysfunction and same rates of sudden cardiac death (Coppini et al., 2014). It 
has also been noted that, although HCM affects men and women at the same rate, 
deaths in young athletes are more common in males (Van Camp et al., 1995). 
 
1.6.2  ? Notable mutations and where to find them 
To date, more than 1400 mutations have been associated with HCM, spanning more 
than 11 genes (Maron et al., 2012). Within these, about 40% are found in the MYH7 
gene, which encodes for ɴ-cardiac myosin II, about 33% in the MBPC3 gene, which 
encodes for MyBP-C, and the remaining are found in all the other genes associated to 
most of the proteins found within the sarcomere, in 1-5% each, including troponin and 
tropomyosin (Maron et al., 2012; Marsiglia and Pereira, 2014). However, with the 
advances in genetic screening, more are found every day (Liu et al., 2015; Lopes et al., 
2015). The majority of hypertrophic cardiomyopathy causing mutations are missense, 
except for the MYBPC3 gene, for which truncations or deletions are more common, as 
extensively reviewed in (Marian and Braunwald, 2017). Each of these mutations affect 
acto-myosin interactions in a different way, with some leading to a more severe clinical 
phenotype than others. However, it has been argued that there is a general trend with 
the effect of HCM mutations on muscle contractility, where they usually linked with an 
increase in calcium sensitivity and impediment of a complete muscle relaxation at low 
calcium, as evidenced from figure 1.14 (Marston, 2011). Furthermore, having multiple 
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different mutations highly increases the chances of a severe phenotype and early 
onset (Kelly and Semsarian, 2009). 
 
 
Figure 1.14: HCM mutations and their effect. List of the most known HCM mutations with their 
associated effect on contraction mechanism. Adapted from (Marston, 2011). 
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One of the most extensively studied mutations is R403Q, the first to be discovered in 
myosin, notable for its severe phenotype (Epstein et al., 1992). It is located in close 
proximity of the actin binding site on myosin head and has been subject of controversy 
since different groups have found contrasting results. In particular, working with full 
mouse myosin and performing both single molecule and in-vitro motility experiments, 
(Tyska et al., 2000) reported that mutation R403Q causes a two-fold increase in 
average force production but not at the single molecule level in laser trap assay 
(Palmiter et al., 2000; Tyska et al., 2000). In contrast, recent experiments performed by 
(Nag et al., 2015) have showed an overall decreased activity in the mutated myosin 
and especially in the actin-activated ATPase activity in the presence of reconstituted 
thin filaments. These differences have been associated with the genetic differences 
between mouse and human ɴ-cardiac myosin and with the use of the recombinant 
truncated versions over the full protein.  
In recent years, the existence of a conserved region in the myosin head (ĐĂůůĞĚ “ŵĞƐĂ ?) 
has been highlighted, where a high number of HCM mutations are located (Spudich, 
2015). Evidence suggests that this region of the myosin head is responsible for the 
turning off of the thick filament, which occurs when the myosin head bends backwards 
binding to the S2 region of myosin (Nag et al., 2017; Robert-Paganing et al., 2018). 
HCM mutations in this regions, such as R249Q, R453C and H251N have been linked to 
a weakening of this interaction, which could lead to an increase in myosin heads 
available for binding to the thin filament and account for the increase in ATPase 
activity and force produced during muscle contraction (Adhikari et al., 2016; Nag et al., 
2017; Trivedi et al., 2017). 
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Other mutations have been found throughout the whole myosin heavy chain and most 
of them seem to affect the ATPase activity and increase calcium sensitivity, such as the 
R719W (Kohler et al., 2002; Kirschner et al., 2005) and D778G (Miller et al., 2003), as 
reviewed in (Marston, 2011) and (Moore et al., 2012). 
Mutations in MyBP-C are somewhat different from the ones found in myosin. Overall, 
its mutations are found to have a mostly mild phenotype and are generally related to 
late onset HCM. However, only one third of all the mutations found seem to be caused 
by a change in a single amino acid (found throughout the whole protein with the 
exception of the Pro-Ala region), while another third are caused by frame shifts, with 
the remaining being truncations, insertion or deletions, mostly affecting the C-terminal 
end of the protein (Harris et al., 2011). Furthermore, like in myosin, patients affected 
by more than one mutation at once experience a more severe phenotype (Van Driest 
et al., 2004). 
Mutations in MyBP-C have been shown to provoke HCM through haploinsufficiency (a 
reduction in the level of expressed functional protein to 50% of the normal amount in 
a cell, resulting in loss of function) (Glazier et al., 2018). Marston et al, studying nine 
different truncation and missense mutations in the MBPC3 gene found that the 
amount of MyBP-C expressed in the sarcomere was 24% lower than the wildtype, 
which they linked to the hypertrophy in the samples (Marston et al., 2009). However, 
they found no specific truncated protein in muscle homogenates, similarly to what 
others reported for different truncating mutations. This would suggest that the 
expressed truncated proteins are quickly degraded either by ubiquitin-proteasome 
system (UPS) or nonsense-mediated mRNA decay (NMD) and do not affect sarcomere 
function per se (Rottbauer et al., 1997; Moolman et al., 2000; Van Dijk et al., 2009; 
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Marston et al., 2012; Leary et al., 2019). On the contrary, missense mutation A31P 
found in subdomain C0 has been reported to alter the subdomain structure and alter 
myocyte function through a poison peptide mechanism (Van Dijk et al., 2016). 
Several studies have used mouse models to reproduce HCM mutations in MyBP-C. 
Among all, (Yang et al., 1998) have reported that the truncation of the C-terminal end, 
containing the binding domains for the thick filament, causes hypertrophy of the heart 
and disarray of the myocytes. Another study by (van Dijk et al., 2015) has shown that 
mice lacking the PA region and subdomain C1 did not produce over-contractility. These 
findings are consistent with what reported in a similar study by (Witt et al., 2001), 
where the same mutation was found to not cause an overall increase in force 
produced, although increasing Ca2+ sensitivity. Phosphorylation of MyBP-C also plays a 
role in hypertrophic cardiomyopathy. In their paper, (Jacques et al., 2008) have found 
that failing hypertrophic human heart muscles showed a 40% decrease in 
phosphorylation compared to normal hearts. However, this change was not dependent 
on whether the failing heart possessed a mutation in MBPC3 gene, since they studied 
mutations that cause a truncation of the protein. 
Tropomyosin mutations are found in about 5% of the patients affected by HCM, 
indicating its importance in regulating the accessibility of the thin filament for myosin, 
since any mutation most likely impacts survivability. Hence, they can give useful 
insights into how tropomyosin regulates acto-myosin interactions and to study the 
cooperative unit size on actin. HCM mutations on tropomyosin have been found in 
large part in the region in close proximity of Cys190, a very conserved residue 
important for Tm-actin interactions (Bai et al., 2013), which is oxidised in failing heart, 
crosslinking the two coils together (Koubassova et al., 2018). 
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Studies have focused on two main aspects of these tropomyosin mutations: their 
effect on its binding to actin and their importance on tropomyosin flexibility. Mutants 
D175N, E180G and L185R fall within both categories but are known to have different 
effects, despite their close position, with E180G having the stronger phenotype. For 
instance, D175N and E180G weaken Tm affinity to actin, while L185R increases it 
(Golitsina et al., 1997; Kremneva et al., 2004; Zheng et al., 2016). Furthermore, using 
circular dichroism (Kremneva et al., 2004) found that the E180G thermal stability is 
reduced both in the absence and presence of actin, meaning that Tm-Tm and Tm-actin 
interactions are weakened, while D175N did not appear different from the control. In 
particular, the E180G thermal denaturation occurred at temperatures closer to normal 
or resting body condition, as also reported by (Wang et al., 2011). E180G and D175N 
have also shown to reduce cooperativity (reduction in the Hill coefficient) in in vitro 
motility assays, while E180G and L185R also increases calcium sensitivity, and ATPase 
activity (Bottinelli et al., 1998; Chang et al., 2005, 2014; Boussouf et al., 2007; Wang et 
al., 2011). Through molecular dynamics simulations and atomic force microscopy 
studies, these changes have been correlated with an increased flexibility of the 
polymer (Li et al., 2012; Loong et al., 2012; Sewanan et al., 2016), thought to be caused 
by a local disruption of coil-coil interactions and actin-Tm interactions (Mathur et al., 
2011; Ly and Lehrer, 2012; Matyushenko et al., 2017). Furthermore, (Bai et al., 2011) 
studied the effects of E180G and D175N on tension produced in reconstituted 
myocardia, showing an increase in low calcium tension for both and stiffness, greater 
calcium sensitivity but reduced cooperativity for E180G. These changes can be related 
to a higher number of cross bridges formation at low calcium, leading to residual force 
and an impaired relaxation during diastole, one of the main causes of Hypertrophic 
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Cardiomyopathy (Mandinov et al., 2000). We must also consider that most of these 
studies have been performed using mutated homodimers, meaning dimers of Tm both 
possessing the mutation. This might arise issues when studying in-vivo cases where the 
mutant isoform is expressed alongside the wild-type in different amounts. In a paper 
by (Janco et al., 2012), differences between homodimers and heterodimers were 
reported. In particular, the E180G heterodimer did not show a significant increase in 
calcium sensitivity and melting curves suggest that it might be less stable than both the 
homodimer mutant and the wild-type. 
Other notable mutations in the tropomyosin chain are V95A, known to increase 
calcium sensitivity and tension while being associated to a mild phenotype contrasted 
by an overall poor prognosis (Karibe et al., 2001; Bai et al., 2011), E41K, associated 
with the inhibition of the on/off state transition (Ochala et al., 2008; Avrova et al., 
2018), E62Q, responsible for an increase in calcium sensitivity and velocity in in-vitro 
motility assay (Farman et al., 2018) and an increase in myosin ATPase activity at high 
calcium (Chang et al., 2014), A63V and K70T, both responsible to increase calcium 
sensitivity by altering the stability of the N-terminal region, as found using circular 
dichroism (Yamauchi-Takihara et al., 1996; Michele et al., 2002; Heller et al., 2003; 
Zheng et al., 2016). 
Several HCM mutations have also been found on the troponin subunits, particularly in 
TnI and TnT, while only few found on TnC (reviewed in (Lu et al., 2013)). Troponin I 
mutations R145G, R145Q, R162W, ȴK183 and K206Q have been seen increase the 
calcium sensitivity of skinned muscle fibres, although being found in different regions 
of the subcomplex (Takahashi-yanaga et al., 2001; Deng et al., 2003). Specifically, both 
mutations R145G and R145Q are found in the inhibitory region and are responsible for 
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a decrease in the inhibitory effect, although the overall TnI affinity for actin remains 
unchanged, while R145G only causes a decrease in the maximum force contraction 
produced and an overall slower relaxation time, thought to be caused by the 
stabilisation of calcium coordinated interactions (Kruger et al., 2005; Lindert et al., 
2015). Mutations R162W and ȴK183 are instead found in the troponin C binding region 
and have been shown to have the opposite effect than the first two, lowering TnI 
affinity for actin without affecting its inhibitory effect, while R162W alone increases 
TnI-TnC interactions in the presence of Ca2+ (Elliott et al., 2000; Iorga et al., 2008). 
Of the mutations found in troponin T, ȴ14, ȴE160, S179F, I79N, R92Q, F110I, E244D, 
R278C and K273E are all known to produce an increase in calcium sensitivity (Yanaga et 
al., 1999; Knollmann and Potter, 2001; Messer et al., 2016), despite being found in 
different regions. Mutations I79N and R92Q are located in the tropomyosin binding 
region and are known to increase force activation and force relaxation as well as cross 
bridge detachment rate (Sirenko et al., 2006), while inhibiting both TnI and Tm 
function, ultimately leading to slower relaxation rate and increased tension during 
diastole (Miller et al., 2001; Javadpour et al., 2003; Sommese et al., 2013; Ferrantini et 
al., 2017; Wang et al., 2018). However, mutation F110I, found in the same region, 
increase the maximum ATPase while not affecting calcium sensitivity (Nakaura et al., 
1999). A similar effect is associated with mutations E244D and R278C, despite these 
two being located in the TnT and TnC binding region, while also being responsible for a 
reduction in the maximum force produced in transgenic mice and impaired diastolic 
relaxation (Hernandez et al., 2005; Sirenko et al., 2006). In particular, (Brunet et al., 
2014) have shown how R278C, when coupled with mutation R145G of TnI, is capable 
ŽĨƌĞƐĐƵŝŶŐƚŚĞůĂƚƚĞƌ ?ƐƉŚĞŶŽƚǇƉĞ, albeit exacerbating the overall loss of function. 
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1.7  ? Experimental techniques used for the study of muscle 
 
Muscle contraction has been a subject of study in modern science for more than 80 
years, and the field has seen a huge variety of biophysical and biochemical 
experimental techniques being used throughout the time to address increasingly 
specific questions. The highly ordered array of muscle fibres enabled scientists to use 
X-ray diffraction and electron microscopy to understand muscle contraction, leading to 
the sliding filament theory (Huxley and Hanson, 1954), to the understanding of the 
lever arm motion of myosin, through which ATP hydrolysis is converted into 
mechanical force (Huxley, 1969), and to Å resolution structures of all the proteins 
involved in the process (Kabsch et al., 1990; Rayment et al., 1993; Houdusse et al., 
1997; Behrmann et al., 2012; von der Ecken et al., 2015), as mentioned in the previous 
sections. Structural techniques, however, suffer from high costs of deployment and 
need high amounts of particularly pure proteins to give reliable results, and might not 
be the best choice for proteins that do not form ordered structures or difficult to 
crystallise. Solution experiments are more easily accessible and have been widely used 
from the very beginning to determine the kinetic properties of myosin, culminating 
with the description of its ATPase cycle (Lymn and Taylor, 1971; Bagshaw and 
Trentham, 1973) and its interactions with the actin filament and its regulatory proteins 
in the three states model (Mckillop and Geeves, 1993). At the same time, different in-
vitro assays started being developed to study acto-myosin interactions in an easy and 
reproducible fashion. One of the most successful is the motility or gliding assay, 
developed by (Kron and Spudich, 1986), where myosin molecules are adhered to the 
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surface of a coverslip assembled in a microfluidic chamber (figure 1.15a). Fluorescently 
labelled actin or thin filaments are then imaged moving over the myosin molecules as 
they go through their working strokes, provided the right conditions for [ATP] and 
[Ca2+] are met  (figure 1.15b, see chapter 2 for technical details). 
 
 
Figure 1.15: The motility assay. a) representation of the microfluidic chamber used in the motility assay 
and b) of its surface, where actin/thin filaments are seen moving over the myosin bed. Adapted from 
(Batters et al., 2014). 
 
This relatively simple assay allowed for a better general understanding of myosin 
properties such as its low duty ratio (Harris and Warshaws, 1993), the approximate 
size and force of a working stroke (Uyeda et al., 1990; Bing et al., 2000) and myosin 
cooperativity (Vanburen et al., 1999), as well as highlighting the crucial role of troponin 
and tropomyosin in turning off the thin filament, with the milestone experiments of 
(Fraser and Marston, 1995), the importance of calcium in the contraction mechanism 
(Homsher et al., 1996; Gorga et al., 2003), and the collective behaviour of actin 
filaments (Butt et al., 2010; Hussain et al., 2013). The motility assay ease of use also 
favoured the study of mutations that lead to cardiomyopathies (as mentioned in the 
previous section and reviewed in (Marston, 2003) and (Marston, 2011)), as well as 
being adapted for the characterisation of other proteins of the myosin superfamily and 
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processive motors linked to the cytoskeleton of cells (Holzbaur and Goldman, 2010; 
Toepfer and Sellers, 2014). 
The motility assay, however, is still in all effects an ensemble assay, i.e. the 
characteristic and properties measured are the result of collective motion/behaviour 
of hundreds of molecules at the same time, leading to an averaged result. Single 
molecule assays try to circumvent this limitation by having a process occur at very low 
protein concentrations, making it possible to discern between single molecules and 
characterise them individually, trying to then scale up the new knowledge and put it in 
context with the ensemble experiments. The downsides of these methods is that they 
are not as easy to perform and, as they are often combined with microscopy 
techniques, they require more advanced and expensive equipment, as well as the 
necessity to label the sample, which could impact the experimental results altogether. 
One of such assays, particularly used in the study of muscle, is the three beads assay, 
which consists in using optical tweezers to study the forces involved in muscle 
contraction. In this assay, as depicted in figure 1.16, a single actin filament is 
suspended between two trapped beads and subsequently lowered onto a pedestal (a 
third bead adhered to the surface), which has been functionalised with a very low 
myosin concentration, allowing the interaction of as low as one myosin per filament. 
As the acto-myosin interactions take place, the position of the two trapped beads are 




Figure 1.16: The three beads assay. Representation of the three beads assay, where an actin/thin 
filament is captured by two optically trapped beads and lowered onto a third bead functionalised with 
myosin, allowing the measure of forces. Taken from (Guilford et al., 1997). 
 
This assay has led to the discovery that myosin interacts with actin transiently (Molloy 
et al., 1995), and to accurately measure the force (Rüegg et al., 2002; Takagi et al., 
2006) and the displacement produced by a single myosin head (Veigel et al., 1998; 
Molloy et al., 2000; Kad et al., 2003, 2005), as already mentioned in section 1.4. 
Moreover, optical trapping allows the study of myosin kinetics under load, for example 
as seen in (Veigel et al., 2003), where the attached lifetime of smooth muscle myosin 
on actin has been shown to increase under high load and decrease at low load, 
followed by a later study by (Kad et al., 2007), where the ADP release kinetics were 
shown to be dependent upon the direction of the applied load. 
For the experiments presented in this thesis a new single molecule approach has been 
used, called the tightropes assay. Initially used for the direct visualisation of proteins 
involved in DNA repair (Kad et al., 2010), this assay takes inspiration from the three 
beads assay but, instead of using optical tweezers to study forces, it exploits oblique 
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angle fluorescence microscopy (OAFM) to visualise the direct binding and release of 
fluorescent proteins to a suspended single actin or thin filament. However, unlike with 
optical trapping, an array of filaments is readily available in the experimental chamber 
at the start of each experiment, thereby improving the collection of data. The array of 
suspended filaments is obtained by flowing an actin or thin filaments solution in a flow 
chamber where poly-L-lysine coated silica beads have been previously adhered to the 
coverslip surface. Using fluorescently labelled myosin (or any other sarcomeric protein 
of interest), it is possible to image its interactions with the filaments in real time and 
with high temporal resolution, as pictured in figure 1.17. In addition, by having the 
filaments raised high above the coverslip surface, there will be no possible interaction 
between the regulatory proteins tropomyosin and troponin and the bottom of the flow 
chamber, at the same time granting the fluorescent proteins full 3D accessibility to 
each suspended filament. 
 
 
Figure 1.17: The tightropes assay. Diagram of the tightrope assay, where an actin/reconstituted thin 
filament is suspended between two silica beads, allowing the visualisation of direct interaction with 
fluorescently labelled sarcomeric proteins in real time. 
43 
 
The tightrope can be used to quantify thin filament activation and myosin 
cooperativity in a variety of conditions. By imaging fluorescently labelled myosin-S1 
molecules binding and releasing from suspended thin filaments in a variety of 
conditions, (Desai et al., 2015) were able to relate the fluorescence intensity to the 
amount of myosin bound to each filament at a specific point in time and space, as 
reported in the histograms in figure 1.18. 
 
 
 Figure 1.18: Analysing myosin cooperativity through fluorescence intensity histograms. Histograms of 
the fluorescence intensity of myosin bound to suspended thin filaments obtained with increasing a) 
myosin concentration and b) calcium concentration, as found in (Desai et al., 2015).  
 
By imaging at different [S1] and [Ca2+] concentration they were able to establish that 
to an increase in myosin concentration corresponds an increase in the occupancy level 
of the thin filament (right shift of the main peak of the intensity histogram) while to 
increases in calcium concentration (figure 1.18b) corresponds not only a right shift of 
the intensity distribution but also its broadening, following the activation of the thin 
filament. By fitting these histograms to a model that takes into account the three 
positions of tropomyosin on actin and the duty cycle of myosin, Desai et al. directly 
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quantified the cooperativity of myosin, stating that at least two myosin heads are 
necessary for thin filament activation and measured the cooperative unit size as  ?11 
actin monomers (Desai et al., 2015). 
The tightropes assay is certainly a powerful technique but is certainly not exempt from 
drawbacks; for instance, the assay takes a long time to set up, with more than 40 
minutes to assemble a fully functional flow chamber ready to be imaged, much longer 
than the 10 minutes usually necessary to set up a motility assay, to name one. 
Furthermore, there is some variability in the number of useful tightropes per chamber 
and imaging sessions can last up to two hours each, either because it is hard to find 
useful tightropes or because there are too many, increasing the amount of time spent 
imaging. Further details on this assay will be given in section 2.9 of chapter 2. 
 
 
1.8  ? Project objectives 
 
As mentioned in the previous section, Hypertrophic Cardiomyopathy has been the 
topic of many physiological studies, aimed at understanding the role the different 
mutations have on heart function and on developing possible therapies. However most 
of these studies have been done in ensemble experiments or on mouse models and 
none, so far, have been able to explicitly point at a molecular cause for the 
disorganisation seen in the myocytes and how the mutations lead to the known 
physiological effects is still not clearly understood. In this thesis, we study acto-myosin 
interactions at the molecular level, following on the study of (Desai et al., 2015). Using 
45 
 
the thin filament tightropes assay we first tackle the role of the E180G tropomyosin 
mutation and its effect on acto-myosin interactions. We show an overall equilibrium 
shift of the thin filament towards the closed state at the expense of both the blocked 
and open state and a reduction of the myosin cooperative unit size, providing an 
explanation for the links between our results and the decrease in relaxation efficiency 
witnessed in hearts affected by HCM. 
Following on, we address the role of tropomyosin in regulating cross bridges: is its role 
entirely passive, hindering the attachment of myosin to actin, or also an active one, 
regulating the detachment rate of cross bridges? Through our results, we report an 
increase in the detachment probability of highly concentrated clusters of myosin, 
suggesting tropomyosin might be more actively involved in sarcomere relaxation. 
Finally, we address the role of Myosin Binding Protein-C in thin-filament activation, in 
order to further the understanding of the second most important protein responsible 
for mutations leading to HCM, revealing the nature behind thin filament activation by 
MyBP-C and its dynamic molecular mechanism of binding to actin. 
Further work will need to be done to bridge the gap between molecular and 
physiological studies, but we hope that the results obtained in this thesis will help shed 
more light into the underlying mechanism of cardiomyopathies and muscle contraction 
at the molecular level, hoping to bring the field a little closer in bridging molecular and 











2.1  ? Myosin purification 
2.1.1  ? Extraction of myosin from chicken pectoralis 
Myosin was purified from chicken pectoralis. Approximately 200 g of pectoralis tissue 
was extracted from a freshly euthanized chicken; excess tendons and fat were 
removed and the tissue rinsed in 0.2 M EDTA. The tissue was then cut into pieces, 
passed through a meat grinder and finally stirred gently with an overhead stirrer for 12 
minutes in 500 ml of Buffer A (150 mM Potassium Phosphate pH 6.7, 300 mM KCl, 20 
mM EDTA, 5 mM MgCl2 , 5 mM DTT, 4 mM ATP), stopping the reaction by adding cold 
H2O up to 2 L. The solution was then filtered through four layers of cheesecloth to 
remove the pulp (which was used in a later step to make acetone powder) and the 
myosin in solution precipitated by addition of cold H2O up to 5 L of total volume 
(diluting the initial volume 10:1), which was then left to settle for 3 hours at 4°C 
(sample M1 in figure 2.1). The precipitate (sample M2) was then centrifuged at 
10000xg for 10 minutes at 10°C in a JA-10 Beckman rotor (samples M3, corresponding 
to the three supernatants (out of three bottles) and M4, the pellet obtained from one 
of them), resuspended in Buffer B (60 mM Potassium Phosphate pH 6.7, 1 M KCl, 20 
mM EDTA, 5 mM DTT) and finally dialysed overnight against 4 litres of Buffer C (25 mM 
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Potassium Phosphate pH 6.7, 600 mM KCl, 5 mM DTT) in 16 mm 12-14 KDa cutoff 
dialysis tubing at 4°C. 
 
 
Figure 2.1: 10% SDS-PAGE gel of the myosin purification protocol. The gel shows samples taken 
throughout the myosin purification protocol, where bands corresponding to the myosin heavy chain 
(MHC), myosin binding protein-C (MyBP-C), actin, tropomyosin (Tm) and the essential (ELC) and 
regulatory light chain (RLC) are seen. 
 
The solution was then diluted 2-fold with cold H2O and stirred gently for 30 minutes to 
let the actomyosin precipitate. It was then centrifuged in a JA-10 Beckman rotor as 
before (samples M5 and M6 being its supernatant and pellet, respectively) and the 
supernatant centrifuged a second time at 48000xg for 1 hour at 4°C in a JA25-50 rotor 
(sample M7 being its pellet). The supernatant was then subsequently diluted 8-fold 
with cold mqH2O and, after 3 hours, centrifuged again for 15 minutes in a JA-10 rotor 
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as above. The pellet was then homogenised in 10 ml of Buffer D (50 mM Potassium 
Phosphate pH 6.7, 3 M KCl, 5 mM DTT) and dialysed against 2 L of Buffer E (50 mM 
Potassium Phosphate pH 7, 600 mM KCl, 5 mM DTT) as before. Finally, myosin was 
clarified by spinning it 41000xg for 2 hours at 4°C in a JA25-50 Beckman rotor (samples 
MP and MS for pellet and supernatant respectively) and stored at -20°C in 50% glycerol. 
The concentration of the final stock of myosin was determined using a Bradford Assay 
and its purity checked with a SDS-PAGE 10% gel, as shown in figure 2.1. Ultimately, out 
of an initial 200 g of tissue, about 80 ml of sample were retrieved, at a concentration 
of 12 mg/ml. 
 
2.1.2  ? Papain digestion of myosin head 
Full-length myosin was used in the motility assay experiments while, when imaging 
single molecules, it was digested to obtained single myosin-S1 heads in solution. The 
digestion followed a modified protocol of (Margossian and Lowey, 1982), which uses 
Papain (from Carica Papaya, Sigma-Aldrich) to remove the S2 part of myosin heavy 
chain, keeping the essential and regulatory light chains. Myosin was first 
deglycerinated by dialysis in 200 mM ammonium acetate pH 7.2, 2 mM MgCl2 and 1 
mM DTT overnight at 4°C. To this solution, 70 µl of Papain solution (1 mg/ml Papain, 5 
mM cysteine pH 6, 2 mM EDTA) per ml of deglycerinated myosin was added to the 
solution and left on a rotating mixer at room temperature for 20 minutes. This timing 
was chosen after doing a small scale time course digestion experiment (figure 2.2a). 
The reaction was stopped by the addition of Iodoacetic acid to a final concentration of 
5 mM. In order to remove all the unwanted heavy chain fragments the sample 
underwent a few purification steps. The solution was first spun down at 8000xg in a 
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JA25.50 rotor for 20 min at 4°C and then dialysed in 10 mM Potassium Phosphate pH 
6.5 overnight at 4°C, to let the remaining heavy chains precipitate. The solution was 
then centrifuged as before and the supernatant further purified using a DEAE FF (GE 
Healthcare) column mounted on an AKTA system, using a salt gradient from no KCl to 
250 mM in 50 mM Imidazole buffer at pH 7 (figure 2.2b). The fractions were pooled 
together and the myosin-S1 either stored in 50% glycerol at -20°C or further used in 
the labelling protocol, as described in section 2.5.3. 
 
 
Figure 2.2: From full-length myosin to S1, digestion and purification. 10% SDS-PAGE gels showing a) the 
progression in time of the full-length myosin digestion reaction and b) of the purification of S1. In the 
time course, the intensity of the band corresponding to the myosin heavy chain (MHC) is seen decrease 
over time, while that of the bands corresponding to the light-mero-myosin (LMM) and the S1 portion 
are seen increase. 
 
As mentioned above, this procedure is expected to maintain the essential and 
regulatory light chain bound to the S1 (Margossian and Lowey, 1982). However, the 
gels shown in figure 2.2 have been overrun and both light chains are not visible. 
Despite this, proof of their presence in the experiments will be given in section 2.5.3, in 
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the form of a gel of the labelled S1 used in the assay carrying both the regulatory light 
chain and the essential light chain. 
 
 
2.2  ? Acetone powder preparation and actin purification 
 
Acetone powder is produced using a shortened version of Pardee and Spudich protocol 
(Pardee and Spudich, 1982). Here, the pulp and pellets obtained from the first few 
steps of the myosin purification were extracted with 500 ml of 50 mM NaHCO3 twice, 
each time for 12 minutes, using an overhead stirrer. This process was then followed by 
a 5 minute extraction using mqH2O and, finally, repeating the same process for three 
times using acetone, each time for 10 minutes. The remaining powder was left to dry 
overnight in a fume hood. 
Actin is then purified by grinding the powder and extracting it in 20 ml of extraction 
buffer (2 mM Tris-Base pH 8, 0.2 mM CaCl2, 1 mM DTT and 0.2 mM ATP) per gram of 
acetone powder. The solution is then stirred gently with an overhead stirrer for 30 
minutes and centrifuged at 24000xg in a JA25.50 Beckman rotor for 20 minutes at 4°C. 
The extraction and centrifugation steps were repeated once more and the 
supernatants combined for the polymerization step, where 50 mM KCl, 2 mM MgCl2 
and 1 mM ATP were added to the solution, which was then left at 4°C for 2 hours. This 
was followed by a high salt wash (sample A1 in figure 2.3a) to loosen the bond 
between actin and tropomyosin, by adding KCl up to 600 mM and stirring the solution 
for 30 minutes at 4°C and a centrifugation at 150000xg in a type 70Ti Beckman rotor 
51 
 
for 1 hour at 4°C (its supernatant being sample A2). The pellet was homogenised and 
dialysed in extraction buffer overnight and then for 24 hours, changing dialysis buffer 
every 8 hours (sample A3). The solution was then clarified by spinning at 150000xg as 
in the previous step and the actin polymerised by adding Imidazole pH 7 up to 10mM 
and MgCl2 to 1 mM (sample A4 corresponding to the supernatant). Finally, actin was 
dialysed and stored in 4 mM Imidazole pH 7, 100 mM KCl, 2 mM MgCl2, 1 mM DTT and 
0.5 mM ATP.  
Actin concentration was determined via Bradford Assay and double checked 
comparing different dilutions of actin to different dilutions of an equal mass of BSA, as 
seen in the 10% SDS-PAGE gel in figure 2.3b. The lack of additional bands in the actin 
lanes indicates the success of this purification procedure. 
 
 
Figure 2.3: 10% SDS-PAGE gels of the actin purification protocol. SDS-PAGE gels showing a) four 
samples taken throughout the purification steps, along with a comparison between the actin stock and 
BSA and finally an overloaded sample (last lane) to check for contaminants; b) the result of the 
concentration test using a standard samples of BSA. No extra protein bands are visible in both gels, 





2.3  ? Obtaining Tropomyosin and its E180G mutant 
2.3.1  ? Molecular biology of the plasmids 
The plasmids for rabbit ɲ-Tropomyosin was kindly donated by professor Michael A. 
Geeves of the University of Kent. The gene also included a N-terminal modification, 
consisting of the addition of an Alanine (Ala) and Serine (Ser) to mimic acetylation 
(Monteiro et al., 1994). 
The plasmid was mutated to human by substituting the Lysine in position 220 into an 
Arginine (K220R), according to the amino acid sequences found in the Uniprot 
database (P58772 and P09493 for rabbit and human respectively), following the 
QuickChange Site-Directed Mutagenesis protocol (Agilent Technologies, 
https://www.agilent.com/cs/library/usermanuals/Public/200523.pdf). This procedure 
consists of copying the original plasmid using polymerase chain reaction (PCR) with 
primers containing the desired mutation. Once copied, the mutated plasmid will not 
be methylated, unlike the original DNA. The solution is then digested with DpnI, 
removing any trace of the original methylated plasmid, and the gene carrying the 
correct mutation can then be transformed into E. coli for the expression and 
purification procedure. This procedure was then repeated to create the human ɲ-
Tropomyosin E180G mutation used in the experiments. 
 
2.3.2  ? Bacterial expression and purification 
The plasmid carrying the gene for the human tropomyosin or its E180G mutation was 
transformed in E. coli BL21(DE3) strain. Cells were grown in LB at 37°C until their OD600 
reached a value ranging between 0.4 and 0.6, after which they were induced with IPTG 
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to a final concentration of 400 µM for 3 hours. After inductions, the cells were spun 
down in a JA10 Beckman rotor at 4400xg and 4°C for 10 minutes and the pellets stored 
at -20°C overnight. The proteins were then purified according to (Kalyva et al., 2012). 
The cell pellets were thawed and resuspended in Buffer A (5 mM Potassium Phosphate 
pH 7, 100 mM NaCl, 5 mM MgCl2) with the addition of 1 mM PMSF, and sonicated on 
ice for 5 cycles of 30 seconds pulses followed by 60 seconds of waiting, to let the cells 
cool down. The cells were then boiled in a water bath for 10 minutes at 80°C, left on 
ice for 30 minutes and centrifuged at 17300xg in a JA25.50 rotor for 30 minutes at 4°C. 
The pH of the supernatant was then dropped to 4.8 to let tropomyosin fall out of 
solution (its isoelectric point being about 4.7) and subsequently centrifuged at 3000xg 
in a JA25.50 rotor for 10 minutes at 4°C. The pellet was then resuspended in Buffer A, 
its pH adjusted to 7 and then further purified using two HiTrap Q HP columns (GE 
Healtcare) combined serially on an AKTA system. This was set to do a salt gradient, 
going from 100 mM NaCl of buffer A to 1 M of buffer B (figure 2.4a). The solution was 
then further cycled through another series of pH drop-column-pH drop (figure 2.4b) 
and resuspended in Buffer C (20 mM Tris pH 7, 100 mM KCl, 5 mM MgCl2). Finally, the 
protein was spun down at 400000xg in a TLA 110 Beckman rotor for 20 minutes at 4°C, 
flash frozen in liquid nitrogen and stored at -80°C. The final stock concentration was 
later calculated using the Bradford Assay and further checked via comparison with BSA 







2.4  ? Expression and purification of the troponin complex 
 
The plasmids necessary to express the human cardiac troponin complex (TnI, TnC and 
TnT, P19429, P45379 and P63316 in the Uniprot database, respectively) were kindly 
donated by professor Michael A. Geeves of the University of Kent. Each component of 
the complex was bacterially expressed separately (as in section 2.3.2) and later 
purified according to (Al-Sarayreh, 2011). The cells pellets were each resuspended in 6 
M Urea, 25 mM Tris pH 7, 200 mM NaCl, 1 mM EDTA, 20% sucrose and 0.1% Triton 
Figure 2.4: The tropomyosin purification 
protocol. Gels of the tropomyosin purification, 
showing a) the first centrifugation, two pH cuts 
and the first round in the HiTrap Q HP column, b) 
the second round of the HiTrap column and c) 
the final pooled samples of the ɲ-tropomyosin 
and its E180G mutant being tested against three 
standard samples of BSA. 
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X100 and sonicated as for the tropomyosin and finally dialysed in 2 M Urea, 10 mM 
Imidazole pH 7, 1 M KCl and 1 mM DTT for 5 hours. The next two steps were aimed at 
reducing the urea and salt concentration, allowing the proteins to refold. Hence, the 
solution was dialysed in 10 mM Imidazole pH 7, 0.75 M KCl, 1 mM DTT overnight and 
finally in 10 mM Imidazole pH 7, 0.5 M KCl, 1 mM DTT for 5 hours. The sample was 
then centrifuged at 17000xg in a JA25.50 for 10 minutes at 4°C and the protein in the 
supernatant precipitated adding 30% ammonium sulphate (NH4)2SO4 to the solution 
and gently stirred at 4°C for up to one hour. It was then centrifuged at 8000xg in a 
JLA16.25 rotor for 30 minutes at 4°C and precipitated again bringing the ammonium 
sulphate concentration to 50%. After leaving it for 30 minutes on ice, the solution was 
centrifuged at 17000xg for 10 minutes at 4°C and its pellet resuspended in 10 mM 
Imidazole pH 7, 200 mM NaCl, 100 µM CaCl2, 1 mM DTT and dialysed in the same 
buffer to remove the (NH4)2SO4. After dialysis, the sample was spin concentrated in a 
10 KDa MWCO column (Amicon Ultra) at 2360xg for 45 minutes and further purified 
using a Sephacryl S-300 column mounted on an AKTA system. Figure 2.5 shows a 10% 
SDS-PAGE gel of the fractions of the gel filtration column. The protein was then spin 
concentrated for the final time and 3% sucrose was added to the solution, before 
flash-freezing and storing it at -80°C for further use. 
The troponin complex appeared difficult to purify efficiently and several bands are 
seen in figure 2.5b. However, the unwanted bands might not have a direct impact on 
the experiments, since the initial steps of the purification procedure involve the 
unfolding of the proteins in solution and refolding is expected only for the troponin 
complex. Therefore, there is a higher chance that the contaminants are not folded 
properly and their impact on the experiments is likely to be little to none. Evidences 
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that this is the case are the experiments reported in the results chapters, where in all 
instances the properties of thin filaments are respected and consistent with the 
literature, as stated in each specific case. 
 
 
Figure 2.5: Purification of the troponin complex. 15% SDS-PAGE gels of a) the initial steps of the 
troponin purification and b) of the fractions eluted from the Sephacryl S-300 gel filtration column, 
highlighting the fractions pooled for the final stock. Note how the single components of the complex 
(TnT, TnI and TnC) are eluted at the same time. 
 
 
2.5  ? Fluorescent labelling of S1 with GFP 
 2.5.1  ? Switching the 6xHis-tag from the N-terminal to the C-
terminal end of the RLC-GFP 
For the single molecules experiments in this thesis, myosin needs to be tagged with a 
fluorescent probe. To this end, our group had previously designed a regulatory light 
chain (expressed in E.coli from chicken gizzard, as section 2.3.2) tagged with an eGFP 
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on its C-terminus and a 6xHis-tag on its N-terminus, to allow for an easy purification. 
However, once expressed in E.coli and extracted from the cells, the S1 tagged with 
6xHis-RLC-GFP was not pure to a good standard, despite repetitive attempts, possibly 
caused by the His-tag being buried within the RLC. Starting from this hypothesis, we 
redesigned the plasmid construct and switched the His-tag to the C-terminus of the 
eGFP. 
The original RLC-GFP gene with a 6xHis-tag at the N-terminus was found in a pQE16b 
vector (sequence containing the 6xHis-RLC-GFP in the Appendix A.1). In order to switch 
the 6xHis-tag to the C-terminus of the GFP, we decided to extract the RLC-GFP gene 
from the pQE16b vector and insert it into a pET21a vector, which contains an out-of-
frame 6xHis-tag at the end of the multiple cloning site (figure 2.6 gives a summary of 
the process). To do so, we first extracted the RLC-GFP gene from the original vector 
using PCR and the following forward and reverse primers 
 
&ŽƌǁĂƌĚƉƌŝŵĞƌ P ? ?-TCTTACATATGAGCAGCAAACGC- ? ?
ZĞǀĞƌƐĞWƌŝŵĞƌ P ? ?-TAGCAAAGCTTGTACAGCTCG- ? ?
 
while adding the NdeI and HindIII restriction sites, chosen to bring the 6xHis-tag in the 
pET21a in frame. The extracted RLC-GFP gene (insert) and the receiving vector pET21a 
were then digested using the NdeI and HindIII restriction enzymes and subsequently 
ligated. Finally, the plasmid was sent for sequencing, to check whether the 6xHis-tag 




Figure 2.6: Switching the 6xHis-tag. Schematic of the process to switch the 6xHis-tag from the N- to the 
C-ƚĞƌŵŝŶƵƐŽĨƚŚĞĞ'&W ?ŚŝŐŚůŝŐŚƚŝŶŐƚŚĞƉƌŝŵĞƌƐ ?ƉŽƐŝƚŝŽŶ ?ďůĂĐŬĂƌƌŽǁƐ )ŽŶƚŚĞŝŶŝƚŝĂůǀĞĐƚŽƌ ?ƉY ? ?ď ) ?




 2.5.2  ? Expression and purification of the RLC-GFP-6xHis 
The plasmid for the RLC-GFP-6xHis was transformed in E. coli BL21(DE3). Cells were 
induced with 1 mM IPTG for 3 hours for protein expression and sonicated as detailed 
in section 2.3.2, with the exception of Buffer A, which consisted in 50 mM Tris pH 7.5 
and 200 mM NaCl. After sonication, the cell lysate was centrifuged in a JA25.50 rotor 
at 24000xg for 30 minutes at 4°C, in a TLA 110 at 230000xg for 45 minutes at 4°C and 
finally dialysed in 50 mM NaH2PO4, 300 mM NaCl, 20 mM Imidazole, pH 8 for 4 hours 
(steps shown in the 10% SDS-PAGE gel in figure 2.7a). The solution was then further 
purified using a custom Ni-NTA column with a bed volume of 1.9 ml. After loading the 
sample, the column was washed with 3 column volumes (CV) of buffer 50 mM 
NaH2PO4, 300 mM NaCl, 20 mM Imidazole pH 8, 3 CV of same buffer with 100 mM 
Imidazole to elute the protein and finally with 3 CV of same buffer with 250 mM 
Imidazole to clean the column from any remaining contaminants. Figure 2.7b shows a 
10% SDS-PAGE gel of a typical purification, where the RLC-GFP-6xHis (along with some 
other undetermined bands) can be found in the second elution aliquot with an 
expected molecular weight of 49.2kDa. However the relative amplitude of the RLC-GFP 
band versus the contaminants one is much higher than the contaminants and, 
considering that this is only an intermediate step, the purification process can be 
considered successful. The RLC-GFP-6xHis was finally stored in 50% glycerol at -20°C 





Figure 2.7: Purification of the RLC-GFP-6xHis. 10% SDS-PAGE gels of the RLC-GFP-6xHis a) induction (pre 
and post, up to overnight) and centrifuge purification steps and b) further purification using the NiNTA 
column, showing the lanes relative to the flowthrough of the sample in the column, the low Imidazole 
(20 mM) washes (LW) and the elution samples. The large band in the second elution lane is the RLC-GFP-
6xHis, with an expected molecular weight of 49.2kDa. 
 
2.5.3  ? Labelling of S1 with RLC-GFP-6xHis and final purification 
The labelling of S1 with the recombinant RLC-GFP-6xHis is carried out through an 
exchange reaction. First, both the S1 and the RLC-GFP-6xHis aliquots are separately 
buffer exchanged using a spin concentrator (30000 MWCO, Amicon Ultra) into 
exchange buffer (50 mM Potassium Phosphate pH 7, 600 mM KCl, 10 mM EDTA, 2 mM 
EGTA, 5 mM DTT and 2 mM ATP). After determining their concentration in a 
spectrophotometer, knowing the extinction coefficient of S1 at 280 nm (࠱280=0.83 
ml·mg-1cm-1 (Barua et al., 2012)) and of GFP at 488 nm (࠱488=56000 M-1cm-1 (Kaishima 
et al., 2016)), several exchange reactions were set up independently, with S1:RLC-GFP 
molar ratios varying between 1:3 and 1:8, depending on the amount of sample 
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available. The reactions were then individually stopped with the addition of 15 mM 
MgCl2 and pooled together.  
 
 
Figure 2.8: Purification of the S1-GFP. 10% SDS-PAGE gels of the a) Sephacryl S-200 gel filtration column 
fractions, b) of the NiNTA column and c) of purified S1-GFP with the essential light chain visible. 
Fractions H4 to H13 were pooled and moved to the next step, the NiNTA column, from which only the 
first three lanes of the elution were subsequently pooled and used in the experiments. LW refers to the 
low imidazole (20 mM) wash, while HW to the high imidazole (250 mM) wash. Sample eluted at 100 mM 
Imidazole, same as in the RLC-GFP-6xHis purification. 
 
The next step consisted in injecting the sample in a Sephacryl S-200 gel filtration 
column (GE Healtcare), to separate the successfully labelled S1-GFP from the 
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unexchanged-S1 and unexchanged-RLC-GFP-6xHis, along with the other contaminants. 
The column was run using a low imidazole wash buffer (50 mM NaH2PO4, 300 mM NaCl, 
20 mM Imidazole pH 8), so that the sample would be already in the right buffer for the 
next purification step, consisting in a final NiNTA column (performed as in section 
2.5.2). This last step is necessary to make sure that there is no unlabelled S1 
contamination in the final sample, which would void any experiment on myosin 
cooperativity. Figures 2.8a and 2.8b show the resulting 10% SDS-PAGE gels of these 
last two steps. Out of the elution fraction of the Ni-NTA column, only the first three 
were pooled together and stored in 50% glycerol and 3% sucrose at -20°C for future 
use. Finally, figure 2.8c shows a 10% SDS-PAGE gel of purified S1-GFP where the 
essential light chain is visible, proving that the papain digestion and the entire 




2.6  ? Myosin Binding Protein-C (MyBP-C) N-terminal fragments 
purification and labelling 
 
MyBP-C N-terminal fragments C0C3, C0C1 and C0C1f (C0C1 with the addition of 17 
amino acids from the following M-domain), both labelled and unlabelled used in this 
thesis are a kind donation of the David Warshaw and Michael Previs laboratories at the 
University of Vermont, Burlington, USA. The proteins were expressed in E. coli and 
purified according to (Colson et al., 2016) in their laboratory and have not been altered 
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during the work for this thesis. All samples were shipped to our laboratory on dry ice 
and stored at -80°C until needed for the experiments. 
In particular, the labelled fragments were all tagged with a Cy3 dye, using the same 
protocol as in (Colson et al., 2016), on cysteine-248 on subdomain C1. Labelling 
efficiencies were 33% for Cy3-C0C3 and Cy3-C0C1f and 43% Cy3-C0C1. Control 
ĞǆƉĞƌŝŵĞŶƚƐ ůŽŽŬŝŶŐ Ăƚ ƚŚĞ ĞĨĨĞĐƚ ŽĨ ƚŚĞ ĨůƵŽƌĞƐĐĞŶƚ ƚĂŐ ŽŶ ƚŚĞ ĨƌĂŐŵĞŶƚ ?Ɛ ĨƵŶĐƚŝŽŶ
were performed by Samantha Previs of the Warshaw laboratory at the University of 
Vermont, showing no significant differences between unlabelled and labelled samples. 
 
 
2.7  ? Reconstitution and labelling of actin thin filaments 
 
Actin filaments where reconstituted by mixing actin with regulatory proteins 
tropomyosin and troponin with a molar ratio Actin:Tm:Tn of 2:0.5:0.25 in 
reconstitution buffer (4 mM Imidazole pH 7, 2 mM MgCl2, 0.5 mM ATP and 1 mM DTT 
(Homsher et al., 1996)). Following an overnight incubation, filaments were labelled 
with an equimolar amount of FITC-phallodin (Sigma-Aldrich), AlexaFluor633-phallodin 








2.8  ? The in-vitro motility assay 
 2.8.1  ? Experimental procedure 
The motility assay is a simple but useful assay that can be used to test the activity of a 
freshly prepared myosin or actin stock, as well as whether the reconstitution of the 
actin thin filaments has been successful. It consists in laying myosin on the surface of a 
coverslip, followed by a solution containing the filaments; depending on the 
concentration of ATP and Ca2+ in the assay, the myosin heads will pull the actin 
filaments around, of which speed and percent motile can be recorded and studied.  
The motility assay is carried out in a flow cell, where a glass coverslip is attached to a 
glass slide by two strips of bi-adhesive tape, forming a chamber of 30 to 40 µl in 
volume. The glass coverslip is previously coated with nitrocellulose (Sterile Collodion 2% 
in Amyl Acetate, Thomas Scientific), to make the surface sticky to the myosin tails 
(Umemoto and Sellers, 1990). To do this, the coverslips are put in a small container 
filled with water. Upon the addition of 50 µl of nitrocellulose solution, a thin layer 
forms on top of the water; removing the water from a purge hole on the bottom of the 
container lowers the water level, until the nitrocellulose layer is in direct contact with 
the coverslip. Finally, the container is placed in an incubator at 37°C for 30 minutes, to 
speed up the evaporation of any residual water left, at the end of which the coverslips 
are ready to be used in assembling the flow cell. 
Before adding the myosin in the flow cell, it is spun down at 220000xg at 4°C in the 
presence of actin (0.3 mg/ml of myosin with 0.05 mg/ml of actin) and 1 mM ATP, to 
pellet any myosin incapable of releasing from actin (so called dead-heads). Finally, 2x 
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30 µl washes of different solutions are incubated in the flow cell, following this specific 
order: 
 
1. 0.1-0.2 mg/ml myosin, 1 min/wash 
2. 1 mg/ml BSA, 1 min/wash, to fill the gaps left by myosin on the coverslip 
3. 1 µM unlabelled actin, 1 min/wash, vortexed for 20 seconds to break up the 
filaments into smaller ones 
4. 1 µM ATP, no incubation time 
5. Actin buffer, no incubation time; these washes, along with steps 3 and 4, are 
used to block any dead-head myosin by letting unlabelled actin bind to them 
without releasing. Any working myosin head will be freed of the actin in step 4 
6. Labelled actin, 30 s/wash 
7. Motility buffer, 3 washes, no incubation time 
 
All solutions from washes 2 to 6 are made in actin buffer (25 mM Imidazole pH 7.4, 25 
mM KCl, 4 mM MgCl2 1 mM EGTA and 10 mM DTT), while the myosin in wash 1 is in 
myosin buffer (same as actin buffer but with 300 mM KCl). The motility buffer is actin 
buffer with the addition of 0.5% Methylcellulose, a 1/50 dilution of oxygen scavenger 
mix (175 mg of Glucose, 0.98 mg of Glucose Oxidase and 1.35 mg of Catalase dissolved 
in 600 µl of water) and the necessary amount of ATP and Ca2+ required by the 
experiment. When working with reconstituted thin filaments the motility buffer also 
contained an excess of regulatory proteins tropomyosin and troponin, 100 nM each. 
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Videos of moving filaments were collected at 10 fps for 30 seconds or longer, using 2 
mW of the 488 nm laser when using FITC-labelled filaments or, when using AF633-
labelled filaments, 1 mW of the 561 nm laser or 5 mW of the 637 nm laser. 
 
2.8.2  ? Data analysis 
The videos collected of moving filaments were analysed by manually collecting the 
instantaneous velocities of filaments using the MtrackJ plugin in ImageJ (Meijering et 
al., 2012), of which an example is given in figure 2.9a. 
 
 
Figure 2.9: Analysing the motility assay data. a) Last frame of a video of the MtrackJ analysis tool for 
ImageJ, showing the tracked filaments (unregulated actin at 1 mM [ATP]); b) histogram of the 
instantaneous velocities of reconstituted thin filaments (RTFs) obtained for the second flow cell at pCa 
5.5 and 1 mM ATP. Two Gaussian distributions are needed to correct for the speed obtained for 
stationary filaments. c) Speed-pCa relationship of RTFs obtained  with the in-vitro motility assay, along 
with the % motile filaments-pCa relationship in the inset. 
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Two or more movies were acquired per flow cell in all the experiments and, after 
tracking the filaments, all the instantaneous velocities for each flow cell were plotted 
as histogram, prior to fitting to up to two Gaussian distributions (figure 2.9b), 
according to  
 
݂݅ݐሺݔሻ ൌ ෍ ൭ܣ௜݁ିሺ௫೔ିఓ೔ሻమଶఙ೔మ ൱ଶ௜ୀଵ  
 
where ܣ is the amplitude of the Gaussian distribution, ߤ its mean (i.e. the average thin 
filament speed within a flow cell) and ߪ its standard deviation. For the fitting, achieved 
using the Solver addin for Microsoft Excel, one of the two Gaussian distribution was 
forced to have a mean speed of zero µm/s, to account for stationary filaments; the 
mean of the second distribution is then used for data analysis, with each flow chamber 
being considered as an experimental replicate. Finally, plotting the speed versus the 
pCa, the graph in figure 2.9c is obtained, highlighting the sigmoidal relationship typical 
of a cooperative process. The fraction of motile filaments was collected by a simple 
count of the total filaments in the field of view minus the filaments that have not 
moved for the entirety of the movie period (between 30 seconds and 1 minute); 
plotting this values versus the pCa results in the graph in the inset of figure 2.9c. These 







2.9  ? The thin filament tightropes assay 
2.9.1  ? Experimental procedure 
The thin filament tightrope assay consists of suspending fully reconstituted thin 
filaments (RTF) between poly-L-lysine coated silica beads, and image the association to 
and dissociation from actin of S1-GFP. The assay is conducted in a microfluidic flow cell, 
as detailed in (Springall et al., 2016) and shown in figure 2.10a. 
 
 
Figure 2.10: The tightrope assay set-up. a) schematic of the assembly of a flow cell and b) photo of flow 
cell connected to the perfusion tube and syringe pump. 
 
The flow cell is constructed using a microscope coverslip (Agar Scientific, sides of 24 x 
40 mm and thickness of 0.16 - 0.19 mm), a glass slide (ThermoScientific), a double 
sided sticky gasket as spacer (15 mm x 10 mm x 0.18 mm) and two small tubes cut to 
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be approximately 2 cm long as inlet and outlet. The glass slide is drilled so that it can 
accommodate the two tubes, resulting in a chamber with a final volume of about 20 µl, 
in which the experiment is conducted. Both the coverslip and the glass slide are 
previously treated before the assembly first by bathing in 2% Silane ((3-Aminopropyl)-
triethoxysilane, Sigma-Aldrich) in Acetone, then with Methoxypolyethylene glycol 
5,000 in Proprionic Acid (Sigma-Aldrich) to help prevent proteins sticking to the inside 
walls of the flow cell. Once assembled, the chamber is washed with 100 µl of water. 
The beads are then adhered to the coverslip surface by washing the flow cell with a 
1/25 dilution of 5 µm silica beads (MicroSil Microspheres, Whitehouse Scientific) in 
water. The density of beads is critical for the formation of tightropes, since too high a 
density will create beads aggregates and prevent the suspension of filaments, while a 
too low density will create filaments suspended only on one end and thus useless, as 
will be explained in section 2.9.3.  
Often, the density is not constant throughout the whole chamber and need to be 
assessed before the filaments are introduced. This is done using a basic light contrast 
microscope every time a flow chamber is built. A typical chamber will have a larger 
amount of beads near the inlet and/or outlet and a very low amount near the borders 
of the gasket (figure 2.11a and b respectively), caused by the geometry of the chamber 
itself and fluid dynamics, and an optimal density around its centre (figure 2.11c). Up to 





Figure 2.11: Determining the beads density. Images of the surface of a flow chamber showing different 
bead density, with a) being too high, b) too low and c) optimal for the formation of suspended filaments. 
Taken from (Springall et al., 2016) 
 
Once the bead density has been determined, the flow cell is washed with the 
appropriate buffer for the experiment (actin or calcium buffer, as above) and then 
connected to a bi-directional syringe pump at the outlet and a perfusion tube at the 
inlet, as shown in figure 2.10b, making the whole assembly air tight. A solution of 500 
nM actin filaments or RTFs (in actin or calcium buffer respectively, with the addition of 
100 nM of Tm/Tn when using RTFs) is then added to the flow chamber through the 
perfusion tube and pumped back and forth through the chamber for 30 to 90 minutes, 
allowing the filaments to suspend between the silica beads, forming tightropes. Finally, 
a solution containing the fluorescent proteins is flowed within the chamber and 
imaged using oblique angle fluorescent microscopy. 
 
2.9.2  ? The Oblique Angle Fluorescence microscope (OAFM) 
Oblique Angle Fluorescence microscopy, also called highly inclined and laminated 
optical sheet (HILO) or variable angle epifluorescence microscopy (Konopka and 
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Bednarek, 2008; Tokunaga et al., 2008; Kad et al., 2010) stems as a trade-off between 
total internal reflection fluorescence microscopy (TIRF) and epi-illumination 
microscopy. It is used to image samples in solution with a better signal to noise ratio 
and resolution along the z-axis than epi-illumination microscopy, while using a similar 
principle of illuminating the sample as in TIRF. In OAFM, the laser is focused at the 
back focal plane of a high numerical aperture objective as in TIRF, with the difference 
that the angle of incidence is not critical and total internal reflection does not occur, 
allowing the collimated beam to exit from the objective at a steep angle. This allows 
fluorescent imaging deep into solution while removing part of the background 
fluorescence, increasing the signal to noise ratio. Figure 2.12 shows a schematic of the 
OAFM optical setup used for the experiments in this thesis. 
In brief, the excitation path consists of four lasers, a 20 mW 488 nm DPSS (JDSU), a 561 
nm (Obis) and a 633 nm laser diode (Vortran Stradus), a dichroic and several lenses to 
focus the laser beam off-centre at the back focal plane of a 100x 1.45 NA objective 
(Olympus). The fluorescence light emitted by the excited molecules in the sample is 
collected by the objective lens and reflected by a dichroic filter towards the Optosplit 
III (Cairn Research), which sorts the fluorescent light based on its wavelength, creating 
three separate images on a Hamamatsu Orca Flash 4.0 V2 camera. 
Combining OAFM with the tightrope assay allows us to conduct multi-colour 
experiments and watch myosin binding to fully reconstituted thin filaments in real time 
and at a high temporal resolution. Furthermore, by using beads to elevate the thin 
filaments into solution, we can ensure that myosin has full 3D accessibility to actin and 
that the motion of regulatory proteins tropomyosin and troponin is not hindered by 




Figure 2.12: The Oblique Angle Fluorescence Microscope set-up. Three laser beams (488 nm, 561 nm 
and 633 nm) are expanded and focused off-centre at the back focal plane of a 100x objective (1.45 NA), 
exciting the sample at an oblique angle. The fluorescent light is then collected through the same 







2.9.3  ? Imaging thin filament tightropes 
Once the flow chamber is assembled and placed on the OAF microscope, the first step 
of every experiment consists in looking for good tightropes to image, taking care to 
avoid bundles and other filaments that are not suitable for data collection. The search 
must be as strict as possible but can only be done on a qualitative basis and is mostly 
down to the experience of the user to recognise good tightropes and discard the 
others. However, bad tightropes usually have some recognisable features and can be 
singled out by following a few simple criteria.  
In figure 2.13 are some representative examples of good and bad tightropes. For 
instance, in every chamber there is a certain amount of bundled up actin or 
reconstituted thin filaments. Generally speaking, bundles can be recognised by the loss 
of a straight shape (figure 2.13a), or for forming very large aggregates (figure 2.13b), as 
ǁĞůůĂƐďǇƚŚĞŝƌ “ƚŚŝĐŬĞƌ ?ĂƉƉĞĂƌĂŶĐĞŝŶĨůƵŽƌĞƐĐĞŶĐĞ ?ƉĂƌƚŝĐƵůĂƌůǇĐůŽƐĞƌƚŽƚŚĞďĞĂĚƐ ?
indicating several filaments joining together and possibly stretching to a nearby bead 
(figure 2.13c, right). Although bundles are easily recognised, bad tightropes do not 
ĂŵŽƵŶƚƚŽŽŶůǇĨŝůĂŵĞŶƚƐƚŚĂƚŚĂǀĞĂƐƉĞĐŝĨŝĐ “ƉŚǇƐŝĐĂů ?ĨĞĂƚƵƌĞ ?ďƵƚĂůƐŽƚŽŽŶĞƐƚŚĂƚ
would not give useful data, for example those that are not parallel to the coverslip 
surface, hence going out partially out of focus (figure 2.13c, left), or those too short 
(figure 2.13d), resulting in less binding seen (due to the low number of binding sites 
and the beads acting as a steric encumber) and poor signal to noise ratio (caused by 
the high noise coming from the nearby beads). Other examples of tightropes that are 
discarded from data collection are those that are not bound to a bead at one end and 
those that are attached but fluctuating in three dimensions. Examples of good 
tightropes are shown in figure 2.13e and f (unregulated actin and reconstituted thin 
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filament, respectively), which appear straight and have a length generally comprised 
between 3 and 10 µm, with a calculated average of 6.98 ± 3.03 µm (mean ± SD, N = 47) 
and 6.41 ± 3.02 µm   (N = 359) for actin and thin filaments, respectively (based on the 
tightropes analysed in the experiments discussed in chapter 5). 
 
 
Figure 2.13: Selecting good tightropes. Bad tightropes can be easily recognised by a) loss of a straight 
shape, b) formation of large aggregates, c) high fluorescence intensity and d) very short length, 
compared to good tightropes of e) unregulated actin and f) reconstituted thin filaments, which are 
straight and have an average length of 6 µm. Scale bars are 5 µm. 
 
All in all, the thin filament tightropes assay is a fairly reproducible technique, in which 
only up to one in ten flow chambers will result in no usable filaments, while there is 
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some variability in the number of filaments imaged per chamber, which can range 
from one to more than ten. Thus, each flow chamber is considered an experimental 
replicate and, regardless of the number of filaments found in a chamber, all data 
acquired in the same experimental conditions are pooled and analysed in the same 
way, with no difference noted between data acquired in chambers with low or high 
amounts of filaments found.  
On average, the search for good tightropes takes about 30% of the overall time spent 
on a single flow chamber, which is usually imaged for about two hours since the 
injection of the fluorescent protein solution. This does not mean that finding good 
tightropes is hard, but that most of the times requires patience. The rest of the time 
spent per flow chamber is used in data collection, with movies that range from 30 
seconds to 5 minutes long, depending on what the experiment requires; for example, 
when imaging S1-GFP at high calcium a lot of interactions can be recorded within a 30 
seconds time window per movie, as opposed to low calcium, where interactions are 
scarce and movies of two minutes each are preferred. Furthermore, movies looking at 
diffusive properties of MyBP-C fragments are generally longer than 3 minutes, caused 
by the long acquisition times required to account for the low processivity of the 
molecules.  
 
2.9.4  ? Data analysis 
Images and videos collected using the OAFM have been analysed using custom written 
macros in ImageJ and using Office Excel for numerical calculations. As the type of 
analysis performed often depends on the question asked and the information required 
from the experiment, details on the analysis are given in full in the results section of 
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each chapter. However, a common requirement in all of the analyses is knowing the 
pixel size of the camera field of view. This was calibrated using a graticule as a 
standard sample, as shown in figure 2.14. 
 
 
Figure 2.14: Calibrating the pixel size of the microscope camera. Microscope image of the calibrating 
graticule (top) with its respective profile (bottom). The distance between each bar corresponds to 10 µm 
and an average of 158.3 pixels. 
 
By knowing the distance between each black bar is of 10 µm and calculating the 
average pixel distance between them (158.3 pixels), we calculated an average pixel 









INVESTIGATING THE EFFECTS OF THE 
HYPERTROPHIC CARDIOMYOPATHY  
ɲ-TROPOMYOSIN E180G MUTATION  
ON THIN FILAMENT ACTIVATION 
 
3.1  ? Introduction 
 
Tropomyosin (Tm), along with the troponin complex, plays a fundamental role in 
muscle contraction, regulating acto-myosin interactions by sterically blocking access to 
myosin binding sites on actin. Hence, mutations in this protein can have important 
consequences on muscle functionality, as is the case with Hypertrophic 
Cardiomyopathy (HCM), often associated with poor prognosis. To date, several Tm 
mutations found all throughout its coiled coil structure have been associated with 
HCM. Glu180Gly (E180G) was among the first such missense mutations to be 
discovered (Thierfelder et al., 1994). The E180G mutation removes a negative charge 
from the surface of tropomyosin, weakening its interaction with the positively charged 
groove on the actin filament, in turn leading to an overall decrease in actin-Tm affinity 
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(Kremneva et al., 2004; Mathur et al., 2011) and an increase in Tm flexibility, with its 
persistence length decrease ranging between 20-30% less than the wild-type (Li et al., 
2012; Loong et al., 2012). It is also associated with an increased sensitivity of the thin 
filaments to calcium (Bing et al., 2000; Boussouf et al., 2007; Wang et al., 2011; Janco 
et al., 2012; Matyushenko et al., 2017), leading to hypercontractility of the thin 
filaments in vivo and impaired relaxation (Bai et al., 2011). 
In this study, we investigate the effects of the E180G mutation on acto-myosin 
interactions at the single molecule level, highlighting the changes in thin filament 
activation. Looking at fluorescent myosin-S1 binding to E180G-RTFs (actin filaments 
reconstituted with troponin and E180G tropomyosin) across various calcium 
concentrations enables us to calculate the size of the actin regulatory unit. Ultimately, 
our results provide an explanation for a molecular mechanism of how a missing charge 




3.2  ? Results 
3.2.1  ? The ɲ-tropomyosin E180G mutation increases thin filament 
calcium sensitivity in the motility assay 
To investigate the calcium sensitivity of the thin filaments reconstituted with the 
mutated ɲ-tropomyosin we used the in-vitro motility assay, following the procedure 
described in section 2.8. Briefly, we performed the experiments at different calcium 
concentration (݌ܥܽ ൌ െ ሾܥܽଶାሿ) for both the wild-type tropomyosin reconstituted 
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thin filaments (WT-RTFs) and the E180G-tropomyosin reconstituted thin filaments 
(E180G-RTFs), collecting two or more movies per flow chamber (or replicate), imaging 
more than 20 filaments per movie. From each flow chamber we extrapolated the 
speed and the % of motile filaments (as detailed in section 2.8.2) and plotted the data 
against each respective pCa, resulting in the curves shown in figure 3.1. 
 
 
Figure 3.1: The motility properties of E180G-RTFs. Comparison of a) speed and b) % of motile filaments 
in the in-vitro motility assay of WT-RTFs (triangles) and E180G-RTFs (crosses), with their respective fit 
(dashes and full line, respectively). Errors are standard error of the mean (SEM) of the averages of speed 
or % of motile filaments obtained from two flow chambers. Fitting parameters are listed in table 3.1. 
 
Each data point in the motility curves in figure 3.1 is a mean of two values obtained 
from two different flow chambers (experimental replicates). The data is fit to the Hill 
equation, 
 




where ߠ corresponds to the property analysed (speed or % of motile filaments), ሾܥܽଶାሿ is the calcium concentration, ݊ the Hill coefficient ܭ௠௢௧ ൌ  ? ?ି௡כ௣஼௔ఱబ  (with ݌ܥܽହ଴ as the calcium concentration for which ఏఏ೘ೌೣ ൌ ଵଶ) and ݋݂݂ an offset. Each single 
experimental replicate has been fit independently and the values obtained averaged to 
determine the standard errors and the significance (table 3.1, distinguished between 












 ࣂ࢓ࢇ࢞ 4.80 ± 0.55 µm/s 88.78 ± 1.53 2.95 ± 0.13 µm/s 79.12 ± 1.04 ࢔ 1.52 ± 0.07 4.07 ± 0.21 0.75 ± 0.14 3.85 ± 0.84 ࢖࡯ࢇ૞૙ 6.05 ± 0.04 6.09 ± 0.04 6.49 ± 0.03 5.99 ± 0.09 െࡸ࢕ࢍሺࡷ࢓࢕࢚ሻ 9.20 ± 0.35 24.81 ± 1.13 4.86 ± 0.91 23.14 ± 5.37 ࢕ࢌࢌ 0.04 ± 0.04 0.44 ± 0.44 0.00 ± 0.00 2.70 ± 0.91 
Table 3.1: Summary of the values obtained from fitting the data using the Hill equation for the WT-RTFs 
and E180G-RTFs, for both speed and % of the motile filaments each. Each value is an average of the 
fitting parameters obtained for each of the two replicates (n = 2) along with the standard error. 
 
A comparison of the fitted parameters shows that the presence of the E180G mutation 
affects only the speed vs. pCa motility curve (figure 3.1a), significantly reducing the Hill 
coefficient of E180G-RTFs (1.52 ± 0.07 for WT-RTFs against  ? ? ? ?± 0.14 for E180G-RTFs, 
with p = 0.0389) and significantly increasing their calcium sensitivity (6.05 ± 0.04 for 
WT-RTFs against  ? ? ? ± 0.03 for E180G-RTFs, with p = 0.0127). In addition, the 
maximum filaments speed is seen substantially decrease in the presence of the E180G 
mutation (4.80 ± 0.55 µm/s for WT-RTFs against  ? ? ? ± 0.13 µm/s for E180G-RTFs), 
although not significantly (p = 0.0820). Finally, the % of motile filaments in the flow 
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chambers seems to not be affected by the E180G mutation, with the two motility 
curves in figure 3.1b almost overlapping.  
These results are in agreement with previous findings from the literature, with both 
the reduction in Hill coefficient and increase in pCa50 already reported in motility assay 
experiments performed by (Bing et al., 2000; Wang et al., 2011), although the E180G 
mutation is also seen pose an effect to the fraction of motile filaments in (Bing et al., 
2000), unlike here. 
 
3.2.2  ? Studying the effects of the ɲ-tropomyosin E180G mutation 
on S1-GFP binding to regulated thin filaments 
In order to understand what the effect of the E180G mutation is on myosin binding 
and its cooperativity, we collected data in our single molecule tightrope assay imaging 
the binding and release of S1-GFP to E180G-RTFs, varying both the [S1-GFP] and the 
[Ca2+], while keeping the [ATP] constant at 0.1 A?DŝŶĂůůĞǆƉĞƌŝŵĞŶƚƐ. Varying the [Ca2+] 
will allow us to study the transition between the thin filament activation states, while 
varying the [S1-GFP] allow us to look directly at myosin cooperativity. Therefore, we 
collected videos of 15 nm S1-GFP binding to E180G-RTFs at pCa 7, 6, 6.5, 5 and 4, as 
well as videos of E180G-RTFs at pCa 4 and [S1-GFP] = 5, 10 and 15 nM. Movies were 
collected for at least 1 minute using an exposure time of 300 ms, imaging three or 
more filaments per condition, with an average of three movies (or kymographs) per 
filament. Our goal is to compare the data acquired with the E180G-RTFs to those found 
for the WT-RTFs in (Desai et al., 2015) using the same experimental technique and data 




 Figure 3.2: Visualising the interactions between S1-GFP and E180G-RTFs. Representative kymographs 
of tightropes imaged varying a) the [Ca2+], keeping the [S1-GFP] at 15 nM, and b) varying the [S1-GFP] 
while keeping the calcium to pCa 4. The intensity of each kymograph was scaled to the one of pCa 4 and 




Representative kymographs are visualised in figure 3.2a, obtained imaging 15 nM S1-
GFP binding to E180G-RTFs at different [Ca2+] (from pCa 7 to pCa 4, top to bottom), 
and 3.2b, obtained imaging 5, 10 and 15 nM S1-GFP (top to bottom) binding to E180G-
RTFs at pCa 4. A qualitative assessment of these kymographs reveals the effect of 
calcium on myosin binding (figure 3.2a): S1-GFP is seen binding in increasing amounts 
from pCa 7 to pCa 4, consistent with an increased availability of actin, caused by both 
the increase in calcium concentration, pushing the equilibrium between the blocked 
and the closed state of the thin filament to the right, and by myosin cooperativity 
(Mckillop and Geeves, 1993; Desai et al., 2015). Figure 3.2b shows the effects on S1-
GFP binding caused by an increase in [S1-GFP], with frequent but short binding events 
at [S1-GFP] = 5 nM compared with binding events as frequent but clustered at [S1-GFP] 
= 10 and 15 nM. 
To extrapolate the intensity of each fluorescent spot in the kymographs, we used a 
custom written Matlab routine (see Appendix A.3 for details), pooled all the values 
obtained per filament at a specific experimental condition and plot these as 
histograms (figure 3.3). These graphs have not been normalised to have a better 
understanding of the variability within each dataset; among all, the largest variation 
seen is relative to the amount of data acquired per filament (Fil), the extreme seen for 
filament # 2 at pCa 7 (figure 3.3a), but also visible in the other datasets. This variability 
is not only linked to the amount of S1-GFP binding at each specified condition, but also 
to the variability in intensity associated to each single molecule imaged, since there 
will always be an error linked to the measurement of each intensity value (Walcott and 





Figure 3.3: Histograms of the extrapolated intensity values. Histograms of the S1-GFP intensity values 
per each filament imaged using 15 nM S1-GFP on E180G-RTFs at a) pCa 7, b) pCa 6.5, c) pCa 6, d) pCa 5 
and e) 5 nM, f) 10 nM, g) 15 nM of S1-GFP at pCa 4; ATP concentration was kept at 0.1 µM in all cases. 
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Considering that the overall intensity distributions in figure 3.3 show little variations 
within the same experimental conditions, we can pool all the data acquired into 
datasets (figure 3.4a and b); the resulting distributions will have, however, each be 
constituted by a different amount of data points, given not only by the differences 
discussed above, but also by the amount of filaments imaged per condition (see figure 
3.3 for the # of filaments), making a direct and meaningful comparison difficult. 
Therefore, to account for these variations, it is necessary to normalise the distributions 
(figure 3.4c and d), allowing for a fair comparison of the changes in S1-GFP binding 
caused by the changes in [Ca2+] or [S1-GFP] with the data presented in (Desai et al., 
2015) and shown in figure 1.18 of Chapter 1. 
The normalised histograms in figure 3.4c show an increase in frequency at larger 
intensity values with increases in calcium concentration. The distributions obtained at 
pCa 6 and 5 also appear to have their maximum peak right-shifted towards higher 
intensity values, compared to the other distributions. A similar trend is seen in the 
histograms in figure 3.3d, with broader distributions and a right shift for [S1-GFP] = 10 
and 15 nM compared to 5 nM. However, no clear difference is seen between the 






Figure 3.4: Quantifying the binding of S1-GFP to E180G-RTFs. Histograms of all the intensity values 
extrapolated from the kymographs in figure 3.2, for a) the changes in [Ca2+] and b) in [S1-GFP]; c) and d) 
show the same plots normalised to the highest peak in the dataset, to account for the different amount 
of filaments imaged per condition. 
 
Although the comparison of the intensity histograms in figure 3.4 gives us insights on 
the amount of S1-GFP binding to E180G-RTFs per experimental condition, a more 
direct way of comparing the data would be to convert the distributions in histograms 
of bound molecules per condition. Since throughout our experiments both the 
illumination power and the collection exposure time were kept constant, so that the 
fluorescence intensity is directly proportional to the amount of S1-GFP molecules 
bound within a specific region (Walcott and Kad, 2015), we can recalculate the 
histograms in figure 3.3 and 3.4 based on the number of myosin, using the same 




Figure 3.5: Determination of a single S1-GFP fluorescence intensity. a) histogram of the extrapolated 
intensities of 15 nM S1-GFP binding to E180G-RTFs at pCa 4 fit to five Gaussian distributions and b) plot 
of the mean intensity of each Gaussian distribution against the associated number of myosin, 
highlighting the necessity of a right shift to minimise the error on the fit. 
 
To achieve the conversion we need to first calculate the intensity of a single binder; 
hence, we took the intensity distribution of binders at pCa 4 and 15 nM of S1-GFP, 
which gives us the highest possible number of binding events, and fit it to up to five 
Gaussian distributions (figure 3.5a and table 3.2). Fitting was performed using least 
square minimization and the Solver Add-in for Office Excel, which uses an algorithm to 
vary the fitting parameters until a minimum value between the data and the fit is 
found. The intensity and the mean of each Gaussian distribution were varied 
independently while their standard deviation was constrained to one value for all, to 
better represent the experimental distribution of intensities associated to multiple 
unresolvable fluorescent molecules. The values of the amplitude, mean and standard 
















ŵƉůŝƚƵĚĞ 141.7 106.8 89.6 54.1 20.2 
DĞĂŶ 135.1 202.5 261.8 344.0 431.9 
^ ? ? 31.53 31.53 31.53 31.53 31.53 
Table 3.2: Summary of the values of amplitude, mean and standard deviation (S.D.) of each Gaussian 
distributions obtained from the histogram in figure 3.4a. 
 
Plotting the mean values in table 3.2 against the expected number of bound S1-GFP 
results in the chart in figure 3.5b. Considering the lowest mean intensity value of 135.1 
as the intensity of a single binder leads to a slope of 73.5 and an intercept equals to 
54.5. However, shifting the plot to the right (considering the lowest mean intensity 
value as a cluster of two S1-GFP molecules) reduces the ratio between the intercept 
and the slope from ~74% to ~25%. A similar approach was used by (Desai et al., 2015) 
when imaging in similar conditions, highlighting both the difficulty in detecting single 
molecules of S1-GFP, due to the low signal to noise ratio, and the reproducibility of the 
tightrope assay, where the same method can be applied to two different datasets, 
yielding similar conclusions. 
Using the slope of the plot in figure 3.5b, which corresponds to a single S1-GFP 
fluorescence intensity, we can convert the histograms in figure 3.3 and 3.4 from 
intensity to number of myosin bound within each fluorescent spot (figure 3.6 for the 





Figure 3.6: Histograms of the # of myosin (S1-GFP) binding to E180G-RTFs at increasing [Ca2+]. 
Histograms of the number of S1-GFP bound per each filament imaged using 15 nM S1-GFP on E180G-





Figure 3.7: Histograms of the # of myosin (S1-GFP) binding to E180G-RTFs at increasing [S1-GFP]. 
Histograms of the number of S1-GFP bound per each filament imaging E180G-RTFs at pCa 4 using a) 5 
nM, c) 10 nM and e) 15 nM of S1-GFP, with b), d) and f) their respective normalisation. 
 
The non-normalised histograms in figure 3.6 and 3.7 show the same level of variability 
discussed for figure 3.3, although these appear smoother because of the transition 
from intensity to # of molecules. Their respective normalised histogram, however, 
show that there is very little variability between # of molecules binding within the 
same experimental conditions, with most of the distributions overlapping and having a 
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maximum at 2 S1-GFP molecules. The only exceptions are pCa 7 (figure 3.6b), with 
filament # 2 being right shifted compared to the others and pCa 6.5 (figure 3.6d), with 
filament # 1 having a somewhat broader distribution. The former, however, does not 
contribute much to the overall number of datapoints acquired at pCa 7 (see figure 
3.6a), while the latter can be attributed to the natural variability of data obtained by 
imaging at the pCa50 of the calcium activation curve (see Chapter 4 for the sensitivity of 
imaging in these conditions and how they affect S1-GFP binding).  
Considering the little variability of the histograms of the # of S1-GFP bound per 
condition, we can pool all the data into one single histogram per experimental 
condition and normalise the frequency for the sum of the total events, giving us the % 
occurrence of having a cluster of N myosin in each of the cases explored (figure 3.8a-g). 
These histograms will be fit simultaneously, similarly to what has been done in (Desai 
et al., 2015), to ensure the quantification of the kinetic parameters for our assay and, 
pooling the data, ensures an appropriate comparison based on the amount each 
number of myosin has been seen bound per condition, ultimately facilitating the 





Figure 3.8: Probability histograms of S1-GFP binding to E180G-RTFs. Histograms of the frequency of 
clustered binding events (% occurrence) for 15 nM S1-GFP binding to E180G-RTFs at a) pCa 7, b) pCa 6.5, 
c) pCa 6, d) pCa 5 and e) 5 nM, f) 10 nM, g) 15 nM of S1-GFP at pCa 4; ATP concentration was kept at 0.1 




Global (or simultaneous) fitting has been used in a number of occasions and has been 
shown to be a powerful tool to study multiple datasets and get accurate common 
modelling parameters (Zhang et al., 2010; Herman and Ching Lee, 2012; Freiburger et 
al., 2015; Li et al., 2017). To fit the histograms in figure 3.8a-g we used the same 




where ܶ is the ATP and ܣ஻, ܣ஼௅ and ܣெ are the actin in the blocked state, in the closed 
state and in the open state respectively, with the restriction that myosin cannot bind 
to ܣ஻. However, unlike in (Desai et al., 2015), to calculate the final binding probability 
distributions, we used the Flory-Schulz distribution (Flory, 1936), used to predict the 
weight fraction of a polymer through the probability of association of its monomers, as 
described by the following equation: 
 
௟ܹ ൌ ݈  ? ݌ሺ௟ିଵሻ  ? ሺ ? െ ݌ሻଶ 
 
where ௟ܹ is the weight fraction, ݌ is the probability of association and ݈ is the number 
of molecules in the cluster (polymer length). In this case, the probability of association 
or of a myosin molecule to bind the thin filament is given by the duty cycle and ݈ is the 
number of myosin in a cluster. The duty cycle is calculated following: 
 ݀ݑݐݕܿݕ݈ܿ݁ ൌ ఛ೚೙ఛ೚೙ାఛ೚೑೑      ߬௢௡ ൌ ଵ௞షವ ൅ ଵ௞೅ሾ஺்௉ሿ      ߬௢௙௙ ൌ ଵ௞೓೤೏ ൅ ଵ௞ೌ೟೟ 
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where ݇ି஽, ்݇ and ݇௛௬ௗ are the ADP dissociation, the ATP association and the ATP 
hydrolysis rate constants respectively, and ݇௔௧௧ the second order S1-GFP attachment 
rate constant. Considering that myosin binds to the thin filament cooperatively, the ݇௔௧௧ will have to be calculated accounting for the differences between a myosin 
binding to the actin closed state versus one binding to the open state. This lead to the 
following: 
 ߬௢௙௙ǡ௖௟ ൌ ଵ௞೓೤೏ ൅ ଵ௞ೌ஺೎೗       ߬௢௙௙ǡ௠ ൌ ଵ௞೓೤೏ ൅ ଵ௞ೌሺ஺೎೗ାௗ஺೘ሻ 
 
where ݀ is the size of the cooperative unit, ݇௔ the myosin intrinsic attaching rate and ܣ௖௟  and ܣ௠ are the relative ratio of actin available in the closed and open state 
respectively, given by 
 
ܣ௖௟ ൌ ܣ஼௅ܣ஻ ൅ ܣ஼௅ ൅ ܣெ ൌ ሾܥܽଶାሿ௡಴ೌܭଶሾܣܶܲሿܭଵܭଶሾܣܶܲሿ൅ሾܥܽଶାሿ௡಴ೌܭଶሾܣܶܲሿ൅ሾܯሿ௡ಾሾܥܽଶାሿ௡಴ೌ 
 
ܣ௠ ൌ ܣெܣ஻ ൅ ܣ஼௅ ൅ ܣெ ൌ ሾܥܽଶାሿ௡಴ೌሾܯሿ௡ಾܭଵܭଶሾܣܶܲሿ൅ሾܥܽଶାሿ௡಴ೌܭଶሾܣܶܲሿ൅ሾܯሿ௡ಾሾܥܽଶାሿ௡಴ೌ  
 
The full calculation to derive the ratios for ܣ௖௟  and ܣ௠ is given in the Appendix of this 
thesis, section A.4. 
Finally, we calculate the probability ݌ for the Flory-Schulz distribution as the sum of 




݌ ൌ ߬௢௡߬௢௡ ൅ ߬௢௙௙ǡ௖௟ ൅ ߬௢௡߬௢௡ ൅ ߬௢௙௙ǡ௠ 
 
and use the Flory-Schulz relationship to fit our data in figure 3.8a-g. The fits were 
optimised globally by calculating the sum of the sum of squared differences (SSSD) of 
each histogram and solving all the fits at once using the Solver Add-in for Office Excel 
as above. We excluded the first point of each histogram since, from figure 3.5b, we 
must take into account that the quality of the data of a single S1-GFP binding might be 
biased by the low signal to noise ratio. The analysis yielded a ݇ି஽ of 500 s-1, ்݇ of     
2.5 µM-1s-1, ݇௛௬ௗ of 100 s-1, ݇௔ of 21.8 s-1, ܭଵ of 7.9·10-8 M, ܭଶ of 5.0·10-5 M, ݊஼௔ of 1, ݊ெ of 2.4 and a cooperative unit ݀ of 7.3 actin subunits, comparable with the values 
obtained in (Desai et al., 2015) (see table 3.3). 
 
 
WT-RTFs E180G-RTFs ࢑ࢇ (/s) 47 21.8 ࡷ૚ (µm) 4.00 ?10-1 7.92 ?10-2 ࡷ૛ (µm) 37.0 49.9 ࢑ࢀ (µm/s) 1.4 2.5 ࢑ିࡰ (/s) 500 500 ࢑ࢎ࢟ࢊ (/s) 100 100 ࢔ 1.08 1.00 ࢊ 11.6 7.3 
Table 3.3: Comparison of the fitting values obtained in this work  
and presented in (Desai et al., 2015). 
 
Considering that the way of analysing our data already intrinsically corrects for myosin 
cooperativity, we used ݊ெ only to find a better constrain for the other parameters, and 
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restored it to 1 once the solving algorithm converged, bringing the SSSD from 870.79 
to 874.43 (a change of 0.4%). Finally, we tried to calculate the confidence intervals of 
the parameters according to the method published in (Kemmer and Keller, 2010); 
however, this resulted in a too difficult a task, since we have too many parameters 
compared to the published method and other ways to calculate the intervals would be 
too computationally demanding, while also lacking in accuracy (Spitzer et al., 2006; 
Herman and Ching Lee, 2012). Therefore, as an alternative we calculated a sensitivity 
plot for each parameter by varying each value by ± 20% and recording the change in 
the SSSD. The square root of the sum of the squared differences between the +20% 
and  W 20% of each parameter gives us the RMSȴSD shown in figure 3.8h, highlighting 
the two most sensitive parameters of the fit as ݇௔ and ்݇. 
 
 
3.3  ? Discussion 
 
In this study, we elucidate the role of the E180G tropomyosin mutation in hypertrophic 
cardiomyopathy, particularly looking at how it affects myosin cooperativity. We first 
used the in vitro motility assay to look at the E180G mutation overall effects on thin 
filaments, finding a statistically significant left shift of the speed-pCa curve of 0.44 ± 
0.05 (from 6.05 ± 0.04 of the WT-RTFs to  ? ? ?± 0.03 of the E180G-RTFs, p = 0.0127) 
and a significant reduction in the Hill coefficient (1.52 ± 0.07 for WT-RTFs against  ? ? ? ?
± 0.14 for E180G-RTFs, p = 0.0389). These results agree well with previous in-vitro 
motility studies as well as ATPase experiments, with increases in calcium sensitivity of 
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up to 0.6 ȴpCa (Bing et al., 2000; Boussouf et al., 2007; Bai et al., 2011; Wang et al., 
2011; Janco et al., 2012; Ly and Lehrer, 2012; Matyushenko et al., 2017). However, the 
fraction of motile filaments in our experiments did not result different from the wild-
type, unlike in (Bing et al., 2000) where, although small, a difference is noted, and with 
(Matyushenko et al., 2017), where at low calcium the fraction of motile filaments 
significantly increased, even up to 70%. These differences are likely to be caused by 
the slight differences in the experimental approaches and the amount of myosin or 
regulatory proteins tropomyosin and troponin used in the motility buffer, known to 
affect the turning on of the thin filament in a concentration dependent manner (Fraser 
and Marston, 1995; Gorga et al., 2003). It is also worth mentioning that, although the 
speed vs. pCa  and the % of motile filaments vs. pCa curves are fit with different Hill 
coefficient values, this is perfectly in line with the studies published in the literature for 
both WT and E180G (Bing et al., 2000; Matyushenko et al., 2017), the fraction of 
motile filaments being steeper to denote how the filaments are completely turned on 
and off (Fraser and Marston, 1995; Homsher et al., 1996; Kad et al., 2005). 
Having validated the mutation produced, using our in-vitro motility data, we used the 
thin filament tightrope assay to directly quantify the level of myosin binding and its 
cooperativity on E180G mutated thin filaments (E180G-RTFs), comparing the data 
obtained with those found in (Desai et al., 2015) for WT-RTFs. Although this 
comparison might raise concerns about the lack of dedicated control experiments, the 
reproducibility of the thin filament tightrope assay allows for similar results to be 
collected even over long periods of time and different users, as can be seen by the 
similarities found in the results obtained in this chapter using the same approach (i.e. 
see figure 3.5b for the calculation of the single molecule intensity, a process that was 
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necessary both in (Desai et al., 2015) and in this work), or by the calculation for the 
second order ATP binding rate constant (see Appendix A.5) among others, coming to 
the same conclusions and validating both the approaches used and the use of 
previously published data as a qualitative comparison. Further discussion on the thin 
filament tightrope assay reproducibility is found in Chapter 6. 
When comparing the data, the level of myosin binding to WT-RTFs in (Desai et al., 2015) 
was seen to visibly increase with the concentration of S1-GFP (see figure 1.18 in 
Chapter 1), leading to a marked right shift of the peak of the intensity histograms, both 
when changing either the [Ca2+] or the [S1-GFP], along with a broadening of the whole 
distribution towards higher fluorescence intensities. However, our results with E180G-
RTFs show a less marked right shift towards higher intensities (figure 3.4), which is 
then further reduced when we converted the intensity datasets into # of S1-GFP 
(figure 3.6 and 3.7), while the broadening of the intensity distributions is still seen 
(figure 3.4) for both changes in [Ca2+] or [S1-GFP] (figure 3.8). 
To quantify these changes we applied the same kinetic model used in (Desai et al., 
2015) to our data using global (or simultaneous) fitting of the experimental conditions 
to obtain common independent parameters. Global fitting is a method that has been in 
use since the 1980s (Eisenfeld and Ford, 1979; Knutson et al., 1983; Beechem and 
Brand, 1986), initially used for the study of fluorescence decay curves; it allows the 
study of multiple datasets at the same time using shared fitting parameters (up to 9 in 
(Li et al., 2017)), overall leading to an improvement of the fitting accuracy (Zhang et al., 
2010; Herman and Ching Lee, 2012; Freiburger et al., 2015; Li et al., 2017). 
The model yielded similar values for most of the fundamental kinetic parameters, with 
the exception of ܭଵ (7.9·10-8 M, leading to a pCa50 of 7.1 for the blocked to closed state 
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transition) and the size of the cooperative unit ݀, which resulted in only 7 actin 
monomers for the E180G-RTFs versus the 11 found for the WT-RTFs (Desai et al., 2015). 
The decrease in the cooperative unit size could be interpreted as a direct result of the 
increased flexibility seen in E180G-tropomyosin in atomic force microscopy or electron 
microscopy studies (Li et al., 2012; Loong et al., 2012). The decrease in ݀ is most likely 
the cause for the early saturation of thin filaments by S1-GFP (as seen in the 
histograms in figure 3.4d) respect to WT-RTFs, reducing myosin cooperativity and 
impeding the formation of larger clusters (figure 3.9). These small clusters would also 
not be able to propagate effectively throughout the thin filament, resulting in a shift in 
the equilibrium between the closed and the open state of tropomyosin towards the 
closed state at high [Ca2+]. The increase in thin filament closed to open state ratio 




Figure 3.9: The effect of E180G on thin filament activation. Cartoon of the model hypothesised for the 
E180G mutation, where the increased tropomyosin flexibility is seen directly affect the amount of actin 




A similar shift towards the closed position of tropomyosin can explain the increased 
calcium sensitivity. Although the E180G mutation is located in the troponin T binding 
region of tropomyosin, it has been shown that it does not affect the TnT affinity for 
tropomyosin (Golitsina et al., 1997, 1999), hinting that the increased calcium 
sensitivity might not be directly linked to calcium itself. An increase in tropomyosin 
flexibility would lead to myosin binding sites on actin being more accessible (i.e. 
increase in the closed to blocked state ratio), facilitating the activation of the thin 
filament at low calcium and resulting in a left shift in the pCa curve. Reinforcing this 
hypothesis are the simulations carried out in (Sewanan et al., 2016), which also link the 
increased calcium sensitivity to a larger population of the thin filament being in the 
closed state, and those found in (Orzechowski, Fischer, et al., 2014), where the E180G 
mutation is seen lower the energy barrier necessary for tropomyosin to transition 
between the different positions on actin. 
Our results also highlights how the thin filament tightropes assay is capable of 
discerning between the thin filament blocked to closed and closed to open transitions, 
unlike the motility assay. This is evident when we compare the pCa50 obtained for the 
two sets of experiments, being 7.1 for the tightrope assay and 6.4 for the in-vitro 
motility assay; in particular, the relationship between the speed or the % of motile 
filaments is seen as a single sigmoidal curve, with the pCa50 representing the thin 
filament blocked to open transition. Hence, single molecule experiments can help 
characterise in more details transitions between the equilibrium state of the thin 
filament. 
Hypertrophic Cardiomyopathy has been associated with an increase in contractile 
properties of the sarcomere at low calcium, leading to impaired relaxation during 
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diastole (Bai et al., 2011; Maragiannis et al., 2018; Cohn et al., 2019). Our results 
directly link the residual contractility at low calcium to an overall increase in the 
probability of finding the thin filament in the closed state, thus providing a molecular 
mechanism for the function of the E180G mutation. Although this mutation is 
associated with a severe phenotype (Wernicke et al., 2004) we must also take into 
account that our results have been obtained with a E180G-tropomyosin homodimer 
which, according to (Janco et al., 2012) shows larger changes when compared to a 





















THE CATASTROPHIC COLLAPSE OF ACTIVE REGIONS 
OF MYOSIN BOUND TO THE THIN FILAMENT AS A 
MECHANISM FOR MUSCLE RELAXATION 
 
4.1  ? Introduction 
 
Muscle contraction is a process driven by the binding of myosin to the thin filament 
and regulated by tropomyosin and troponin. The activation of the thin filament is a 
cooperative process initiated by calcium, which binds to troponin and allows the 
movement of tropomyosin from its blocked to the closed position, partially uncovering 
myosin binding sites (Mckillop and Geeves, 1993; Risi et al., 2017). Myosin, being now 
able to bind actin tightly, can then push tropomyosin further and allow more myosin 
molecules to bind in a cooperative fashion (Heeley et al., 2006), resulting in 
contraction of the sarcomere. When the calcium concentration within the sarcomere 
drops, the thin and thick filaments slide back in the relaxed position, with tropomyosin 
sterically blocking myosin binding sites on actin. However, a clear molecular model of 
how the thin filament goes back in relaxing position is lacking, and a few questions 
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remain unanswered: how does tropomyosin goes back from its open to blocked 
position, in the presence of a high local concentration of myosin? Is tropomyosin a 
passive protein, waiting for myosin to complete is cycle and leave or has it an active 
role? Does the thin filament turn off all at the same time, in a cooperative fashion, or 
rather gradually?  
In this chapter I describe the use of the tightrope assay to address these questions, 
looking at acto-myosin interactions at a calcium concentration that does not allow the 
thin filament to be fully turned on. Our laboratory have previously shown that under 
these conditions myosin binds at very high local concentration, forming clusters that 
can suddenly disappear (Desai et al., 2015). By studying the binding and release of 
myosin from these regions and comparing our results with simulated data, we are able 
to shed light on the process of deactivation of the thin filament, showing that 
tropomyosin might have a more active role in relaxation than previously thought. 
 
 
4.2  ? Results 
4.2.1 - Sub-maximal thin filament activation promotes local 
clusters of myosin 
In order to study the process behind muscle relaxation using our single molecule 
tightrope assay, it is necessary to create a condition in which we have a high local 
concentration of myosin molecules but not a fully activated thin filament. We can 
achieve the latter by working close to the pCa50 of the thin filament, which falls around 
pCa 6 in our system (see figure 3.1 in chapter 3). A high local concentration of myosin 
104 
 
can be achieved by both increasing the S1-GFP concentration in the assay (5 to 10 nM) 
and by prolonging the duration of the acto-myosin complex by working at low [ATP]. 
Knowing that the lifetime of any given myosin molecule on actin is directly determined 
by the rate of ADP and Pi release and the waiting time for a new molecule of ATP to 
bind myosin (Gorga et al., 2003; Kad et al., 2005; Desai et al., 2015), we used a low ATP 
concentration (0.1 µM) to increase the probability that a new myosin molecule would 
bind within an already locally activated area, preventing the complete turning on of 
the thin filament. By promoting the local recruitment of myosin, we can thus study   
S1-GFP detachment dynamics within highly concentrated active regions. 
Figure 4.1a shows a representative kymograph of a thin filament in sub-maximal 
activating conditions, obtained by working at pCa 6, 0.1 µM ATP and S1-GFP at 5 nM. 
S1-'&WŝƐƐĞĞŶďŝŶĚŝŶŐƚŽƚŚĞƚŚŝŶĨŝůĂŵĞŶƚŝŶ “ƉĂƚĐŚĞƐ ?ŽƌůŽĐĂůůǇĂĐƚŝǀĞƌĞŐŝŽŶƐ ?ƐŽŵĞ
labelled A to E) throughout the tightrope. Although these can exist in more than one 
position witŚŝŶ ƚŚĞ ƐĂŵĞ ƚŝŵĞĨƌĂŵĞ ? ƚŚĞ ƚŚŝŶ ĨŝůĂŵĞŶƚ ĚŽĞƐŶ ?ƚ ĂƉƉĞĂƌ ƚŽ ďĞ ĂĐƚŝǀĞ
throughout its full length, since regions depleted of fluorescence are clearly visible in 
the kymograph, demonstrating myosin preferential binding to already activated 
regions. The patches are also capable of shifting along the tightrope with respect to 
their starting position (e.g. patches C and E) with no apparent directional bias (Desai et 
al., 2015), suggesting that the binding of a new S1-GFP to an already existing patch is 





Figure 4.1: Highlighting locally active regions in a kymograph. a) representative kymograph of a thin 
filament in sub-maximal activating conditions, with some of the locally active regions highlighted by red 
boxes and labelled A to E and b) plot of the number of myosin molecules over time of each highlighted 
active region. Sudden collapse of the active region is seen in particular for area A, B and C, while regions 
D and E show more stochastic behaviour. Data was obtained imaging the interactions of 5 nM of S1-GFP 
with thin filaments at pCa 6, in the presence of 0.1 µM ATP. 
 
We can plot the profile of the intensity vs. time for each patch and relate the intensity 
to the number of myosin molecules (as in figure 3.4 in chapter 3), obtaining the graph 
depicted in figure 4.1b. The binding of S1-GFP is seen to occur mostly in a step-wise 
fashion, as expected (patches B to E). The detachment of S1-GFP, however, is seen 
occur both via a stochastic step-wise release (patches D and E and middle part of A and 
C), mostly with transitions of a single myosin per event, and via a sudden collapse of up 
ƚŽ ĨŝǀĞ ŵŽůĞĐƵůĞƐ Ăƚ ŽŶĐĞ  ?ƉĂƚĐŚĞƐ  ?  ĂŶĚ  ) ? ǁŚŝĐŚ ǁĞ ƚĞƌŵĞĚ  “ĐĂƚĂƐƚƌŽƉŚŝĐ
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ĐŽůůĂƉƐĞ ? ? ŽŶƐŝĚĞƌŝŶŐ ƚŚĂƚ ƚŚĞ ƉƌŽďĂďŝůŝƚǇŽĨĂŐŝǀĞŶ ƵŵďĞƌEŽĨ^ ?-GFP molecules 
detaching from the thin filament at the same time scales with the N-th power of the 
probability of each single event, the catastrophic collapse of an active region should be 
a highly unfavourable event; to understand the occurrence of these events in our 
kymographs we analysed our datasets using an unbiased statistical approach, aimed at 
visualising the probability of occurrence of the sudden collapse of active regions versus 
the stochastic detachment and step-wise release mechanism. 
 
4.2.2  ? De-convoluting kymographs into transition matrices 
To study the catastrophic collapse of myosin patches and the binding or release events 
within each kymograph, we de-convolved the fluorescent intensity values in each pixel 
of a kymograph into number of myosins, using the Reversible-jump Markov Chain 
Monte Carlo (RJMCMC) stochastic algorithm. This particular analysis has been 
performed in collaboration with Dr. Hongsheng Dai and Madalina Mihailescu of the 
Department of Mathematical Sciences at the University of Essex, therefore is only 
explained in details in the Appendix (A.6). The output of the algorithm is a linear series 
of intensity values corresponding to the most likely intensity of a specific number of 
S1-GFP molecules. A kymographs is, as such, converted into number of molecules and 
then analysed using a script written in R (by M. Mihailescu and Dr. H. Dai), which 
ĐŽŶƐŝĚĞƌƚŚĞŶƵŵďĞƌŽĨŵǇŽƐŝŶƐŝŶĞĂĐŚƉŝǆĞůĂƐĂ “ƐƚĂƚĞ ?ŽĨƚŚĞĂĐƚŽ-myosin system, 
therefore allowing us to study the binding and release of S1-GFP from the thin filament 
as transitions between states. 
With this method, we measured the number of S1-GFP transitioning from an initial 
state ݅ to a final state ݆ after a single time frame (equivalent to a single frame or 
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vertical slice in a kymograph) and calculated the percentage of occurrence of each one, 
finally assembling the results into transition matrices shown in figure 4.2. Each table is 
the averaged result of three kymographs, each related to a different filament imaged 
at pCa 6 in the presence of 0.1 µM ATP and either 5 or 10 nM of S1-GFP (figure 4.2a 
and c respectively), with the number of transitions (figure 4.2b and d) being calculated 
as the sum of the transitions visualised in two of the three kymographs (one being 
unfortunately lost by our collaborators). The transition matrices have also been colour 
coded as a heat map to better visualise the differences in probabilities, according to 
the legend in figure 4.2. 
The tables are read from left to right, with the first column representing the initial 
state ݅. Along each row of the following columns, we find the probability of transition 
to the each final state ݆ state, ݌௜՜௝, normalised such as  ? ݌௜՜௝௡௝ୀ଴ ൌ  ?, where ݊ is the 
maximum number of myosin molecules seen in a cluster per condition (݊ = 8 for S1-
GFP = 5 nM and ݊ = 10 for S1-GFP = 10 nM, figure 4.2a and 4.2b respectively). This 
normalisation is done considering the maximum number of S1-GFP seen in a 
kymograph as the maximum state each active region can reach. Therefore, according 
to the rules of probability, the sum of each transition probability related to a given 
initial state (i.e. a raw) must be equal to one. The diagonal of each matrix is 
represented as dashes, to indicate that pauses (or missed transitions) within a time 
window are not noted in the calculation of the transition probabilities. Finally, the 
tables have been colour coded as a heat map from blue to red, blue representing the 





Figure 4.2: Experimental transition matrices of myosin patches. Probability of myosin binding and 
release events of thin filament at pCa 6, 0.1 µM ATP and S1-GFP equals to a) 5 nM and c) 10 nM, along 
with their respective number of events seen per transition b) and d). Each raw of the tables has been 




As an example, consider an active region with an initial number of S1-GFP molecules 
equal to 4 (i.e. ݅ = 4); if to this region were to bind an extra two S1-GFP molecules 
within a frame (0.3 seconds), its final state would be equal to 6 (i.e. ݆ = 6) and the 
probability of such transition would be equal to 0.049 for S1 = 5 nM and 0.059 for S1 = 
10 nM (equivalent of saying that this transition occurs 4.9% and 5.9% of the times for 
an active region with 4 S1-GFP molecules). Conversely, if from this region one S1-GFP 
molecule were to release from the thin filament, its final state would be equal to 3, 
with the probability of such transition occurring being 0.149 and 0.073 for S1 = 5 nM 
and 10 nM respectively. However, if all the S1-GFP molecules were to release within 
0.3 seconds, the final state of this active region would be 0, with the probability of this 
transition to occur being 0.64 S1 = 5 nM and 0.61 for S1 = 10 nM. Finally, if this patch 
was to neither acquire nor lose a S1-GFP within a frame, its final state would still be 
equal to 4 and thus fall on the diagonal of the matrix and its probability indicated by a 
dash, as it is not considered in the analysis and subsequent normalisation. 
 
4.2.3  ? Modelling the transition probability within an active region 
To better understand our experimental results, we compared the tables shown in 
figure 4.2 with predicted transition matrices, obtained by modelling each transition as 
a purely stochastic process dependent on the rate of attachment and detachment of 
S1-GFP. Knowing that the ATP second-order binding rate constant ்݇ is 2.03 µM-1s-1 
(see the appendix, A.5), the ATP concentration in our assay is 0.1 µM and the time 
between frames in our videos is 300 ms, therefore we calculate the probability of 




ௗܲ ൌ  ? െ ݁ି ௞௧ 
 
where ݇ ൌ  ்݇ כ ሾܣܶܲሿ, making the term ݁ି௞௧ the probability of an ATP molecule of 
binding to myosin, hence the probability of myosin staying attached to the thin 
filament. Since we are assuming that the detachment of multiple molecules from the 
thin filament is a stochastic process, the cumulative probability of detachment of ݊ 
molecules in a cluster will scale with the ݊th power of ௗܲ. We can write ݊ as a 
difference between the initial (݅) and the final (݆) number of molecules ݊ ൌ ݅ െ ݆ (with  ? ൑ ݆ ൏  ݅and ݅ ൐  ?) and therefore our probability of ݊ molecules detaching ܲௗሺ௡ሻ, 
corresponding to a transition ݅ ՜ ݆, becomes:  
 ܲௗሺ௡ሻ ൌ ௗܲ௡ כ ݅Ǩ݆Ǩ ݊Ǩ 
 
where, the term 
௜Ǩ௝Ǩ௡Ǩ acts as a scaling factor to account for all the possible combinations 
of molecules.  
Likewise, the probability of a myosin joining an already active region can be calculated 
using the݊th power of the attachment probability, ௔ܲ. Therefore, we calculated the 
probability of ݊ molecules binding to a cluster, transitioning from an initial state ݅ to a 
final state ݆, so that  ? ൏ ݆ ൐  ݅and ݅ ൒  ?, as: 




Considering the nature of our assay, ௔ܲ cannot be modelled reliably; we can, however, 
extrapolate it from the experimental data shown in figure 4.2, by simply calculating the 
mean of our transition rates where only one myosin is seen joining an active region, i.e. 
all the values directly to the right of the diagonal of the transition matrices. The mean 
attachment probabilities, when using either 5 nM or 10 nM of S1-GFP are found to be 
not statistically significantly different from each other (0.15 ± 0.03 (SEM) and 0.11 ± 
0.01 (SEM) respectively, with p = 0.1853). 
Figure 4.3 shows the resulting predicted matrices. As in figure 4.2, each matrix has 
been normalised so that the sum along each raw is equal to 1, and the diagonal is 
indicated by dashes since the model does not take into account missed transitions. 
 
 
Figure 4.3: Calculated transition matrix of S1-GFP on thin filaments. Probability of myosin binding and 
release events scaled for different patches sizes. Each raw has been normalised to give a sum equal to 1. 
The table has been colour coded as a heat map to better visualise the differences in probabilities. 
 
Looking at a similar cases used as examples for figures 4.2, we consider an active 
region with an initial number of S1-GFP molecules equal to 4; in the predicted 
transition matrix, the probability of this active region to gain an extra two S1-GFP 
molecules within a frame (0.3 seconds), thus going from an initial state ݅ = 4 to a final 
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state ݆ = 6, has a probability to occur of 0.058 (equivalent of saying that this transition 
can occur 5.8% of the times). Conversely, the probability of an S1-GFP molecule to 
release from an active region with 4 other molecules is of 0.517. However, the 
probability of all the S1-GFP molecules to release within 0.3 seconds would be equal to 
2.19·10-5, highlighting the difference between the experimental data and the 
probabilistic model.  
 
 
4.3  ? Discussion 
 
The comparison of the experimental transition matrices with the calculated matrix, 
allows us to understand the nature of the association and dissociation of myosin to the 
thin filament. The modelled transition matrix show that the probability of association 
and dissociation decreases further away from the diagonal along each raw in an 
exponential fashion, as expected from a stochastic model. The same is seen in the 
experimental transition matrices for both concentrations of S1-GFP used, showing an 
inverse proportionality of the transition probability to the number of myosin molecules 
that leave the thin filament at once. These results indicate that the association and 
dissociation within an open active region is a stochastic process, dependent only on 
the power of the binding and release rate of a single myosin. 
Furthermore, in the calculated matrix, the probability of a single myosin association is 
inversely proportional to the cluster size, the opposite of what is found for the 
detachment probability. In the experimental matrices, however, it is hard to define a 
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specific trend, with association and dissociation probabilities being similar all 
throughout. Since each experimental transition matrix is an average of only three 
transition matrices obtained in the same experimental conditions, we correlate this 
difference with the experimental error caused by the low number of data points. 
Furthermore, by looking at the number of times each transition has been observed 
throughout all experiments, it is clear that the transitions 0 to 1 and 1 to 0 (i.e. the 
binding and release of a single S1-GFP) are preferred against the formation of clusters, 
which highlights the different significance within the probabilities seen for large 
number of clusters and the difficulty, as well as the importance, in tuning the 
experimental conditions to achieve sub-maximal activating conditions. 
The main difference between the experimental and calculated transition matrices is, 
however, seen in the first column (݆ = 0), in the form of a highly increased probability 
for the complete collapse of an active region in our experimental dataset. This 
behaviour is the most seen for each cluster size ݅ (figure 4.2b and d) and is in line with 
the raw data seen in the kymograph in figure 4.1, where the fluorescence intensity of 
active regions drops suddenly, hinting at the simultaneous release of a large number of 
myosin molecules. 
We can exclude photobleaching as a cause for the increased probability, since we 
know that at 0.1 µM ATP the average lifetime of a single S1-GFP on a thin filament is of 
2.3 seconds (see appendix A.5), longer than our time resolution of 300 ms; moreover, 
photobleaching would be seen as a step-wise decay in fluorescence and would not 
explain the high probability of detachment seen for large myosin clusters, leaving us 




The only likely protein that would be capable of exerting such a critical effect is 
tropomyosin, meaning that the catastrophic collapse observed here could be an active 
way of turning off the thin filament during sarcomere relaxation. Our data also 
suggests that the thin filament is not turned off all at once, since in the kymographs we 
can still see regions of activation further away from a collapsed myosin patch (figure 
4.1). Several studies have found that the regulatory unit size of the thin filament spans 
up to 14 actin monomers (Geeves and Lehrer, 1994; Maytum et al., 1999; Kad et al., 
2005) and can contain up to 11 myosin molecules (Desai et al., 2015). These results are 
consistent with our findings, since the maximum number of myosin molecules found 
within an active region in our experiments is 7 at [S1-GFP] = 5 nM and 10 at [S1-GFP] = 
10 nM, as shown in figure 4.2a and c. This suggests that the active regions created in 
sub-maximal activating conditions are similar in size than a thin filament regulatory 
unit, a distance determined by tropomyosin shifting from the closed to the open 
position, caused by the binding of a first myosin, further implying that tropomyosin 
must be involved in the catastrophic collapse mechanism. 
However, the resolution of our optical microscope is diffraction limited, and prevent us 
to distinguish each single myosin molecule and precisely model the relaxation 
mechanism. Many questions still need to be answered: how would tropomyosin 
provoke the instantaneous release of myosin? Is its mechanism based on elastic forces, 
where the more myosin molecules present, the more strain is exerted on tropomyosin, 
leading to a force build-up that eventually breaks down and causes tropomyosin to 
return to a less energetic position? Is calcium releasing from the troponin complex 
partly responsible, allowing direct competition between the TnI subdomain and 
myosin, forcing tropomyosin back in its blocked position? Is actin involved in this 
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process and how? Would it be possible for a large amount of myosin molecules to 
modify its helical structure until it is not sustainable anymore? More detailed 
experiments are necessary to answer all these questions, but this study could pave the 
way for a better understanding of the relaxation process of the sarcomere, leading to a 
better understanding of diseases that impair heart relaxation, such as Hypertrophic 























CHARACTERIZING THE CONSEQUENCES OF  
N-TERMINAL MYOSIN BINDING PROTEIN-C 
FRAGMENTS INTERACTIONS WITH ACTIN  
 
5.1  ? Introduction 
 
Cardiac myosin binding protein-C (cMyBP-C) is a sarcomeric protein that is thought to 
function as a modulator of muscle contraction and is known to play an important role 
in Hypertrophic Cardiomyopathy (HCM) (Harris et al., 2011). As mentioned in chapter 1, 
about 33% of HCM causing mutations are found in cMyBP-C, making it the second 
most important protein that leads to the genetic disease (Maron et al., 2012). However, 
before embarking on understanding the role of these mutations in disease, we must 
first have a clear understanding of its role in muscle contraction. To this end, we 
focused our studies in understanding cMyBP- ?Ɛ ƌŽůĞ ŝŶ ƚŚŝŶ ĨŝůĂŵĞŶƚ ĂĐƚŝǀĂƚŝŽŶ ?
working with three different murine cMyBP-C N-terminal fragments, namely C0C3, 
C0C1 and C0C1f (C0C1 with the addition of the next 17 amino acids from the M-
domain). We explored the role of each fragment on myosin binding to thin filaments, 
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as well as their binding behaviour on thin filaments on their own. These studies 
provide evidence for the molecular mechanism of how cMyBP-C could function both as 
an activator and repressor of muscle contraction. 
 
 
5.2  ? Results 
5.2.1  ? Investigating the effects of cMYBP-C N-terminal fragments 
on myosin binding to thin filaments 
The effects of C0C3, C0C1f and C0C1 on acto-myosin interactions were investigated by 
examining the level of 15 nM of S1-GFP binding to the thin filament in the presence 
and absence of 1 µM of unlabelled fragments, both at low and high calcium (pCa 7 and 
pCa 4 respectively), imaging ten or more tightropes across more than 3 flow cells per 
condition. Figure 5.1 shows examples of kymographs obtained in the experiments. 
In agreement with (Desai et al., 2015), the kymograph at low calcium with no fragment 
in figure 5.1a shows very few S1-GFP binding events, since 93% of the thin filament is 
in its blocked state (Desai et al., 2015). However, introducing C0C3 increases the 
number of binding events, while the presence of C0C1 and C0C1f does not affect S1-
GFP binding. The opposite is observed at high calcium or pCa 4 in the top panel of 
figure 5.1b where, in the absence of fragment, myosin is seen binding frequently to the 
thin filament, with the formation of clusters caused by myosin cooperativity. In 
contrast, when C0C3 is introduced in the assay at high calcium, the amount of myosin 
binding to the thin filament is drastically reduced. As for low calcium, the presence of 




Figure 5.1: Effects of cMyBP-C N-terminal fragments on acto-myosin interactions. Representative 
kymographs of S1-GFP binding to reconstituted thin filaments in the absence and presence of cMyBP-C  
N-terminal fragments (from top to bottom, no fragment, C0C3, C0C1 and C0C1f) obtained at a) low 
calcium (pCa 7) and b) high calcium (pCa 4). Data were collected using 15 nM of S1-GFP and 1 µM of 
fragment, imaging more than 10 tightropes per condition throughout more than 3 flow chambers. 
 
To quantify the changes in S1-GFP binding we calculated the average intensity per pixel 
for each kymograph and averaged all data collected in the same experimental 
conditions. Normalising the data to the binding of S1-GFP at the same calcium 
concentration in the absence of the construct gives us the relative change in intensity 
caused by the presence of the cMyBP-C fragment, as shown in the bar chart in figure 
5.2 (with n being the number of filaments imaged over the number N of replicated 





Figure 5.2: Quantifying cMyBP-C N-terminal fragments effect on S1-GFP binding to thin filaments. Bar 
chart of the average intensity/pixel ratio in the kymographs in figure 5.1 of S1-GFP binding in the 
absence and presence of different cMyBP-C N-terminal fragments. The values have been normalised to 
each respective control experiment (i.e. no fragment present at same [Ca2+]). Data were collected using 
15 nM S1-GFP w/ or w/o 1 µM of fragment, with n values representing the number of tightropes imaged 
per condition while the N in parenthesis indicate the number of flow chambers used per condition. Only 
results obtained in the presence of C0C3 showed a statistically significant (indicated by the *) increase 
(61.2% ± 11.7 (SEM), p < 0.001) or reduction (45.5% ± 11.9 (SEM), p = 0.009) in S1-GFP binding at low 
and high calcium, respectively. 
 
At low calcium there is a significant (p < 0.0001) increase in S1-GFP binding (61.2% ± 
11.7) in the presence of C0C3. Whereas at high calcium, S1-GFP binding is significantly 
(p = 0.009) reduced to 45.5% ± 11.9 with C0C3. Interestingly, no significant difference 
in myosin binding is seen throughout the experiments performed with the shorter 
fragment C0C1f (16.0% ± 8.2, p = 0.1390 at low calcium and 7.5% ± 13.8, p = 0.6126 at 
high calcium) and C0C1 (2.4% ± 6.2, p = 0.7072 at low calcium and -6.8% ± 13.7,            
p = 0.6189 at high calcium), indicating that the deleted subdomains M to C3 are 
necessary for the modulation of acto-myosin interactions. 
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5.2.2  ? Visualising cMyBP-C N-terminal fragments binding to actin 
Previous studies have shown that cMyBP-C N-terminus directly binds myosin in its S2 
region and its regulatory light chain (Starr and Offer, 1978; Gruen and Gautel, 1999; 
Kunst et al., 2000; Ratti et al., 2011; Kampourakis et al., 2014). Other groups also show 
that it can bind to actin through several sites found throughout its whole N-terminus 
(Mun et al., 2011, 2014; Belknap, Harris and White, 2014; Harris et al., 2016). Since in 
our previous experiments we are not able to determine whether the fragments are 
binding directly to S1-GFP, the thin filaments, or both, we cannot exclude these 
scenarios. Therefore, in order to have a better understanding of cMyBP-C mechanism, 
we fluorescently tagged the fragments with Cy3 (see section 2.6) and studied their 
binding properties in our tightrope assay in the absence of myosin. Data were 
collected by visualising 20 nM of fragment on actin filaments or on reconstituted thin 
filament at both low and high calcium, throughout 2 or more flow chambers, and with 
each tightrope being exposed for 1 sec. 
Figure 5.3 shows examples of images of C0C3 bound to tightropes in different 
conditions. There is a striking difference between the images, where only a few 
molecules are seen bound on unregulated actin (figure 5.3a) and to thin filaments at 
low calcium (figure 5.3b), unlike at high calcium, where thin filaments appear highly 





Figure 5.3: Imaging fluorescent C0C3. Pictures of tightropes obtained with 20 nM of Cy3-C0C3 on  
a) unregulated actin filaments and on thin filaments at b) low calcium (pCa 7) and c) high calcium (pCa 4), 
collected using an exposure time of 1 second. 
 
On the contrary, no difference is observed in images of C0C1f and C0C1 on regulated 





Figure 5.4: Imaging fluorescent C0C1f and C0C1. Pictures of 20 nM of a) Cy3-C0C1f and b) Cy3-C0C1  
on thin filament tightropes at low and high calcium (pCa 7 and pCa 4 respectively), collected using an 
exposure time of 1 second. 
 
We can quantify the level of decoration by calculating the average number of 
molecules bound per unit length of thin filament (µm). To do this, we can follow the 
approach used by (Desai et al., 2015) and (Iino et al., 2001) and fit each fluorescence 
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point spread function to a Gaussian distribution, the intensity of which determines 
how many molecules are associated within it. This requires knowing the fluorescence 
intensity of a single molecule bound to the thin filament, which we measured by fitting 
a distribution of intensity values at low calcium, where molecules are assumed to bind 
mostly as single entities (an example is seen in figure 5.5 for C0C3). 
 
 
Figure 5.5: Calculating the fluorescent intensity of a single binder. A histogram of the intensities of the 
fluorescence point spread function of C0C3, collected at pCa 7. The histogram is fit to a number of 
Gaussian distributions, whose mean values are plot as a function of the hypothetical number of 
molecules associated with it and fit to a straight line, where the slope corresponds to the intensity of a 
single binder (inset). 
 
Throughout these experiments we kept the frame rates constant, to ensure that the 
fluorophores emit approximately the same amount of light (Walcott and Kad, 2015). 
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The histogram in figure 5.5 was fitted to six Gaussian distributions (see Appendix A.7 
for details) using the least square displacement method and the Solver Add-in for 
Office Excel, which uses an algorithm to vary the fitting parameters until a minimum 
value between the data and the fit is found. The intensity and the average of each of 
the six Gaussian distributions were fit independently while their standard deviation 
was constrained to one value for all, to better represent the experimental distribution 
of intensities associated to multiple unresolvable fluorescent molecules. Table 5.1 
summarises the values of the amplitude, mean and standard deviation (S.D.) obtained 















ŵƉůŝƚƵĚĞ 170.94 87.43 22.61 12.96 7.98 4.89 
DĞĂŶ 439.06 757.19 1139.28 1407.72 1859.92 2330.27 
^ ? ? 110.38 110.38 110.38 110.38 110.38 110.38 
Table 5.1: Summary of the values of amplitude, mean and standard deviation (S.D.) of each Gaussian 
distributions obtained from the histogram in figure 5.5. 
 
Plotting the mean values of each Gaussian distribution versus the predicted number of 
molecules gives us the linear chart in the inset of figure 5.5, with a slope of 372.36 and 
an intercept of 18.97. We consider the slope as the average fluorescence intensity of a 
single C0C3 molecule and the intercept its associated error. Using this value we 
determined the level of C0C3 decoration at low and high calcium to be 1 ± 0.12 and 
5.69 ± 0.55 molecules/µm respectively. These two values are found to be statistically 
significantly different, with a p < 0.0001. Remarkably, C0C3 decoration of unregulated 
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actin with no calcium yielded a value of 1.22 ± 0.11 molecules/µm, not statistically 
significant from the decoration of C0C3 seen on thin filaments at pCa 7 (p = 0.1813). 
For C0C1f, no change in decoration of thin filaments was observed (figure 5.4a) 
between high and low calcium (1.14 ± 0.11 and 1.61 ± 0.21 molecules/µm respectively, 
p = 0.0523), while C0C1 (figure 5.4b) decorated thin filaments more avidly at pCa 7 
(2.76 ± 0.37 molecules/µm) compared to pCa 4 (0.73 ± 0.23 molecules/µm; 
significantly different with p = 0.0055). Table 5.2 shows a summary of all the 
decoration results, along with details on the number of filaments imaged (n) and flow 
cells used (N). 
 
 
C0C3 C0C1f C0C1 
 ACTIN THIN FILAMENTS THIN FILAMENTS THIN FILAMENTS 
[Calcium] - pCa 7 pCa 4 pCa 7 pCa 4 pCa 7 pCa 4 
Mean 
(molecules/µm) 
1.22 1.00 5.69 1.14 1.61 2.76 0.73 
SEM 0.11 0.12 0.55 0.11 0.21 0.37 0.23 
n (filaments) 47 50 28 94 99 68 19 
N (flow cells) 2 11 2 9 5 7 4 
Table 5.2: Results of the decoration of unregulated actin/reconstituted thin filaments by cMyBP-C 
fragments, indicating the mean (molecules/µm), standard error of the mean (SEM), filaments imaged (n) 
and flow chambers used (N). 
 
The number of molecules per fluorescent spot also provides information on the 
cooperative binding of cMyBP-C fragments. Figure 5.6 shows histograms of the 
number of molecules within each fluorescent spot or cluster for C0C3 and C0C1f at low 





These histograms can be fit using a Flory-Schulz distribution (Flory, 1936), which 
predicts the weight fraction of a polymer through the probability of association of its 
monomers, as described by the following equation: 
 
௟ܹ ൌ ݈  ? ݌ሺ௟ିଵሻ  ? ሺ ? െ ݌ሻଶ 
 
where ௟ܹ  is the weight fraction (termed % occurrence in figure 5.6), ݌  is the 
probability of association and ݈ is the number of molecules in the cluster (polymer 
length). The probability is calculated via a quadratic binding isotherm taking into 
account the cMyBP-C fragment concentration ሾܥሿ, the available actin concentration ሾܣሿ and the fragment affinity for actin ܭ஼, as described by: 
 
Figure 5.6: The distribution of cMyBP-C 
fragment molecules per cluster. 
Histograms of cluster sizes calculated 
based on the fluorescence intensity of a 
single Cy3-labelled fragment for a) C0C3 
on unregulated actin, b) C0C3 and c) 




݌ ൌ ሺሾܣሿ ൅ ሾܥሿ ൅ ܭ஼ሻ െ ඥሺሾܣሿ ൅ ሾܥሿ ൅ ܭ஼ሻଶ െ  ?ሾܥሿሾܣሿ ?ሾܥሿ  
 
However the available actin concentration depends on the thin filament activation 
state and consequently on the calcium concentration ሾܥܽଶାሿ. Hence, when using thin 
filaments, we calculated it according to: 
 
ሾܣሿ ൌ ሾܥܽଶାሿ݇஼௔ ൅ ሾܥܽଶାሿ כ ߮ 
 
where ܭ஼௔ is the thin filament calcium affinity and ߮ is a scaling factor that accounts 
for the loss of thin filaments as they are suspended between the beads in our assay. 
This value was constrained to be larger than zero and lower or equal to the maximum 
amount of actin in the flow cell (or nominal concentration), which is the concentration 
of unregulated actin/reconstituted thin filaments flowed in the microfluidic chamber 
to suspend the filaments. When considering C0C3 binding to unregulated actin, ሾܣሿ 
was set to be equal to nominal concentration, since there is no calcium dependent 
mechanics that alters the availability of actin binding sites. 
The ܭ஼௔ (affinity of calcium binding to thin filaments) was determined to be 0.3 µM 
(pCa50 of ~6.5), the C0C3 affinity for unregulated actin was determined to be 486.3 nM, 
while for reconstituted thin filaments (RTFs) at pCa 7 and pCa 4 was 212.8 nM and 
153.1 nM respectively. Finally, C0C1f was found to have an affinity to RTFs equals to 
207.7 nM and 470.1 nM at pCa 7 and pCa 4 respectively. The magnitude of the change 
in COC3 affinity between calcium concentrations is not substantial therefore we can 
state that calcium does not affect the binding of C0C3; C0C1f, however, shows a larger 
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change and therefore calcium may be reducing the binding affinity to thin filaments for 
this construct, although to no effect on the number of bound molecules, as seen in 
figure 5.6c. Insufficient binding of C0C1 at high calcium did not allow us to conduct the 
same analysis reliably. 
 
5.2.3  ? Dynamics of cMyBP-C N-terminal fragments on RTFs 
So far we have discussed the effect of calcium on C0C3 binding to thin filament 
without taking into account its dynamics. However, upon closer inspection of the 
kymographs and on long timescales, some of the C0C3 molecules have been seen 
diffuse along the tightrope, evident as movement along the y-axis (figure 5.7a). We set 
out to further investigate this by collecting movies of filaments imaged at 1 frame per 
second (fps) for up to 5 minutes, at a concentration of 20 nM of C0C3 on unregulated 
actin and RTFs at pCa 7, as well as 20 nM of C0C1f or C0C1 at pCa 7; at pCa 4, to 
compensate for decoration levels that enable individual molecules to be distinguished, 
5 nM C0C3 and C0C1f or 20 nM C0C1 was used. Figure 5.7b shows a bar chart of the % 
of diffusing molecules per condition, with N being the number of replicated flow 
chambers and n the total number of molecules imaged. To prove that diffusion is not 
concentration dependent and was not altered by the ratio of labelled:unlabelled 
molecules (see Chapter 2, section 2.6), we collected movies on thin filaments at low 
calcium using 20 nM of fluorescent C0C3 and 90 nM of unlabelled C0C3 (indicated as 





Figure 5.7: Comparing the dynamics of cMyBP-C fragments on actin and thin filaments. a) kymograph 
of molecules of C0C3 diffusing along a thin filament tightrope imaged at pCa 7, along with static ones; 
b) comparison of the % of diffusing molecules for C0C3 on unregulated actin and C0C3, C0C1f and C0C1 
on thin filaments at low calcium (pCa 7) and high calcium (pCa 4). Values are averages of percentages 
calculated over N different flow cells, while (n) is the total number of molecules visualised. A control 
experiment was necessary to confirm that diffusion was not caused by the labelled:unlabelled ratio, 
therefore we collected data on thin filaments at low calcium using 20 nM of fluorescent C0C3 and 90 
nM of unlabelled C0C3, indicated as pCa 7 (+). 
 
The number of diffusing C0C3 molecules was found to be not significantly different     
(p = 0.3232) when imaging with an excess of unlabelled C0C3 (26.5 % ± 5.3 molecules 
diffusing at pCa 7 (+), N = 11, where N is the number of experiments performed) or 
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with fluorescent C0C3 only (19.4 % ± 4.6 molecules diffusing at pCa 7, N = 11). 
However, this amount decreased significantly (p = 0.029) to 6.0 % ± 1.8 (N = 8) at high 
calcium. The value obtained at high calcium is, however, not significantly different (p = 
0.1882) than the one found when using unregulated actin, with only 2.7 % ± 1.3 (N = 6) 
molecules diffusing. This last result in particular also proves that diffusion is not caused 
by aggregation of molecules in solution and that the difference in C0C3 concentration 
used between pCa 7 and pCa 4 does not alter diffusional properties. 
In comparison, C0C1f showed no significant difference (p = 0.2025) in diffusive 
behaviour at both low and high calcium, 27.3 % ± 2.2 (N = 9) and 32.3 % ± 3.1 (N = 6) 
respectively. Similarly, C0C1 also showed no change in the level of diffusion with 
calcium, with about 24.5 % ± 6.4 (N = 7) of the molecules diffusing at pCa 7 versus 47.7 % 
± 26.2 (N = 3) at pCa 4 (p = 0.2542). 
Throughout all the conditions explored, about 60% of the diffusing molecules where 
diffusing individually, while the rest diffused in clusters of 2 or more molecules; the 
only exception we found was C0C1 at low calcium, where only 35% of the molecules 
were diffusing individually. Using only the molecules diffusing individually, we 
calculated the diffusion constants and alpha coefficient using the mean squared 
displacement MSD: 
 
ܯܵܦ ൌ  ?݊෍൫ݔ௜ሺݐሻ െ ݔ௜ሺ ?ሻ൯ଶ௡௜ୀଵ ൌ  ?ܦݐఈ  
 
where ܦ is the diffusion constant of the molecule, t is the time between each 
diffusional step ݔ௜  respect to its reference position ݔ௜ሺ ?ሻ and Ƚ is a coefficient that 
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denotes the nature of the diffusion, being it driven by a force (Ƚ > 1), random (Ƚ = 1) or 
constrained by other mechanisms (Ƚ < 1). Applying this analysis to our data, results in 
the values of D and Ƚ listed in table 5.3. 
 
 
C0C3 C0C1f C0C1* 
 
pCa 7 (+) pCa 7 pCa 4 pCa 7 pCa 4 pCa 7 
 
D ɲ D ɲ D ɲ D ɲ D ɲ D ɲ 
Mean 
4.23  ?10-3 1.05 6.28  ?10-3 0.98 6.81  ?10-4 1.36 4.06  ?10-3 1.00 2.95  ?10-3 0.88 1.13  ?10-3 0.71 
SEM 
8.91  ?10-4 0.06 1.24  ?10-4 0.07 2.13  ?10-4 0.16 8.99  ?10-4 0.07 1.15  ?10-3 0.08 3.96  ?10-4 0.09 
n 37 39 32 33 5 6 39 39 15 15 9 12 
Table 5.3: Values of the mean diffusion constant (in µm2/s) and coefficient alpha in the different 
conditions explored, along with the standard error of the mean (SEM) and the number of molecules (n) 
used in the calculation. *Due to insufficient binding, diffusion data was not acquired for C0C1 at pCa4. 
 
These results indicate that the fragments are diffusing randomly along the thin 
filament. We can check the statistical differences between the diffusion constant 
values in logarithmic space (since the MSD depends on the ɲ power of D), resulting in 
no difference between the diffusion at low calcium of C0C3 and C0C1f and a 
statistically significant difference when compared to C0C1 (p = 0.1516 and p < 0.0001 
respectively). In addition, the diffusion of C0C3 at low calcium is found to be 
statistically significantly lower than that at high calcium (p < 0.0001), although the 
same cannot be said for C0C1f (p = 0.4569). The addition of extra unlabelled fragment 
is also seen to not produce any effect on the diffusive characteristics of C0C3, with no 
statistically significance seen between the two diffusion constants (p = 0.1822). 
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Diffusion along a lattice can be described as multiple discrete steps, allowing us to 
calculate the average step size of the fragments on the thin filament, provided the 
lifetime of each one on actin is known. Laser trap studies (Weith et al., 2012) indicated 
that C0C3, C0C1f and C0C1 can bind to actin with two different lifetime populations, a 
very short one of less than 30 ms and one longer than 200 ms. Considering that the 
reported longer events were ~60 times less frequent in their experiments (Weith et al., 
2012), we used the short attached lifetime to calculate the step size for each fragment 
at low calcium, according to the following equations (Kad et al., 2010): 
 ݏݐ݁݌ݏݏ ൌ  ?߬ൌ  ?ܦ݈ଶ ݈ ൌ  ? ?ܦ߬ 
 
where ߬ is the attached lifetime, ܦ is the diffusion constant and ݈ is the average step 
size. This provides in an average step size of 16.63 ± 2.80 nm (SD) for C0C3,             
12.42 ± 1.69 nm (SD) for C0C1f and 6.88 ± 1.32 nm for C0C1. 
 
 
5.3  ? Discussion 
5.3.1  ? The whole N-terminus of cMyBP-C is responsible for thin 
filament activation 
Truncation constructs of cMyBP-C enabled us to isolate which fragments have the 
capability to modulate thin filament activity. Only the full N-terminal fragment C0C3 
was found to be able of both activating and inhibiting myosin attachment to thin 
filaments.  The activation observed at low calcium was seen to be caused by a direct 
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increase in myosin binding to the thin filament, whereas inhibition was caused by a 
substantial decrease in the amount of myosin binding at high calcium. This implies that 
the modulation of velocity observed in vitro motility assays experiments (Razumova et 
al., 2006; Weith et al., 2012) derives from the availability of myosin for motion 
generation. In agreement with the ATPase data in (Belknap et al., 2014), removing of 
the M- along with the C2 and C3 subdomains produced fragments that neither 
activated nor inhibited myosin binding. However, restoration of the first 17 residues of 
the M-domain (C0C1f), previously known to inhibit in vitro motility velocity (Weith et 
al., 2012), did not affect myosin association significantly in our thin filament tightropes 
assay (Figure 5.1). Although our results agree with previous studies in terms of these 
shorter fragments being unable to activate thin filaments, the disagreement in the thin 
filament inhibition characteristic of C0C1f suggests that, in the in vitro motility assay, 
inhibition occurs through a different mechanism. Previous studies have suggested that 
cMyBP-C can function as a viscous load, slowing thin filament speed (Previs et al., 
2012), or increasing force production in hearts lacking cMyBP-C (Korte et al., 2003), 
suggesting that both competition and viscous load must be taken into account to fully 
explain inhibition by cMyBP-C (Walcott et al., 2015). However, force or load do not 
play a role in our assay and the only possible mechanism we can detect is direct 
competition or inhibition; therefore, we can assert that the discrepancy seen with 
C0C1f must be caused by its viscous interactions with the actin and/or the surface in 
the motility assay (Weith et al., 2012). 
As with our studies without the M-domain, the myosin ATPase was seen to be 
unaffected by C0C1 at low and high calcium (Belknap et al., 2014). This highlights the 
importance of a complete M-domain for the stimulation and inhibition of thin 
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filament-myosin interactions. Taken together with previous studies (Weith et al., 2012; 
Belknap et al., 2014; Mun et al., 2014), this suggests the presence of multiple sites in 
the M-domain with alternate activities, likely modulated by phosphorylation (Stelzer et 
al., 2006; Shaffer et al., 2009; Previs et al., 2016). 
 
5.3.2  ? cMyBP-C possesses a weak binding state to actin 
The N-terminal domains C0 and C1 have been known to possess actin binding 
properties (Lu et al., 2011; Mun et al., 2011; Orlova et al., 2011; Harris et al., 2016), 
while the M-domain is known to possess the ability to modulate actin binding (Bezold 
et al., 2013; Mun et al., 2014; Previs et al., 2016). These properties have also been 
shown in our data, where all the fragments showed thin filaments binding capabilities 
with only C0C3 being capable of increasing myosin binding to the thin filaments. 
However, our results highlight a new mode of actin binding for the N-terminal region 
of cMyBP-C. Figure 5.7 shows that at low calcium for C0C3 and regardless of calcium 
for C0C1f and C0C1, about 20-30% of the molecules observed diffuse along the thin 
filament. From the diffusional characteristics we were able to define this as an 
unbiased random walk, as would be expected from cMyBP-C, since it is not a motor 
protein. Using data from (Weith et al., 2012) we were able to calculate that the 
ĨƌĂŐŵĞŶƚƐ ?ĚŝĨĨƵƐŝŶŐƐƚĞƉƐŝǌĞ ranges between ~7 and ~15 nm, consistent with 1 to 3 
actin monomers, although the optical resolution in our microscope set-up does not 
allow us to visualise individual steps. The fact that the diffusion constant and amount 
of molecules diffusing are the same for all fragments at low calcium, suggests that 
diffusion is a general mechanism and that it is linked to the thin filament activation 
state. However, our data also suggest that the interaction of subdomains C0 and C1 is 
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not enough for thin filament activation (figure 5.1), whereas the whole N-terminal 
region is required to increase/decrease myosin binding to the thin filament. Hence, the 
interactions of subdomains M to C3 could lead to a further shift in position of Tm, 
exposing more binding sites at high calcium, leading to a significant shift towards all 
static binding. Knowing that tropomyosin moves across the face of actin (Mckillop and 
Geeves, 1993; Poole et al., 2006) and that these structural positions are in thermal flux 
(Schaertl et al., 1995; Moore et al., 2016), it is possible that cMyBP-C association is 
facilitated at high calcium, as indicated by our decoration data for C0C3 at pCa 4 
(figure 5.3). Once cMyBP-C binds to the thin filament, it would hold the Tm in the 
closed position (Mckillop and Geeves, 1993; Mun et al., 2014) permitting myosin 
binding and activation of the thin filament, at the same time potentiating its own 
binding capability. This is also demonstrated by the C0C3 significant decrease in 
diffusion constant at high calcium compared to low calcium, indicating that not only 
the number of molecules diffusing decreases with the opening up of the thin filament, 
but that their motility also slows down. 
The observation that 70-80 % of the molecules are not diffusing does not mean that 
the majority of cMyBP-C fragments are strongly associated. At equilibrium there will 
be molecules free in solution, therefore the true determinant of association is the 
relative numbers of free versus bound molecules. Although it would be interesting to 
have a better understanding of the kinetic mechanism behind the diffusion-to-static 
transition, the thin filament tightropes assay can only measure attached molecules, 
thus preventing a more in depth analysis on that front. Other experiments are 
necessary to cover that aspect of the mechanism, possibly performed through 
concentration dependency studies of the amount of cMyBP-C bound. Therefore, the 
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most likely scenario based on our current knowledge and experiments is that the high 
percentage of static versus motile molecules actually represents the outcomes of 
successful diffusional searches, with unsuccessful searches eventually leading to 
detachment of the cMyBP-C N-terminal fragment.  
In muscles tissue,  cMyBP-C is C-terminally anchored to the thick filament in the C-zone 
of the sarcomere (Freiburg and Gautel, 1996; Flashman et al., 2004), raising doubts 
over whether diffusion would happen in vivo at all. Knowing that N-terminal fragments 
have been shown to modulate thin filament sliding in a calcium concentration 
dependence in in vitro motility assay (Razumova et al., 2006, 2008; Mun et al., 2014) 
and that it has been thought to function as a viscous load (Walcott et al., 2015), it is 
difficult to rule out that our in vitro observations on cMyBP-C diffusion do not have a 
physiological role. In this scenario, diffusion might be a response mechanism to the 
shortening of the sarcomere, where cMyBP-C binding would switch from a static 
position on the thin filament to a dynamic attachment/detachment mechanism during 
muscle contraction, with the C-terminus fixed on the thick filament and the N-terminus 
transiently binding to the thin filament, which would be seen as a viscous load in 
motility assay experiments, or as diffusive motion in our thin filament tightrope assay. 
This hypothesis however, does not fit well with the results shown here, since the 
amount of C0C3 diffusing molecules is drastically reduced for thin filaments at high 
calcium and unregulated actin (figure 5.3 and table 5.1) and, knowing that the thin 
filament tightropes assay does not allow us to measure load or study cMyBP-C tension 
dependence binding to the thin filament, it is impossible to draw a meaningful 
conclusion on this mechanism. 
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Another possibility is that the diffusion we observed in our experiments represents a 
weak interaction of the cMyBP-C N-terminus with actin and tropomyosin. Indeed, such 
an interactions could depend on the calcium concentration or the thin filament 
activation state, where multiple cMyBP-C binding sites becoming more accessible as 
tropomyosin shifts its position on actin, as discussed above. Therefore, our 
experiments points strongly towards a two binding states working model for the         
N-terminus of cMyBP-C in the sarcomere: a first weak binding interaction (diffusive), in 
which the C0 and C1 domains interact with the thin filament, binding and releasing 
quickly, and a subsequent strong and stable binding, characterised by a higher affinity 
for the thin filament, in which subdomains M to C3 also contribute to actin binding, 
facilitating the movement of tropomyosin from the blocked to the closed state as well 
as myosin binding, finally resulting in the activation of the whole thin filament.  
 
5.3.3  ? Inhibition of myosin binding is due to cooperative proximal 
binding of cMyBP-C to thin filaments 
The distribution of single molecules bound to thin filaments provides insight into the 
spatial coordination of cMyBP-C binding and its dependence on calcium. C0C3 clearly 
shows a significant increase in thin filament binding at pCa 4. Detailed examination of 
the binding indicates C0C3 forms clusters (Figure 5.3c and 5.6b), indicating that C0C3 is 
increasing its own binding proximally, hence binding cooperatively. Interestingly, 
comparing these results with unregulated actin highlights how this binding is not 
caused by a larger amount of actin exposed at high calcium, indicating rather that the 
regulatory proteins themselves play a role in clustering cMyBP-C. Using a polymer 
138 
 
growth model we are able to estimate the affinity of cMyBP-C fragments for thin 
filaments as ~200 nM. However, this value is tighter than the affinity we found for 
unregulated actin (486.3 nM, figure 5.6a) and considerably tighter than ~2 µM 
reported elsewhere (Belknap et al., 2014). Our value for the binding constant derives 
from directly imaging cooperative binding and therefore is likely to represent 
monomer binding affinity. This ݇஼  however, is not a simple value in the context of 
cooperative binding, since it is still not clear how this could inhibit myosin ATPase or 
thin filament speed in the motility assay (Razumova et al., 2006). 
Within the sarcomere, cMyBP-C is fixed in position along the thick filament lattice, 
through its C-terminus, at an enforced spacing of ~43 nm, which would preclude 
clustering. However, considering that each thin filament in a muscle lattice is 
surrounded by three thick filaments, our observations suggest that these could bind in 
the near vicinity to one another and cluster, although at a lower density level to what 
seen in our experiments. This may explain the reduced force response seen in stretch 
















In this thesis work I used a single molecule approach to study how tropomyosin, its 
E180G mutation and myosin binding protein-C regulate and modulate acto-myosin 
interactions and cross bridge formation, in order to expand our understanding of how 
errors in the molecular mechanism of muscle contraction can lead to hypertrophic 
cardiomyopathy. 
To understand how the E180G tropomyosin mutation leads to hypertrophic 
cardiomyopathy, we looked at how it affects myosin binding and cooperativity, while 
comparing our results with data obtained in (Desai et al., 2015) for the wild-type 
tropomyosin. Through in-vitro motility assay experiments, we found that thin filaments 
possessing the E180G tropomyosin homodimer mutation have increased sensitivity to 
calcium, (ȴpCa = 0.44 ± 0.05) and exhibit reduced cooperativity (highlighted by the 
reduced Hill coefficient), confirming the results shown in (Bing et al., 2000) and 
(Matyushenko et al., 2017), among others. Using our thin filament tightropes assay, we 
confirmed the increase in calcium sensitivity (ȴpCa > 0.5) and linked the reduced 
cooperativity found in the motility experiments to a reduction in the myosin 
cooperative unit, from 11 actin subunits found for wild-type tropomyosin to 7 for the 
E180G mutation. These findings are also supported by other studies found in the 
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literature, with the increased calcium sensitivity visible not only in motility assay 
experiments, but also in ATPase assays and tension vs. pCa curves (Bing et al., 2000; 
Boussouf et al., 2007; Bai et al., 2011; Wang et al., 2011; Janco et al., 2012; Ly and 
Lehrer, 2012; Matyushenko et al., 2017), while the increase in flexibility of the 
tropomyosin chain was observed both using electron microscopy and Atomic Force 
Microscopy (despite these studies disagreeing in the flexibility measurements by a 2-
fold factor) (Li et al., 2012; Loong et al., 2012).  
Our experiments, however, are the first to be conducted using a single molecule assay, 
which allowed to directly quantify myosin binding to actin and study how its 
cooperativity is affected by the E180G mutation. The results showed that increases in 
[Ca2+] did not lead to a significant shift towards the formation of larger clusters of 
myosin molecules bound to the thin filament, unlike what has been shown from the 
wild-type measurements performed in (Desai et al., 2015). The same is seen for 
changes in [S1-GFP] concentration, where the amount of S1 bound at 10 and 15 nM 
were indistinguishable. Both of these results suggest a shift in the activation state of 
the thin filament towards the closed state at the expense of both the blocked and the 
open states.  
In the context of hypertrophic cardiomyopathy these findings would imply that hyper-
contractility is a result of myosin binding to the thin filament at low calcium, which is 
translated in an apparent increase in calcium sensitivity. Since calcium does not 
directly bind to tropomyosin, but instead affects tropomyosin position indirectly 
through troponin, it is unlikely that a mutation in the tropomyosin chain would affect 
the affinity of TnC to calcium. The E180G mutation is positioned within the TnT binding 
region and (Golitsina et al., 1997, 1999) have showed that, although the overall Tn 
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affinity to Tm is weaker in the presence of the E180G mutation, the TnT affinity did not 
change and the stoichiometry was always close to 1:1 Tn:Tm or TnT:Tm. However, 
(Dong et al., 2003) have reported that the troponin complex acts as a cooperative unit 
during thin filament deactivation which, when coupled to tropomyosin, leads to 
regional stress build-up within the polymeric chain that propagate (releasing the 
accumulated stress) to neighbouring monomers through Ca2+ binding to troponin 
(Robinson et al., 2004). Therefore, it is possible that the removal of a negative charge 
that occurs in the E180G mutation from tropomyosin chain would impair its binding to 
actin, reducing the overall polymer chain cooperativity through its ability to propagate 
stress/forces via head to tail interactions. This is further supported by the simulations 
carried out in (Orzechowski, Fischer, et al., 2014) and (Orzechowski, Moore, et al., 
2014), where tropomyosin mutations that lead to Hypertrophic Cardiomyopathy have 
shown causing a reduction of the difference in energy necessary to switch between 
binding states on actin, lowering the energy barrier necessary to shift from the blocked 
to the closed position, facilitating myosin binding to actin, as indicated by our results 
obtained in the thin filament tightropes assay. As suggested by (Bai et al., 2011) this 
would ultimately translate into an increase in the force generated at low calcium, 
impairing relaxation during diastole (Huelnhagen et al., 2018; Maragiannis et al., 2018; 
Wu et al., 2019). 
To better understand the relaxation process, we also looked at whether tropomyosin 
role in regulating acto-myosin interactions is only passive, working as a steric block for 
myosin binding sites on actin, or if it also actively limits the number of myosin bound 
within a regulatory unit. Imaging myosin binding to the thin filament in sub-maximal 
activating conditions ([ATP] = 0.1 µM, [S1-GFP] = 5 and 10 nM and [Ca2+] = 10-6 M) 
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allowed us to study the release process of myosin molecules from clusters in locally 
active regions. We were able to related the intensity of the bound S1-GFP molecules at 
each given time through our collaboration with Dr. Hongsheng Dai and Madalina 
Mihailescu of the Department of Mathematical Sciences at the University of Essex who, 
using a Reversible-Jump Markov Chain Monte Carlo (RJMCMC) approach helped us 
determine the transition probabilities of myosin detachment from the thin filament. A 
further comparison with a purely stochastic model based on the probability of random 
detachment/attachment of multiple S1-GFP within a set timeframe (300 ms) revealed 
an increased probability for multiple myosin molecules detaching at the same instant, 
resulting in the catastrophic collapse of the locally active region. Considering that 
these results cannot be explained simply by fluorophore photobleaching or stochastic 
release, we suggested an active role for tropomyosin in suppressing myosin cross 
bridges during relaxation. Such a concerted relaxation mechanism could be based on 
tropomyosin rigidity and, as mentioned above, would be supported by the studies on 
the energy landscapes of tropomyosin binding to actin performed by (Orzechowski, 
Moore, et al., 2014) ?ǁŚŝĐŚŝŵƉůǇƚŚĂƚƚƌŽƉŽŵǇŽƐŝŶĐŽƵůĚďĞĐĂƉĂďůĞŽĨ “ƐůŝŶŐŝŶŐ ?ďĂĐŬ
to the blocked position (where its energy is at the minimum) during muscle relaxation 
(Moore et al., 2016). This mechanism would have further implications in 
cardiomyopathies and tie with the results presented in Chapter 3, since an increase in 
tropomyosin flexibility caused by the E180G mutation would mean a decrease in the 
elastic force exerted by tropomyosin during the open to blocked transition, overall 
reducing its capability to actively regulate myosin release from actin and lead to an 
increased tension during diastole (Bai et al., 2011; Cohn et al., 2019). 
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Following on, to better understand the molecular mechanism behind cardiomyopathy, 
it would be interesting to look at how different mutations lead to disease using our 
single molecule assay and the methodologies used in this thesis. For instance, carrying 
out the catastrophic collapse experiments in the presence of the E180G mutation 
would be an obvious follow up to both the experiments presented in Chapter 3 and 4, 
to understand whether the collapse mechanism can be disrupted or enhanced by 
mutations. Other interesting mutations could be D175N (Asp175Asn) and L185R 
(Leu185Arg) which, although being found in close proximity of E180G, have been 
shown to have different effects and overall severity (Thierfelder et al., 1994; Golitsina 
et al., 1997; Chang et al., 2014) and, understanding how they affect myosin binding at 
the single molecule level or the catastrophic collapse of myosin active regions could 
help shed light on the overall molecular implications of cardiomyopathies for muscle 
relaxation. To this end, than is no real restriction posed by our single molecule assay 
itself and potentially any mutation in any protein of the sarcomere can be studied 
following the same methodologies shown in this thesis. 
I also studied three cardiac myosin binding protein-C (cMyBP-C) N-terminal fragments 
(C0C3, C0C1f and C0C1) to elucidate their role in acto-myosin interactions and thin 
filament activation. The results show that only the full N-terminal domain (C0C3) is 
capable of activating the thin filament at low calcium and affect myosin binding at high 
calcium, highlighting the presence of one or more actin binding sites further away from 
the C1 subdomain. These results are partly in line with what has been seen in the 
literature for N-terminal fragments using the in-vitro motility assay (Razumova et al., 
2006; Mun et al., 2014), with the activation at low calcium seen for C0C3 and the 
modulation at high calcium seen for both C0C3 and C0C1f. Thus, the controversy lies 
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with the shorter fragment C0C1f, with C0C3 being thought to cause the activation of 
the thin filament through subdomains C1 and/or M (depending whether the protein is 
from human or mouse (Belknap et al., 2014)) directly interacting with tropomyosin, 
stabilising the closed position (Mun et al., 2014; Risi et al., 2018). Using our tightropes 
assay, we are the first to show that the activation mechanism seen at low calcium is 
caused by C0C3 directly increasing myosin binding to the thin filament, while the 
modulation effect seen at high calcium for both fragments in motility experiments is 
most likely a combination of direct competition and viscous drag (Walcott et al., 2015) 
and C0C3 direct competition in ours, meaning that C0C1f lacks the necessary 
subdomains to provide a significant steric encumbrance to myosin. 
We also looked at fluorescent constructs of the same cMyBP-C N-terminal fragments 
to establish the mechanism behind thin filament activation. Imaging at both low and 
high calcium, we have seen how C0C3 binding to the thin filament is calcium 
dependent and cooperative, unlike C0C1f and C0C1. Fitting our data also revealed an 
increased affinity of C0C3 for thin filaments, in contrast with the affinity values 
reported previously in the literature (Belknap et al., 2014). Further dynamic studies of 
the fragments binding properties to the thin filament revealed that ~25% of the 
imaged molecules randomly diffused, with only C0C3 diffusion being reduced 
significantly at high calcium and for unregulated actin. Taking all our data into 
consideration, we were able to define a two-step model for MyBP-C binding to the thin 
filament, in which the first step consist in a weak association of the C0 and C1 
subdomains to actin, characterised by rapid binding and release seen as diffusion in 
our assay, with the follow-up step characterised by the binding of the further sub-
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domains to actin, displacing tropomyosin from the blocked to its closed position and 
facilitating further binding of either cMyBP-C or myosin. 
An essential follow-up to these results would be performing dual colour experiments, 
where both S1 and cMyBP-C N-terminal fragments are labelled, in an effort to answer 
whether S1 binding to the thin filament is driven by the fragment, working as a direct 
recruiter (Starr and Offer, 1978; Kunst et al., 2000; Ratti et al., 2011; Nag et al., 2017), 
or as a two steps mechanism (S1 binding upon thin filament activation by cMyBP-C 
fragment). It would be also of interest to perform concentration dependence studies 
of C0C3, to accurately characterise its cooperativity and understand the kinetics 
behind its diffusive behaviour. Furthermore, knowing the ability of cMyBP-C to change 
its conformation upon phosphorylation (Colson et al., 2016; Previs et al., 2016), it 
would be interesting to study how phosphorylation of C0C3 affects its thin filament 
binding, activation, cooperativity and diffusion capabilities. 
A final theme arising in all the experiments performed in this thesis is the ability of the 
thin filament tightrope assay and, more generally, single molecule experiments to be 
able to pinpoint the independent mechanistic roles of calcium and myosin. As pointed 
out earlier for the E180G results, we were able to see the different effects that calcium 
and myosin have on thin filament activation separately, by looking at how calcium 
affects myosin binding and how myosin concentration affects its cooperativity. A 
similar picture is seen when looking at the binding characteristics of fluorescent C0C3 
on thin filaments, where we can distinguish between its calcium induced cooperative 
binding and its role in promoting myosin binding. In contrast, using ensemble 
experiments such as the in-vitro motility assay only results in a partial understanding of 
the mechanism of action, seen both for our data with the E180G (figure 3.1) and with 
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the known literature on cMyBP-C (Razumova et al., 2006). This is because in the 
motility assay, both the calcium and myosin cooperativity dependence of thin 
filaments motion is described by a single sigmoidal, thus making it harder to pinpoint 
molecular mechanism of action.  
The results in this thesis demonstrate the capabilities of single molecule approaches 
and highlight their importance as a powerful addition to ensemble experiments 
(Månsson et al., 2018). However, these approaches are not exempt from drawbacks 
and the thin filament tightrope assay is no exception. For instance, as mentioned in 
Chapter 1 and 2, the assay can take a long time to set-up and master compared to 
other techniques. Furthermore, there are inherent difficulties that stem from the 
helical shape of actin and the three dimensional structure of our assay, meaning that 
myosin can bind to both sides of the filament independently and there is currently no 
easy way to distinguish the two cases, which needs to be kept in mind when discussing 
clustering and cooperativity. In addition to this, using a diffraction limited microscope, 
which limits the spatial resolution of our microscope to about 200 nm, makes it so that 
data analysis usually requires more advanced analytical and computational methods to 
identify the single molecules, some of which might be time consuming and could lead 
to difficult to interpret results; examples of these can be the simultaneous fitting of 
the binding data discussed in Chapter 3 which, despite its advantages, takes time to 
optimise and implement, the deconvolution of intensity datasets into transition 
matrices shown in Chapter 4, only applicable because of the high amount of data each 
kymographs inherently possesses, and the application of the Flory-Shulz distribution to 
fit the cMyBP-C fragments binding data in Chapter 5.  
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However, despite the challenges, the thin filament tightrope is still a viable alternative 
to other single molecule techniques available and its reproducibility is highlighted by 
some of the experiments carried out here. For instance, the calculation of the second 
order ATP binding rate constant provided in the Appendix A.5 is consistent with what 
has been found previously by other users using the same assay and methodology (2.03 
µM-1s-1 vs. the 1.88 µM-1s-1 declared in (Desai et al., 2015), as well as the correction 
necessary to calculate the single S1-GFP intensity, leading to a right shift of the linear 
plot in figure 3.5b, showing as the same assays leads to similar conclusions over time 
and with different users (Desai et al., 2015). Furthermore, the collapse of myosin 
active regions discussed in Chapter 4 has also been achieved in similar conditions to 
what had been reported in their paper. 
Concluding, there are still questions that remain unanswered in the field of muscle 
contraction towards reaching a better understanding of cardiomyopathies and how 
they affect acto-myosin interactions and, although there is still much work to be done 
in that regard, I hope that the results and methodologies reported in this thesis will 













A.1  ? Sequencing results of the 6xHis-RlC-GFP 
 
       1   K  I  Y  L  L  C  E  R  I  T  I  I  I  D  S  I  V  S  G  * 
       1  K  N  L  F  A  L  *  A  D  N  N  Y  N  R  F  N  C  E  R  I  
       1 *  K  F  I  C  F  V  S  G  *  Q  L  *  *  I  Q  L  *  A  D   
       1 TAAAAATTTATTTGCTTTGTGAGCGGATAACAATTATAATAGATTCAATTGTGAGCGGAT 
       1          10        20        30        40        50          
       1 ATTTTTAAATAAACGAAACACTCGCCTATTGTTAATATTATCTAAGTTAACACTCGCCTA 
      21   Q  F  H  T  E  F  I  K  E  E  K  L  S  M  H  H  H  H  H  H 
      21  T  I  S  H  R  I  H  *  R  G  E  I  K  H  A  P  S  P  S  P  
      21 N  N  F  T  Q  N  S  L  K  R  R  N  *  A  C  T  I  T  I  T   
      61 AACAATTTCACACAGAATTCATTAAAGAGGAGAAATTAAGCATGCACCATCACCATCACC 
      61          70        80        90        100       110         
      61 TTGTTAAAGTGTGTCTTAAGTAATTTCTCCTCTTTAATTCGTACGTGGTAGTGGTAGTGG 
      41   A  S  M  S  S  K  R  A  K  A  K  T  T  K  K  R  P  Q  R  A 
      41  C  *  H  E  Q  Q  T  R  E  S  E  N  H  Q  K  T  P  A  A  R  
      41 M  L  A  *  A  A  N  A  R  K  R  K  P  P  K  N  A  R  S  A   
     121 ATGCTAGCATGAGCAGCAAACGCGCGAAAGCGAAAACCACCAAAAAACGCCCGCAGCGCG 
     121          130       140       150       160       170         
     121 TACGATCGTACTCGTCGTTTGCGCGCTTTCGCTTTTGGTGGTTTTTTGCGGGCGTCGCGC 
      61   T  S  N  V  F  A  M  F  D  Q  S  Q  I  Q  E  F  K  E  A  F 
      61  D  Q  Q  R  V  C  D  V  *  S  E  P  D  S  G  I  *  R  S  V  
      61 R  P  A  T  C  L  R  C  L  I  R  A  R  F  R  N  L  K  K  R   
     181 CGACCAGCAACGTGTTTGCGATGTTTGATCAGAGCCAGATTCAGGAATTTAAAGAAGCGT 
     181          190       200       210       220       230         
     181 GCTGGTCGTTGCACAAACGCTACAAACTAGTCTCGGTCTAAGTCCTTAAATTTCTTCGCA 
      81   N  M  I  D  Q  N  R  D  G  F  I  D  K  E  D  L  H  D  M  L 
      81  *  H  D  *  S  E  P  R  W  L  Y  *  *  R  R  S  A  *  Y  A  
      81 L  T  *  L  I  R  T  A  M  A  L  L  I  K  K  I  C  M  I  C   
     241 TTAACATGATTGATCAGAACCGCGATGGCTTTATTGATAAAGAAGATCTGCATGATATGC 
     241          250       260       270       280       290         
     241 AATTGTACTAACTAGTCTTGGCGCTACCGAAATAACTATTTCTTCTAGACGTACTATACG 
     101   A  S  M  G  K  N  P  T  D  E  Y  L  E  G  M  M  S  E  A  P 
     101  G  E  H  G  Q  K  P  D  R  *  I  S  G  R  H  D  E  R  S  A  
     101 W  R  A  W  A  K  T  R  P  M  N  I  W  K  A  *  *  A  K  R   
     301 TGGCGAGCATGGGCAAAAACCCGACCGATGAATATCTGGAAGGCATGATGAGCGAAGCGC 
     301          310       320       330       340       350         
     301 ACCGCTCGTACCCGTTTTTGGGCTGGCTACTTATAGACCTTCCGTACTACTCGCTTCGCG 
     121   G  P  I  N  F  T  M  F  L  T  M  F  G  E  K  L  N  G  T  D 
     121  G  P  D  *  L  Y  H  V  S  D  H  V  W  R  K  T  E  R  H  R  
     121 R  A  R  L  T  L  P  C  F  *  P  C  L  A  K  N  *  T  A  P   
     361 CGGGCCCGATTAACTTTACCATGTTTCTGACCATGTTTGGCGAAAAACTGAACGGCACCG 
     361          370       380       390       400       410         






     141   P  E  D  V  I  R  N  A  F  A  C  F  D  E  E  A  S  G  F  I 
     141  S  G  R  C  D  S  Q  R  V  C  V  L  *  *  R  S  E  R  L  Y  
     141 I  R  K  M  *  F  A  T  R  L  R  A  L  M  K  K  R  A  A  L   
     421 ATCCGGAAGATGTGATTCGCAACGCGTTTGCGTGCTTTGATGAAGAAGCGAGCGGCTTTA 
     421          430       440       450       460       470         
     421 TAGGCCTTCTACACTAAGCGTTGCGCAAACGCACGAAACTACTTCTTCGCTCGCCGAAAT 
     161   H  E  D  H  L  R  E  L  L  T  T  M  G  D  R  F  T  D  E  E 
     161  S  *  R  S  S  A  R  T  A  D  H  H  G  R  S  L  Y  R  *  R  
     161 F  M  K  I  I  C  A  N  C  *  P  P  W  A  I  A  L  P  M  K   
     481 TTCATGAAGATCATCTGCGCGAACTGCTGACCACCATGGGCGATCGCTTTACCGATGAAG 
     481          490       500       510       520       530         
     481 AAGTACTTCTAGTAGACGCGCTTGACGACTGGTGGTACCCGCTAGCGAAATGGCTACTTC 
     181   V  D  E  M  Y  R  E  A  P  I  D  K  K  G  N  F  N  Y  V  E 
     181  S  G  *  N  V  S  R  S  A  D  *  *  K  R  Q  L  *  L  C  G  
     181 K  W  M  K  C  I  A  K  R  R  L  I  K  K  A  T  L  T  M  W   
     541 AAGTGGATGAAATGTATCGCGAAGCGCCGATTGATAAAAAAGGCAACTTTAACTATGTGG 
     541          550       560       570       580       590         
     541 TTCACCTACTTTACATAGCGCTTCGCGGCTAACTATTTTTTCCGTTGAAATTGATACACC 
     201   F  T  R  I  L  K  H  G  A  K  D  K  D  D  G  A  P  S  G  S 
     201  I  Y  P  H  S  E  T  W  R  E  R  *  R  *  W  R  A  F  R  *  
     201 N  L  P  A  F  *  N  M  A  R  K  I  K  M  M  A  R  L  Q  V   
     601 AATTTACCCGCATTCTGAAACATGGCGCGAAAGATAAAGATGATGGCGCGCCTTCAGGTA 
     601          610       620       630       640       650         
     601 TTAAATGGGCGTAAGACTTTGTACCGCGCTTTCTATTTCTACTACCGCGCGGAAGTCCAT 
     221   S  G  T  S  S  G  T  S  M  V  S  K  G  E  E  L  F  T  G  V 
     221  L  W  H  F  K  R  Y  *  Y  G  E  Q  G  R  G  A  V  H  R  G  
     221 A  L  A  L  Q  A  V  L  V  W  *  A  R  A  R  S  C  S  P  G   
     661 GCTCTGGCACTTCAAGCGGTACTAGTATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG 
     661          670       680       690       700       710         
     661 CGAGACCGTGAAGTTCGCCATGATCATACCACTCGTTCCCGCTCCTCGACAAGTGGCCCC 
     241   V  P  I  L  V  E  L  D  G  D  V  N  G  H  K  F  S  V  S  G 
     241  G  A  H  P  G  R  A  G  R  R  R  K  R  P  Q  V  Q  R  V  R  
     241 W  C  P  S  W  S  S  W  T  A  T  *  T  A  T  S  S  A  C  P   
     721 TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCG 
     721          730       740       750       760       770         
     721 ACCACGGGTAGGACCAGCTCGACCTGCCGCTGCATTTGCCGGTGTTCAAGTCGCACAGGC 
     261   E  G  E  G  D  A  T  Y  G  K  L  T  L  K  F  I  C  T  T  G 
     261  R  G  R  G  R  C  H  L  R  Q  A  D  P  E  V  H  L  H  H  R  
     261 A  R  A  R  A  M  P  P  T  A  S  *  P  *  S  S  S  A  P  P   
     781 GCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACCACCG 
     781          790       800       810       820       830         
     781 CGCTCCCGCTCCCGCTACGGTGGATGCCGTTCGACTGGGACTTCAAGTAGACGTGGTGGC 
     281   K  L  P  V  P  W  P  T  L  V  T  T  L  T  Y  G  V  Q  C  F 
     281  Q  A  A  R  A  L  A  H  P  R  D  H  P  D  L  R  R  A  V  L  
     281 A  S  C  P  C  P  G  P  P  S  *  P  P  *  P  T  A  C  S  A   
     841 GCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTACGGCGTGCAGTGCT 
     841          850       860       870       880       890         
     841 CGTTCGACGGGCACGGGACCGGGTGGGAGCACTGGTGGGACTGGATGCCGCACGTCACGA 
     301   S  R  Y  P  D  H  M  K  Q  H  D  F  F  K  S  A  M  P  E  G 
     301  Q  P  L  P  R  P  H  E  A  A  R  L  L  Q  V  R  H  A  R  R  
     301 S  A  A  T  P  T  T  *  S  S  T  T  S  S  S  P  P  C  P  K   
     901 TCAGCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAG 
     901          910       920       930       940       950         
     901 AGTCGGCGATGGGGCTGGTGTACTTCGTCGTGCTGAAGAAGTTCAGGCGGTACGGGCTTC 
     321   Y  V  Q  E  R  T  I  F  F  K  D  D  G  N  Y  K  T  R  A  E 
     321  L  R  P  G  A  H  H  L  L  Q  G  R  R  Q  L  Q  D  P  R  R  
     321 A  T  S  R  S  A  P  S  S  S  R  T  T  A  T  T  R  P  A  P   
     961 GCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG 
     961          970       980       990       1000      1010        




     341   V  K  F  E  G  D  T  L  V  N  R  I  E  L  K  G  I  D  F  K 
     341  G  E  V  R  G  R  H  P  G  E  P  H  R  A  E  G  H  R  L  Q  
     341 R  *  S  S  R  A  T  P  W  *  T  A  S  S  *  R  A  S  T  S   
    1021 AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCA 
    1021          1030      1040      1050      1060      1070        
    1021 TCCACTTCAAGCTCCCGCTGTGGGACCACTTGGCGTAGCTCGACTTCCCGTAGCTGAAGT 
     361   E  D  G  N  I  L  G  H  K  L  E  Y  N  Y  N  S  H  N  V  Y 
     361  G  G  R  Q  H  P  G  A  Q  A  G  V  Q  L  Q  Q  P  Q  R  L  
     361 R  R  T  A  T  S  W  G  T  S  W  S  T  T  T  T  A  T  T  S   
    1081 AGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAACGTCT 
    1081          1090      1100      1110      1120      1130        
    1081 TCCTCCTGCCGTTGTAGGACCCCGTGTTCGACCTCATGTTGATGTTGTCGGTGTTGCAGA 
     381   I  M  A  D  K  Q  K  N  G  I  K  V  N  F  K  I  R  H  N  I 
     381  Y  H  G  R  Q  A  E  E  R  H  Q  G  E  L  Q  D  P  P  Q  H  
     381 I  S  W  P  T  S  R  R  T  A  S  R  *  T  S  R  S  A  T  T   
    1141 ATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACA 
    1141          1150      1160      1170      1180      1190        
    1141 TATAGTACCGGCTGTTCGTCTTCTTGCCGTAGTTCCACTTGAAGTTCTAGGCGGTGTTGT 
     401   E  D  G  S  V  Q  L  A  D  H  Y  Q  Q  N  T  P  I  G  D  G 
     401  R  G  R  Q  R  A  A  R  R  P  L  P  A  E  H  P  H  R  R  R  
     401 S  R  T  A  A  C  S  S  P  T  T  T  S  R  T  P  P  S  A  T   
    1201 TCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACG 
    1201          1210      1220      1230      1240      1250        
    1201 AGCTCCTGCCGTCGCACGTCGAGCGGCTGGTGATGGTCGTCTTGTGGGGGTAGCCGCTGC 
     421   P  V  L  L  P  D  N  H  Y  L  S  T  Q  S  A  L  S  K  D  P 
     421  P  R  A  A  A  R  Q  P  L  P  E  H  P  V  R  P  E  Q  R  P  
     421 A  P  C  C  C  P  T  T  T  T  *  A  P  S  P  P  *  A  K  T   
    1261 GCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACCCAGTCCGCCCTGAGCAAAGACC 
    1261          1270      1280      1290      1300      1310        
    1261 CGGGGCACGACGACGGGCTGTTGGTGATGGACTCGTGGGTCAGGCGGGACTCGTTTCTGG 
     441   N  E  K  R  D  H  M  V  L  L  E  F  V  T  A  A  G  I  T  L 
     441  Q  R  E  A  R  S  H  G  P  A  G  V  R  D  R  R  R  D  H  S  
     441 P  T  R  S  A  I  T  W  S  C  W  S  S  *  P  P  P  G  S  L   
    1321 CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTC 
    1321          1330      1340      1350      1360      1370        
    1321 GGTTGCTCTTCGCGCTAGTGTACCAGGACGACCTCAAGCACTGGCGGCGGCCCTAGTGAG 
     461   G  M  D  E  L  Y  K  *  E 
     461  R  H  G  R  A  V  Q  V  R  K  
     461 S  A  W  T  S  C  T  S  K  K 
    1381 TCGGCATGGACGAGCTGTACAAGTAAGAAAG 
    1381          1390      1400      1410       









A.2  ? Sequencing results of the RlC-GFP-6xHis 
 
       1   Y  F  V  Y  F  K  K  E  I  Y  I  *  A  A  N  A  R  K  R  K 
       1  I  F  C  L  L  *  E  G  D  I  H  M  S  S  K  R  A  K  A  K  
       1 D  I  L  F  T  L  R  R  R  Y  T  Y  E  Q  Q  T  R  E  S  E   
       1 GATATTTTGTTTACTTTAAGAAGGAGATATACATATGAGCAGCAAACGCGCGAAAGCGAA 
       1          10        20        30        40        50          
       1 CTATAAAACAAATGAAATTCTTCCTCTATATGTATACTCGTCGTTTGCGCGCTTTCGCTT 
      21   P  P  K  N  A  R  S  A  R  P  A  T  C  L  R  C  L  I  R  A 
      21  T  T  K  K  R  P  Q  R  A  T  S  N  V  F  A  M  F  D  Q  S  
      21 N  H  Q  K  T  P  A  A  R  D  Q  Q  R  V  C  D  V  *  S  E   
      61 AACCACCAAAAAACGCCCGCAGCGCGCGACCAGCAACGTGTTTGCGATGTTTGATCAGAG 
      61          70        80        90        100       110         
      61 TTGGTGGTTTTTTGCGGGCGTCGCGCGCTGGTCGTTGCACAAACGCTACAAACTAGTCTC 
      41   R  F  R  N  L  K  K  R  L  T  *  L  I  R  T  A  M  A  L  L 
      41  Q  I  Q  E  F  K  E  A  F  N  M  I  D  Q  N  R  D  G  F  I  
      41 P  D  S  G  I  *  R  S  V  *  H  D  *  S  E  P  R  W  L  Y   
     121 CCAGATTCAGGAATTTAAAGAAGCGTTTAACATGATTGATCAGAACCGCGATGGCTTTAT 
     121          130       140       150       160       170         
     121 GGTCTAAGTCCTTAAATTTCTTCGCAAATTGTACTAACTAGTCTTGGCGCTACCGAAATA 
      61   I  K  K  I  C  M  I  C  W  R  A  W  A  K  T  R  P  M  N  I 
      61  D  K  E  D  L  H  D  M  L  A  S  M  G  K  N  P  T  D  E  Y  
      61 *  *  R  R  S  A  *  Y  A  G  E  H  G  Q  K  P  D  R  *  I   
     181 TGATAAAGAAGATCTGCATGATATGCTGGCGAGCATGGGCAAAAACCCGACCGATGAATA 
     181          190       200       210       220       230         
     181 ACTATTTCTTCTAGACGTACTATACGACCGCTCGTACCCGTTTTTGGGCTGGCTACTTAT 
      81   W  K  A  *  *  A  K  R  R  A  R  L  T  L  P  C  F  *  P  C 
      81  L  E  G  M  M  S  E  A  P  G  P  I  N  F  T  M  F  L  T  M  
      81 S  G  R  H  D  E  R  S  A  G  P  D  *  L  Y  H  V  S  D  H   
     241 TCTGGAAGGCATGATGAGCGAAGCGCCGGGCCCGATTAACTTTACCATGTTTCTGACCAT 
     241          250       260       270       280       290         
     241 AGACCTTCCGTACTACTCGCTTCGCGGCCCGGGCTAATTGAAATGGTACAAAGACTGGTA 
     101   L  A  K  N  *  T  A  P  I  R  K  M  *  F  A  T  R  L  R  A 
     101  F  G  E  K  L  N  G  T  D  P  E  D  V  I  R  N  A  F  A  C  
     101 V  W  R  K  T  E  R  H  R  S  G  R  C  D  S  Q  R  V  C  V   
     301 GTTTGGCGAAAAACTGAACGGCACCGATCCGGAAGATGTGATTCGCAACGCGTTTGCGTG 
     301          310       320       330       340       350         
     301 CAAACCGCTTTTTGACTTGCCGTGGCTAGGCCTTCTACACTAAGCGTTGCGCAAACGCAC 
     121   L  M  K  K  R  A  A  L  F  M  K  I  I  C  A  N  C  *  P  P 
     121  F  D  E  E  A  S  G  F  I  H  E  D  H  L  R  E  L  L  T  T  
     121 L  *  *  R  S  E  R  L  Y  S  *  R  S  S  A  R  T  A  D  H   
     361 CTTTGATGAAGAAGCGAGCGGCTTTATTCATGAAGATCATCTGCGCGAACTGCTGACCAC 
     361          370       380       390       400       410         
     361 GAAACTACTTCTTCGCTCGCCGAAATAAGTACTTCTAGTAGACGCGCTTGACGACTGGTG 
     141   W  A  I  A  L  P  M  K  K  W  M  K  C  I  A  K  R  R  L  I 
     141  M  G  D  R  F  T  D  E  E  V  D  E  M  Y  R  E  A  P  I  D  
     141 H  G  R  S  L  Y  R  *  R  S  G  *  N  V  S  R  S  A  D  *   
     421 CATGGGCGATCGCTTTACCGATGAAGAAGTGGATGAAATGTATCGCGAAGCGCCGATTGA 
     421          430       440       450       460       470         
     421 GTACCCGCTAGCGAAATGGCTACTTCTTCACCTACTTTACATAGCGCTTCGCGGCTAACT 
     161   K  K  A  T  L  T  M  W  N  L  P  A  F  *  N  M  A  R  K  I 
     161  K  K  G  N  F  N  Y  V  E  F  T  R  I  L  K  H  G  A  K  D  
     161 *  K  R  Q  L  *  L  C  G  I  Y  P  H  S  E  T  W  R  E  R   
     481 TAAAAAAGGCAACTTTAACTATGTGGAATTTACCCGCATTCTGAAACATGGCGCGAAAGA 
     481          490       500       510       520       530         
     481 ATTTTTTCCGTTGAAATTGATACACCTTAAATGGGCGTAAGACTTTGTACCGCGCTTTCT 
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     181   K  M  M  A  R  L  Q  V  A  L  A  L  Q  A  V  L  V  W  *  A 
     181  K  D  D  G  A  P  S  G  S  S  G  T  S  S  G  T  S  M  V  S  
     181 *  R  *  W  R  A  F  R  *  L  W  H  F  K  R  Y  *  Y  G  E   
     541 TAAAGATGATGGCGCGCCTTCAGGTAGCTCTGGCACTTCAAGCGGTACTAGTATGGTGAG 
     541          550       560       570       580       590         
     541 ATTTCTACTACCGCGCGGAAGTCCATCGAGACCGTGAAGTTCGCCATGATCATACCACTC 
     201   R  A  R  S  C  S  P  G  W  C  P  S  W  S  S  W  T  A  T  * 
     201  K  G  E  E  L  F  T  G  V  V  P  I  L  V  E  L  D  G  D  V  
     201 Q  G  R  G  A  V  H  R  G  G  A  H  P  G  R  A  G  R  R  R   
     601 CAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGT 
     601          610       620       630       640       650         
     601 GTTCCCGCTCCTCGACAAGTGGCCCCACCACGGGTAGGACCAGCTCGACCTGCCGCTGCA 
     221   T  A  T  S  S  A  C  P  A  R  A  R  A  M  P  P  T  A  S  * 
     221  N  G  H  K  F  S  V  S  G  E  G  E  G  D  A  T  Y  G  K  L  
     221 K  R  P  Q  V  Q  R  V  R  R  G  R  G  R  C  H  L  R  Q  A   
     661 AAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCT 
     661          670       680       690       700       710         
     661 TTTGCCGGTGTTCAAGTCGCACAGGCCGCTCCCGCTCCCGCTACGGTGGATGCCGTTCGA 
     241   P  *  S  S  S  A  P  P  A  S  C  P  C  P  G  P  P  S  *  P 
     241  T  L  K  F  I  C  T  T  G  K  L  P  V  P  W  P  T  L  V  T  
     241 D  P  E  V  H  L  H  H  R  Q  A  A  R  A  L  A  H  P  R  D   
     721 GACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGAC 
     721          730       740       750       760       770         
     721 CTGGGACTTCAAGTAGACGTGGTGGCCGTTCGACGGGCACGGGACCGGGTGGGAGCACTG 
     261   P  *  P  T  A  C  S  A  S  A  A  T  P  T  T  *  S  S  T  T 
     261  T  L  T  Y  G  V  Q  C  F  S  R  Y  P  D  H  M  K  Q  H  D  
     261 H  P  D  L  R  R  A  V  L  Q  P  L  P  R  P  H  E  A  A  R   
     781 CACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGA 
     781          790       800       810       820       830         
     781 GTGGGACTGGATGCCGCACGTCACGAAGTCGGCGATGGGGCTGGTGTACTTCGTCGTGCT 
     281   S  S  S  P  P  C  P  K  A  T  S  R  S  A  P  S  S  S  R  T 
     281  F  F  K  S  A  M  P  E  G  Y  V  Q  E  R  T  I  F  F  K  D  
     281 L  L  Q  V  R  H  A  R  R  L  R  P  G  A  H  H  L  L  Q  G   
     841 CTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGA 
     841          850       860       870       880       890         
     841 GAAGAAGTTCAGGCGGTACGGGCTTCCGATGCAGGTCCTCGCGTGGTAGAAGAAGTTCCT 
     301   T  A  T  T  R  P  A  P  R  *  S  S  R  A  T  P  W  *  T  A 
     301  D  G  N  Y  K  T  R  A  E  V  K  F  E  G  D  T  L  V  N  R  
     301 R  R  Q  L  Q  D  P  R  R  G  E  V  R  G  R  H  P  G  E  P   
     901 CGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCG 
     901          910       920       930       940       950         
     901 GCTGCCGTTGATGTTCTGGGCGCGGCTCCACTTCAAGCTCCCGCTGTGGGACCACTTGGC 
     321   S  S  *  R  A  S  T  S  R  R  T  A  T  S  W  G  T  S  W  S 
     321  I  E  L  K  G  I  D  F  K  E  D  G  N  I  L  G  H  K  L  E  
     321 H  R  A  E  G  H  R  L  Q  G  G  R  Q  H  P  G  A  Q  A  G   
     961 CATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGA 
     961          970       980       990       1000      1010        
     961 GTAGCTCGACTTCCCGTAGCTGAAGTTCCTCCTGCCGTTGTAGGACCCCGTGTTCGACCT 
     341   T  T  T  T  A  T  T  S  I  S  W  P  T  S  R  R  T  A  S  R 
     341  Y  N  Y  N  S  H  N  V  Y  I  M  A  D  K  Q  K  N  G  I  K  
     341 V  Q  L  Q  Q  P  Q  R  L  Y  H  G  R  Q  A  E  E  R  H  Q   
    1021 GTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAA 
    1021          1030      1040      1050      1060      1070        
    1021 CATGTTGATGTTGTCGGTGTTGCAGATATAGTACCGGCTGTTCGTCTTCTTGCCGTAGTT 
     361   *  T  S  R  S  A  T  T  S  R  T  A  A  C  S  S  P  T  T  T 
     361  V  N  F  K  I  R  H  N  I  E  D  G  S  V  Q  L  A  D  H  Y  
     361 G  E  L  Q  D  P  P  Q  H  R  G  R  Q  R  A  A  R  R  P  L   
    1081 GGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTA 





     381   S  R  T  P  P  S  A  T  A  P  C  C  C  P  T  T  T  T  *  A 
     381  Q  Q  N  T  P  I  G  D  G  P  V  L  L  P  D  N  H  Y  L  S  
     381 P  A  E  H  P  H  R  R  R  P  R  A  A  A  R  Q  P  L  P  E   
    1141 CCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAG 
    1141          1150      1160      1170      1180      1190        
    1141 GGTCGTCTTGTGGGGGTAGCCGCTGCCGGGGCACGACGACGGGCTGTTGGTGATGGACTC 
     401   P  S  P  P  *  A  K  T  P  T  R  S  A  I  T  W  S  C  W  S 
     401  T  Q  S  A  L  S  K  D  P  N  E  K  R  D  H  M  V  L  L  E  
     401 H  P  V  R  P  E  Q  R  P  Q  R  E  A  R  S  H  G  P  A  G   
    1201 CACCCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGA 
    1201          1210      1220      1230      1240      1250        
    1201 GTGGGTCAGGCGGGACTCGTTTCTGGGGTTGCTCTTCGCGCTAGTGTACCAGGACGACCT 
     421   S  *  P  P  P  G  S  L  S  A  W  T  S  C  T  S  L  R  P  H 
     421  F  V  T  A  A  G  I  T  L  G  M  D  E  L  Y  K  L  A  A  A  
     421 V  R  D  R  R  R  D  H  S  R  H  G  R  A  V  Q  A  C  G  R   
    1261 GTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGCTTGCGGCCGC 
    1261          1270      1280      1290      1300      1310        
    1261 CAAGCACTGGCGGCGGCCCTAGTGAGAGCCGTACCTGCTCGACATGTTCGAACGCCGGCG 
     441   S  S  T  T  T  T  T  T  E  I  R 
     441  L  E  H  H  H  H  H  H  *  D  P  A  
     441 T  R  A  P  P  P  P  P  L  R  S  G 
    1321 ACTCGAGCACCACCACCACCACCACTGAGATCCGGCT 
    1321          1330      1340      1350       
    1321 TGAGCTCGTGGTGGTGGTGGTGGTGACTCTAGGCCGA 
 
 
A.3  ? Matlab script for the extraction of intensity data 
 
To extract the intensity data from each of the kymographs used in chapters 3 and 4 we 
used a custom written Matlab script, of which a representative picture of its interface 
is shown in figure A.1.  
This routine takes every vertical slice of a kymograph (equal to a single frame in a 
movie) and, based on a previously assigned threshold, finds the regions where the 
fluorescence intensity is greater than the sum of the assigned threshold and the 
minimum value of intensity and the minimum intensity value averaged through all the 
frames of the kymograph. The intensity values for each slice of the middle panel are 
then fitted to up to eight Gaussian distributions, identifying their mean position, 
amplitude (intensity of the fluorophore), standard deviation and an offset 
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(corresponding to the noise level). Finally, the data are manually screened, based on 
the original kymograph, to separate the fluorescence intensity values from random 
background noise that has not been filtered out by the threshold. 
 
 
Figure A.1: Extracting the fluorescence intensity from a kymograph. Representative picture of the 
output of the Matlab script sued to determine the intensity of each fluorescent spot in a kymograph. In 
the left panel is the original kymograph, in the middle panel is a representation of all the pixels that pass 









 ܭଵ ൌ ஺ಳൣ஼௔మశ൧೙಴ೌ஺಴ಽ           ܭଶ ൌ ஺಴ಽሾெሿ೙ಾ஺ಾሾ஺்௉ሿ  
 ஺ಳ஺಴ಽ ൌ ௄భሾ஼௔మశሿ೙಴ೌ      ஺ಾ஺಴ಽ ൌ ሾெሿ೙ಾ௄మሾ஺்௉ሿ      ஺ಳ஺ಾ ൌ ௄భ௄మሾ஺்௉ሿሾ஼௔మశሿ೙಴ೌሾெሿ೙ಾ  
 ܣ௖௟ ൌ ܣ஼௅ܣ஻ ൅ ܣ஼௅ ൅ ܣெ ൌ  ?ܣ஻ܣ஼௅ ൅  ? ൅ܣெܣ஼௅ൌ ሾܥܽଶାሿ௡಴ೌܭଶሾܣܶܲሿܭଵܭଶሾܣܶܲሿ൅ሾܥܽଶାሿ௡಴ೌܭଶሾܣܶܲሿ൅ሾܯሿ௡ಾሾܥܽଶାሿ௡಴ೌ  








A.5  ? Calculating the second order ATP binding rate constant 
 
The second order ATP binding rate constant of myosin was calculated using the thin 
filament tightrope assay, looking at the binding of 5 nM S1-GFP on unregulated actin 
thin filaments in the same imaging experimental conditions used in the results 
chapters (300 ms exposure time, 5 mW of 488 nm laser power). 
 
 
 Figure A.2: Calculating the second order ATP binding rate constant. a) and b) are histograms of the 
lifetimes of the S1-GFP on unregulated actin concentration at the stated ATP concentration; c) plotting a 
graph of the S1-GFP binding frequency vs. the ATP concentration resulted in a linear relationship having 
a slope equals to the second order ATP binding rate constant, 2.03 µM-1s-1. All the data acquired are 




We looked at the time spent by S1-GFP on the actin filaments (lifetime) and plot all the 
values in histograms (figure A.2a and b). Fitting these histograms to a decaying 
exponential distribution, yielded the myosin binding frequency. A plot of the myosin 
binding frequency at different [ATP] yielded a linear relationship with a slope being the 
second order ATP binding rate constant of 2.03 µM-1s-1, consistent with the value 
found by (Lymn and Taylor, 1971) and (Desai et al., 2015). 
 
 
A.6  ? The Reversible Jump Markov-Chain Monte Carlo 
(RJMCMC) and generation of transition matrices 
 
The RJMCMC algorithm is a statistical analysis that allow the modelling of stochastics 
transitions based only on the present state, without knowledge of past transitions. The 
algorithm models the data in a series of iterations, reaching convergence and 
outputting the probability of each transition in a kymograph. 
Four independent Markov chains were generated for a kymograph, in order to 
calculate the average mean and variance value for each population of binders, where 
the mean corresponds to the predicted intensity values for a defined number of 
binders. The number of components (maximum number of binders) used in the 
RJMCMC algorithm was constrained so that the intensity would have a linear 
dependence with the number of binders. Table A1 shows the average of four 
simulated RJMCMC chains with two different numbers of components is shown in. For 
both 7 components (equivalent to background plus 6 binders) and 9 components 
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(equivalent to background plus 8 binders) clear increments between binders are seen. 
However the 9 component simulation provides a better linear relationship and was 
used as the basis for further analysis. Further confirmation of the choice of component 
number derives from the weighting or relative abundance of these binders. For 9 
components the predominant population is between 1 and 5 molecules per bound 
cluster, few components are seen for 6 to 8. 
 
 
 Total of 6 Binders (7 components) Total of 8 Binders (9 components) 
 Mean Variance Weight Mean Variance Weight 
No 
Binders 
57.17 34.73 0.12 24.52 35.58 0.10 
1 Binder 150.75 42.07 0.21 138.57 41.54 0.15 
2 Binders 198.26 50.68 0.20 173.87 46.04 0.16 
3 Binders 254.73 60.71 0.15 210.90 51.35 0.16 
4 Binders 314.23 69.58 0.14 264.22 55.51 0.14 
5 Binders 401.37 85.73 0.11 322.20 62.04 0.11 
6 Binders 551.86 111.40 0.07 382.67 80.58 0.08 
7 Binders    490.73 72.01 0.05 
8 Binders    652.38 91.13 0.04 
 
Table A1: Summary results of the average of four RJMCMC chains. The values of mean, variance and 
weight resulted from the RJMCMC of a kymograph, to test the model for a total of either 6 or 8 myosin 
molecules, and find the fluorescence intensity ranges of myosin clusters, used in the analysis of the 
experimental data. 
 
The midpoint between successive means for the 9 component simulation was used as 
the cut-off pixel intensity value for that population of binders (calculated as the mean 
between two subsequent binders intensity), in order to discern between different 
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clusters of myosin. Table A2 provides a breakdown of all the values used for these cut-
offs. These mean and cut-off values were carried forward into the analysis of all 
subsequent kymographs to generate datasets of number of bound myosin molecules 
within a cluster, and finally derive the transition matrices. 
 
 Lower Bound Upper Bound 
Range of values for 0 binders 0 81.54 
Range of values for 1 binder 81.55 156.21 
Range of values for 2 binders 156.22 192.38 
Range of values for 3 binders 192.39 237.55 
Range of values for 4 binders 237.56 293.20 
Range of values for 5 binders 293.21 352.43 
Range of values for 6 binders 352.44 436.69 
Range of values for 7 binders 436.70 571.55 
Range of values for 8 binders 571.56 641.55 
Range of values for 9 binders 641.56 711.55 
Range of values for 10 binders 711.56 781.55 
Range of values for 11 binders 781.56 >781.56 
 
Table A2: Range of intensity values for each cluster of myosin molecules. These values have been used 








A.7  ? Determination of the number of Gaussian distributions 
for the fitting of the C0C3 intensity histogram 
 
To determine average number of cMyBP-C molecules bound per unit length of thin 
filament (µm) we need to calculate fluorescence intensity value associated with a  
single molecule. Using the same approach of (Desai et al., 2015) and (Iino et al., 2001), 
we pooled into a histograms all the fluorescence point spread function intensity values 
obtained imaging 20 nM Cy3-C0C3 on thin filaments at pCa 7 and then fitted it to a 
number of Gaussian distribution, as described in section 5.2.2. The mean intensity of 
each distribution would then follow a linear relationship with their associated number 
of molecules, leading us to the intensity of a single Cy3 fluorophore. This linear 
relationship can also be used to evaluate the right number of Gaussian distributions 
chosen for the fitting. Figure A.3 shows an example of this procedure. 
 
 
Figure A.3:  Selecting the number of Gaussian distributions. 
Histograms of the intensities of the fluorescence point 
spread function of C0C3, collected at pCa 7, fitted to a) five 
or b) six or c) seven Gaussian distributions. The mean value 
of each distribution then follows a linear relationship with 
the associated number of molecules (insets). 
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Although the intensity histogram can be fit adequately with up to seven Gaussian 
distributions (figure A.3), each resulting linear relationship yield different values of 
slope and intercept. In particular, fitting the Cy3 intensity histogram using five 
Gaussian distributions (figure A.3a) produces a slope (single molecule intensity) of 
350.9 and an intercept (single molecule intensity associated error) of 69.7, with an R2 
of 0.994, while using seven Gaussian distributions (figure A.3c) brings the slope down 
to 305.5 and the intercept up to 108.7, with an R2 of 0.990. Considering that using six 
Gaussian distributions (figure A.3b) results in an in-between value of R2 (0.992), a 
lower intercept (19.0) and a similar value of slope to figure A.3 a, we chose six as the 
optimal number of Gaussian distributions to fit out intensity histogram and proceeded 
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